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Abstract 
Transglutaminase type 2 (TG2) catalyses the formation of an ε-(γ-glutamyl)-lysine isopeptide 
bonds between adjacent peptides or proteins including those of the extracellular matrix 
(ECM). ECM crosslinking has been associated with both the acceleration of collagen 
deposition while conferring the ECM with resistance to proteolytic degradation. Subsequently 
the cellular secretion of TG2 has been associated with wound healing and aberrant wound 
healing leading to kidney, lung, liver and heart fibrosis as well as atherosclerosis. TG2 has no 
signal peptide and cannot be transported classically. It is unknown how TG2 is targeted to the 
cell surface and secreted into ECM. Understanding TG2 transport may help to develop 
specific mechanisms to interfere with TG2 action in the scarring process. 
In this study, we identified that amino acids 88-106 in N-terminal β-sandwich domain of TG2 
molecule is crucial for TG2 externalisation using deletion and mutation analysis in three 
renal tubular epithelial cells (TEC). Of interest, this TG2 export motif (aa88-106) itself 
appeared to be able to target other proteins for extracellular secretion.  Yeast-two-hybrid 
studies were then performed to identify what the TG2 export motif would bind to and thus 
give clues as to the downstream mechanism of trafficking. Large T antigen (LTA) and tapasin 
were identified as binding partners. The interaction between LTA or tapasin and TG2 was 
confirmed by co-immunoprecipitation using endogenous protein from wild-type cells. TG2 
externalisation was significantly decreased when LTA and tapasin were knockdown using 
siRNA suggesting that large T antigen and tapasin is involved in TG2 externalisation 
process. 
The possible TG2 externalisation pathway was explored further using fluorescent imaging 
including co-localisation analysis and live cell imaging. TG2 was predominantly co-localised 
with endoplasmic reticulum (ER) around the cell nucleus, but not localised with Golgi 
apparatus and lysosomes. We observed plasma membrane blebbing in the cells transfected 
with wild-type TG2 but not in the cells transfected withTG2 carrying a mutation in the export 
motif.  Plasma membrane blebbing or a direct molecular trap is the most likely mechanism 
for TG2 externalisation based on the data generated. 
In conclusion, the amino acid sequence 88-106 in β-sandwich domain of TG2 is critical to 
TG2 externalisation in TEC. This export motif binds to large T antigen and tapasin. Large T 
antigen and tapasin is involved in TG2 externalisation possibly through plasma membrane 
blebbing or direct molecular trap in TEC.   
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1.1 Chronic Kidney Disease 
Chronic kidney disease (CKD) is defined as functional or structural 
abnormalities of the kidney for at least 3 months (2002). Stage 1 is defined by 
an estimated glomerular filtration rate (eGFR) of >90 ml/min/1.73 m2 and either 
>20 mg/dl of albumin in the urine, an albumin/creatinine ratio ≥30 mg/g, or other 
evidence of structural damage to the kidney. Stage 2 has a similar definition, 
but an eGFR of 60–89. Stages 3, 4, and 5 are defined solely by an eGFR of 
30–59, 15–29, and less than 15, respectively (Table 1). The five-stage 
classification was developed through analysis of data from the National Health 
and Nutritional Examination Survey (NHANES), and is based on an eGFR 
(calculated from the serum creatinine level) and level of proteinuria. 
 
End-stage renal disease (ESRD) or Stage 5 CKD has reached epidemic 
proportion with over 1 million individuals affected worldwide.  The ESRD 
population is projected to reach 650,000 by 2010, but the rising ESRD 
population is just a small tip of the large CKD iceberg. For each patient with 
ESRD, there are more than 100 with various stages of CKD (reviewed in 2002). 
Based on the definitions of CKD, it is estimated that 13-16% of U.S. individuals 
 
Figure 1.1-1 Definition and stages of chronic kidney disease (CKD) 
(Modified from KDOQI CKD guideline 2002) 
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and 11.9% of the general population in Taiwan have CKD, however only half of 
the patients are aware of their kidney disease (Wen et al. 2008). According to 
the annual report of United States Renal Data System (USRDS), end-stage 
renal disease (ESRD) patients account for 0.16% of the population covered by 
health insurance in the USA, however, they consumed up to 6.9% of the total 
medical cost. The importance of CKD as a public health problem and an 
economic burden in every country can’t be over emphasised (USRDS 2009). 
In the previous century, infectious disease was the major cause of death and 
disability (Beaglehole et al. 2003). However, non-infectious diseases and 
non-communicable diseases such as diabetes, hypertension, metabolic 
syndrome, cardiovascular disease, and cancer have become the leading cause 
of death and morbidity during the 20th century (Beaglehole et al. 2003; Atkins 
2005). The prevalence of diabetes is increasing worldwide and 30% of patients 
with diabetic nephropathy eventually enter ESRD. Diabetes has become the 
major cause of ESRD as a result of a global pandemic of type 2 diabetes 
(USRDS 2009). In general diabetes, hypertension, and glomerulonephritis 
accounts for 90% of individual with ESRD (USRDS 2009). Although the 
etiology of CKD varies, renal fibrosis is the final pathway for every types of CKD 
(Meguid El Nahas et al. 2005; Liu 2006). 
1.1.1 Renal fibrosis and CKD 
Stage V CKD or ESRD was defined as a GFR less than 15 ml/min/1.73m2 when 
dialysis treatment or kidney transplantation is needed. Despite the large 
variations in the underlying diseases that cause ESRD, they all lead to an 
indistinguishable scared and fibrotic kidney (Klahr et al. 1988; Bohle et al. 1989; 
Strutz et al. 1995; Remuzzi et al. 1998). The fibrotic kidney or end-stage kidney 
is characterised by nephron loss, glomerulosclerosis, tubulointerstitial fibrosis, 
increased mesangial volume, expansion of extracellular matrix and capillary 
collapse (Melk et al. 2001; Hill et al. 2003). As the development of renal fibrosis 
is independent of the underlying diseases, this leads to speculation that there 
must be a common pathogenic pathway for renal fibrosis. More attractively, 
treatment targeted against renal fibrosis may stop the disease progression 
regardless of the underlying disease. 
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1.1.2 The mechanism of renal fibrosis 
Renal fibrosis is characterised by glomerular and interstitial fibrosis that leads 
to an excessive accumulation of extra-cellular matrix (ECM) components, renal 
parenchyma destruction, and a decrease of functional nephrons. Renal 
interstitial fibrosis is considered the hallmark of progressive renal disease. The 
cellular events and signalling mediators in renal fibrosis are summarized in 
Figure 1.1-2. The cellular events include mesangial and ﬁbroblast activation, 
tubular epithelial to mesenchymal transition, monocyte/macrophage & T-cell 
inﬁltration, and cell apoptosis (Liu 2004). Transforming growth factor-β (TGF-β) 
and its downstream Smad signalling play an essential role in kidney fibrosis 
(Hirschberg 2005; Liu 2006). TGF-β correlates with increasing renal fibrosis 
and the progress of kidney disease (Miyazaki et al. 1997; Spurgeon et al. 2005; 
van de Wetering et al. 2006). The inhibition of TGF-β may decrease renal 
fibrosis and preserve renal function (Petersen et al. 2008). Transfection of the 
TGF-β gene into rat glomeruli results in progressive glomerulosclerosis (Isaka 
et al. 1993) and mice transgenic to TGF-β develop spontaneous 
glomerulosclerosis (Kopp et al. 1996). Under the influence of TGF-β, renal 
tubular epithelial cells may transit into an embryonic phenotype. The process is 
called epithelial/endothelial mesenchymal transition (EMT). The tubular 
epithelial cells or glomerular endothelial cells acquire mesenchymal properties 
similar to those of fibroblasts and myofibroblasts (Fan et al. 1999; Lan 2003). 
Myofibroblast can also come from interstitial fibroblast or mesangial cells 
through TGF-β activation. Myofibroblasts synthesise large amounts of fibrillar 
collagens such as type I& III, but can also produce increased amounts of 
collagen IV, proteoglycans and fibronectin (Tomasek et al. 2002; Qi et al. 2006). 
The activated renal cells produce chemotactic cytokines, which guide 
inflammatory monocyte/macrophages and T cells to the injury site and result in 
infiltration of inflammatory cells. 
 5 
 
Smad refers to a large family of proteins which also includes Smad 
transcriptional corepressors such as SnoN (Ski-related novel gene, non 
Alu-containing), Ski (Sloan-Kettering Institute proto-oncogene), and TGIF 
(TG-interacting factor). The Smad signalling pathway can protect tissue from 
unwanted TGF-β reaction (Yang et al. 2003). The Smad signalling pathway is a 
critical pathway for TGF-β and angiotensin II to induce tubular 
epithelial-myofibroblast transdifferentiation in vitro (Fan et al. 1999; Lan 2003). 
 
Figure 1.1-2 The major cellular events and key signalling mediators in 
renal fibrosis 
Multiple cellular events and mediators interact in concert in renal fibrogenesis, often 
in a mutually stimulating manner. A stress on the cell results in the activation of 
TGF-β1/Smad activation that interacts with NF-κB and Akt & Bcl-2 signalling 
pathway. The activation of TGF-β1/Smad pathway initiates 
epithelial/endothelial-mesenchymal-transition (EMT) of epithelial cells into 
myofibroblasts. Loss of epithelial adhesion and interrupt of basement membrane 
(BM) are characteristics of EMT. Myofibroblast can be also transformed from in situ 
fibroblasts through the activation of cytokines released from monocyte & T-cell. 
These lead to the increase of extracellular matrix (ECM) protein 
accumulation/deposition and thus result in fibrosis formation. The final events of 
kidney fibrosis include loss of renal parenchyma tubular atrophy, loss of capillary 
and depletion of podocytes (Liu 2006). 
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1.1.3 Transforming growth factor-β (TGF-β) and TG2 
TG2 plays a role in the activation of TGF-β. TGF-β also actives the PI3K-Akt 
pathway and thus increases TG2 expression in human subconjunctival 
fibroblasts (Jung et al. 2007). TGF-β can be activated through the 
crossslinking of TG2, large latent TGFb1 complex and ECM proteins (Figure 
1.1-3). TGF-β is produced as dimeric precursors (Pro-TGF-β) and is 
intracellularly cleaved by furin into mature TGF-β ( 25 kDa)(Koli et al. 2001). 
The mature TGF-β is associated with latent associated peptide (LAP) to form 
the small latent complex that is biologically inactive. Latent TGF-β binding 
protein (LTBP) facilitates the extracellular secretion of the small latent TGF-β 
complex (Mangasser-Stephan et al. 1999) forming a large latent complex. One 
activation route for TGF-β is the crosslinking of the LTBP in this large latent 
complex into the extracellular matrix (ECM) by a TG2 dependent mechanism 
(Nunes et al. 1997). The large latent TGF-β complex is then cleaved by ECM 
proteinases such as plasminogen and the small latent TGF-β is released from 
the large latent complex (Godar et al. 1999). The small latent TGF-β then 
binds to Manossue 6 phosphate or IGF-II receptors on the cell surface where 
cell surface associated plasmin can cleave the LAP to release the active 
TGF-β1 dimer. The active TGF-β1 dimer binds to TGF receptors on cell 
surface and up regulates TGF-β synthesis that result in a positive feedback 
loop (Annes et al. 2003). These result in the activation of TGF-β and Smad 
pathway and thus initiate fibrogenic events including 
epithelial/endothelial-mesenchymal-transition, activation of myofibroblast, and 
an increase of ECM protein production as described in Section 1.1.2.    
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Figure 1.1-3 Extracellular processing of transforming growth factor beta 
(TGF-β) 
TGF-β is produced as dimeric precursors (Pro-TGF-β) and is cleaved by furin into 
mature TGF-β (25 kDa). The mature TGF-β associates with latency associated 
peptide (LAP) to form the small latent complex that is biologically inactive. Latent 
TGF-β binding protein (LTBP) facilitates the extracellular secretion of small latent 
TGF-β complex forming the large latent complex. The large latent complexes 
crosslinked to the extracellular matrix (ECM) by TG2 dependent linkage of LTBP to 
fibronectin and other ECM proteins. The large latent TGF-β complex is cleaved by 
ECM proteinases to release the small latent complex.  This is able to bind to 
mannose 6 phosphate and ILGF-2 receptors on the cell surface. One bound cell 
surface plasmin can cleave the LAP to release the active dimer. The active TGF-β  
binds to TGF receptor on cell surface. This not only up regulate TGF-β but also 
activate Smad pathway causing a range of fibrogenic responses such as 
epithelial/endothelial-mesenchymal-transition, increase the production of ECM 
proteins by fibroblasts (Gressner et al. 2002). 
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1.1.4 Mechanism for renal fibrosis - the role of extracellular matrix 
In response to renal damage, kidney tissue generates a series of repair and 
recovery processes to accelerate recover. Glomerular or interstitial 
inflammatory cells are activated and produce inflammatory and fibrotic 
cytokines. Thereafter, the mesangial cells, fibroblasts, and tubular epithelial 
cells undergo phenotypic activation or transition that result in extra cellular 
matrix (ECM) accumulation (Liu 2006). ECM in normal tissues is balanced by 
matrix production and degradation. The excessive ECM accumulation in renal 
fibrosis is caused by over production of ECM proteins and decreased 
degradation of ECM proteins. Plasminogen/plasmin and matrix 
metalloproteinase systems are proteolytic enzymes that able to degrade ECM. 
Plasminogen activator inhibitors and tissue inhibitor of matrix 
metalloproteinases (TIMP) inhibit these proteolytic enzymes, therefore 
increasing ECM accumulation. Excess accumulation of ECM leads to fibrous 
scars, distortions of normal kidney tissue, and a decrease in viable nephrons. 
The outcome for glomerular and tubular injury is dependent on whether healing 
or scarring occurs. The resolution of inflammatory infiltrate, prevention of 
excess ECM formation, and the removal of deposited ECM favour recovery 
from damage (El Nahas 2005). 
1.1.5 Renal fibrosis and tissue transglutaminase (TG2) 
The accumulation of ECM is central to the development of glomerulosclerosis 
and tubulointerstitial fibrosis (El Nahas 2005). The association between TG2 
and renal fibrosis is linked to its role in ECM accumulation.  TG2 crosslinks 
ECM proteins such as fibronectin, fibrinogen/fibrin, von Willebrand factor, 
vitronectin, dermatane sulfate proteoglycans, collagen I, III, IV, V, osteonectin, 
laminin, nidogen and osteopontin in the ECM (Aeschlimann et al. 2000). TG2 
crosslinking of the ECM renders it resistant to degradation by MMPs (Fisher et 
al. 2009).  Further TG2 accelerates the rate of ECM deposition by providing a 
none conventional deposition and stabilisation route. Together this causes 
increased accumulation of ECM (Fisher et al. 2009).  
In the rat 5/6 subtotal nephrectomy model of renal scarring, cells in areas 
showing fibrotic changes have higher TG2 activity while levels of TG2 and its 
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protein crosslink product, ε(γ-glutamyl) lysine, correlate with scar tissue 
formation suggesting the association between TG2 activity and the 
development of renal fibrosis (Johnson et al. 1997). The inhibition of TG2 
activity decreased the ECM accumulation and preserved renal function 
(Johnson et al. 2007). In CKD patients, TG2 activity is robustly associated with 
the development of kidney fibrosis regardless of the underlying renal disease 
(Johnson et al. 2003).  In the rat streptozotocin model of diabetic nephropathy, 
the development of diabetic nephropathy is associated with the activation of 
TG2 and the inhibition of TG2 decreases the ECM accumulation (Skill et al. 
2001; Huang et al. 2009). 
1.2 Transglutaminase 
1.2.1 Transglutaminase family 
Transglutaminases (TGs) were first found by Clarke et al in 1957 in guinea-pig 
liver (Sarkar et al. 1957). Ten years later, Pisano et al found a 
ε-(γ-glutamyl)lysine isopeptide bond in stable fibrin during blood clotting. This 
bond is characterized by an acyl transfer reaction between the γ-carboxamide 
group of peptide-bound glutamine and the ε-amino group of peptide-bound 
lysine (Pisano et al. 1968). The catalytic function of TGs is achieved through 
the cysteine active site to form an acyl-enzyme thioester intermediate with 
polypeptide-bound glutamine (Folk et al. 1977). As TGs have similar catalytic 
triad to papain, and papain-like cysteine protease, they are in the same 
structural classification in the protein database (Fesus et al. 2002). So far nine 
types of transglutaminase have been identified and the characteristics of them 
are shown in Table 2 (Lorand et al. 2003). 
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Blood-coagulation factor XIII is essential for blood coagulation and mutations of 
the encoding gene results in bleeding disorder (Haemophilia). TG1 is important 
in cell envelope formation in the differentiation of keratinocytes and erythrocyte 
membrane formation.  The mutation of TG1 gene is linked to ichthyosis (Laiho 
et al. 1997) and inhibition of TG1 results in severe skin disease such as 
parakeratosis (Harrison et al. 2007). The TG3 has a similar function to TG1 in 
skin maturation and integrity. The prostate secretary TG4 is essential for fertility 
in rodents (Dubbink et al. 1998). TG5 is associated with cornified envelope in 
the keratinocyte (Aeschlimann et al. 1998; Candi et al. 2001).  The 
physiological function for TG6 & 7 is unknown. Band 4.2 is an ATP-binding 
protein and may have a role in maintaining the shape of red blood cells. In 
Table 1.2-1 Characteristics of Transglutaminases Family 
(Lorand et al. 2003) 
Protein Synonyms MW Tissue 
expression 
Localisation Function 
Factor 
XIIIA 
Fibrin-stabilizing 
factor, Laki-Lorand 
factor, 
Pro-fibrinoligase, 
plasma pro-TG 
83 Platelets, 
astrocytes, 
dermal 
dendritic cells, 
chondrocytes, 
placenta, 
plasma, 
synovial fluid 
Cytosolic, 
extracellular 
Blood 
coagulation, 
bone growth 
TG1 TGK, kerationcyte 
TG, particulate TG 
90 Keratinocytes, 
brain 
Membrane, 
cytosolic 
Cell-envelope 
formation 
TG2 TGC, tissue TG 80 Ubiquitous Cytosolic, 
nuclear, 
membrane, 
cell surface, 
extracellular 
Multiple 
TG3 TGE, epidermal TG, 
callus TG, hair follicle 
TG, bovine snout TG 
77 Squamous 
epithelium, 
brain 
Cytosolic Cell-envelope 
formation 
TG4 TGP, prostate TG, 
vesiculase dorsal 
prostate protein 1 
(DP1), major 
androgen-regulated 
prostate secretory 
protein 
77 prostate Unknown Semen 
coagulation in 
rodents 
TG5 TGX 81 Ubiquitous 
except for the 
CNS and 
lymphatic 
system 
Unknown Unknown 
TG6 TGY Unknown Unknown Unknown Unknown 
TG7 TGZ 81 Ubiquitous Unknown Unknown 
Band 
4.2 
B4.2; ATP-binding 
erythrocyte 
membrane protein 
band 4.2 
72 Red blood 
cells, bone 
marrow, fetal 
liver& spleen 
Membrane Membrane 
skeletal 
component 
MW: molecule weight 
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comparison to other TGs, TG2 has a diverse range of functions. 
1.2.2 Transglutaminase Type 2 / Tissue transglutaminase (TG2) 
TG2 is a 76-kDa protein consisting of 686 amino acids and has peliotrophic 
function according to the location of cells. TG2 has four distinct domains 
(Figure 1.2-1): an N-terminal β-sandwich (with fibronectin and integrin binding 
sites), a catalytic core (containing the catalytic triad for the acyltransfer reaction 
and a conserved Trp277 essential for this catalytic activity (Murthy et al. 2002) 
and two C-terminal β-barrel domains (the second contains a phospholipase C 
binding sequence (Hwang et al. 1995). In cells with a relatively high intracellular 
calcium environment, TG2 can crosslink cellular proteins, modify proteins by 
amine incorporation, cause protein deamidation, and act as an isopeptidase 
(reviewed in Fesus et al. 2002). At the plasma membrane, TG2 can bind to and 
hydrolyse guanosine triphosphate (GTP) with an affinity similar to those of the α 
subunits of large heterodimeric G proteins and small Ras-type G proteins 
(Iismaa et al. 2000; Martinez-Salgado et al. 2008). TG2/Gh is involved in 
coupling the α1b- and α1d- beta adrenoreceptors, thromboxane, and oxytocin 
receptors to phospholipase C, thereby mediating inositol phosphate production 
in response to agonistic activation (Mehta et al. 2006). When TG2 binds to 
GTP/GDP, TG2 cannot catalyze protein cross-linking reactions, but calcium can 
reverse this inhibition and regulate the transamindation functions of the TG2 
 
Figure 1.2-1 Three-dimensional structure of TG2 (PDB ID:2Q3Z) 
The four structural domains are indicated by different colour: blue for the β-sandwich, 
red for catalytic core, yellow for β-barrel1 and green for β-barrel2 domain. TG2 is in its 
linear calcium activated shape (Pinkas et al. 2007). 
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(reviewed in Fesus et al. 2002). Such calcium-dependent activation of TG2 has 
been implicated in diverse biologic functions, such as differentiation, 
receptor-mediated endocytosis, cell adhesion, and induction of apoptosis 
(Mehta et al. 2006). Importin-3 may be an important transporter for the 
translocation of TG2 into the nucleus that is associated with cell apoptosis 
(Peng et al. 1999; Milakovic et al. 2004). As TG2 is majorly distributed in the 
cytosol fraction of the cells (Campisi et al. 2003; Shin et al. 2004) containing 
ribosomes and mitochondria, it is likely that TG2 is synthesised in the cytosolic 
free ribosomes of the cell. Glycosylation and disulfide bond are important 
process of post-translational protein modification for classical protein 
synthesised and transported through the Golgi/ER network. Although six 
potential glycosylation site were identified in TG2, TG2 is not glycosylated 
(Ikura et al. 1988). TG2 has a disulfide bond between two surface cysteine 
residues, C370 and C371, which causes the intervening peptide bond to 
assume a cis conﬁguration of TG2 (Pinkas et al. 2007). TG2 can be inactivated 
by the formation of a intra-molecular disulfide bond that is not related to the 
active cysteine (Connellan et al. 1969; Chung et al. 1970) and can be related 
to a redox features of TG2 (Begg et al. 2006). As disulfide bond can be formed 
in free ribosomes (Yin et al. 2004) and blocking Golgi/ER network did not stop 
TG2 synthesis and externalisation (Zemskov et al. 2011), the intra-molecular 
disulfide bond of TG2 does not suggested that TG2 is synthesised in rough ER 
and modified in Golgi network. It is possible that TG2 is synthesised in 
cytosolic ribosomes and externalised through an non-classical protein 
transport pathway. The activation of TG2 required a high calcium and low GTP 
environment (Achyuthan et al. 1987), thus most of TG2 is inactive in the cells 
where the calcium is low and the GTP is high. TG2 became active in 
extracellular environment where the calcium is high and GTP is low. 
Extracellular TG2 is more likely to be associated with fibrosis formation in 
human disease. 
1.2.3 TG2 externalisation and wound healing 
The externalisation of TG2 in epithelial cells is essential for ECM stabilisation, 
cell adhesion, migration, and remodelling. The major characteristics of wound 
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healing are inflammation, tissue formation / stabilisation, and remodelling 
(Verderio et al. 2004). In a broad definition, organ repair after injury is a form of 
wound healing and kidney fibrosis is faulty wound healing. The migration of 
cells into open wounds is dependent on transglutaminase-mediated (factor 
XIIIa) cross-linked ﬁbrin with incorporated plasma ﬁbronectin (Hoffner et al.). 
Fibronectin acts as a provisional matrix for cell migration and cell adhesion by 
interaction of its epitopes with transmembrane receptors such as syndecan-4. 
Cells within the thrombus, predominantly activated platelets, release many 
wound healing mediators (such as platelet-derived growth factor, PDGF) 
leading to the activation of macrophages and ﬁbroblasts (Nunes et al. 1997). 
Macrophages continuously play an important role in phagocytosis of 
microorganisms and remnants of the ECM as well as in the secretion of wound 
healing cytokines such as PDGF, vascular endothelial growth factor (VEGF) 
(Isaka et al. 1993), transforming growth factor (TGF-β) and basic and acidic 
ﬁbroblast growth factor (FGF), which all mediate the transition between 
inﬂammation and tissue repair. Fibroblasts migrate into the wound area and 
synthesise new ECM replacing the provisional matrix with a collagen matrix 
(Verderio et al. 2004). Matrix metalloproteases (MMPs) and tissue inhibitors of 
matrix metalloproteases (TIMPs) are responsible for matrix remodelling and 
create a path for cell migration in wound healing (Stetler-Stevenson 1999). 
As TG2 modulates cell-matrix interaction, ECM stability, and a variety of cell 
functions, TG2 also plays an important role in wound healing.  Activation of 
TGs is directly associated with wound healing and angiogenesis (Bowness et al. 
1988; Haroon et al. 1999) and the activation of the TG1 gene may facilitate skin 
repair (Inada et al. 2000). TG2 is able to bind fibronectin through a 
gelatin-binding domain (Turner et al. 1989; Jeong et al. 1995) and modify 
fibronectin matrix by calcium-dependent transamindation (Belkin et al. 2001; 
Gross et al. 2003). Many of TG2’s roles in wound healing are related to its 
binding to fibronectin. Another important pathway that TG2 is involved in during 
wound healing is through the activation of cytokines such as TGFβ1 related to 
cell inflammation, repair, proliferation, matrix formation, and neovascularisation 
(reviewed in Verderio et al. 2004). The role of TG2 in human disease is 
associated with its externalisation. 
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1.2.4 TG2 externalisation and atherosclerosis 
TG2 is expressed in endothelial cells, smooth muscle cells, fibroblasts and 
monocytes-macrophages (Thomazy et al. 1989). TG2 is increased in 
neointimal tissue of atherosclerotic coronary arteries with atherosclerosis 
progression. (Cho et al. 2008). Calcification lesions indicate the presence of 
atherosclerotic plaque and the calcification lesions are well co-localised with 
ε-(γ-glutamyl) lysine cross-link in the atherosclerotic lesion of the carotid artery 
(Matlung et al. 2009).  This suggests that TG2 is directly involved in the 
formation of atherosclerotic plaque. TG2 is involved in several steps in the 
pathogenesis of atherosclerosis including the response of endothelial cells to 
disturbed blood flow, monocyte attachment, vascular remodeling and plaque 
stability. TG2 was up-regulated by turbulent shear stress in the coronary artery 
endothelial cells (Ohura et al. 2003). Cell surface TG2 associates with 
integrins and is important for monocyte adhesion (Akimov et al. 2000) and 
transmigration (Thomas-Ecker et al. 2007). An arteries exposure to TG2 
results in arterial remodelling. The induced arteries remodelling can be 
blocked by TG2 inhibitor (Bakker et al. 2005). The cross-linking of extracellular 
proteins by TG2 is important for atherosclerotic plaque stability (Haroon et al. 
2001). TG2 must be transported to extracellular space to play its key role in 
atherosclerosis. 
1.2.5 TG2 externalisation and liver fibrosis  
In liver fibrosis, TG2 accumulates in the cells adjacent to fibrotic tissue with 
most of the TG2 from dying cells released into ECM (Piacentini et al. 1999). 
TG2 cross-linking plays an important role in the accumulation of ECM in liver 
cirrhosis (Grenard et al. 2001). Resolution of fibrotic tissue is dependent on 
TG2 cross-linking, hepatic satellite cells and protein accumulation in the ECM 
(Issa et al. 2004). Cell surface TG2 binds to integrin and provides a high 
binding affinity to fibronectin (Akimov et al. 2000). The fibronectin-TG2 complex 
binds to collagen in the extracellular matrix and the crosslinking of ECM 
proteins by TG2 causes the ECM to become resistant to degradation by MMP 
(Johnson et al. 1999). The fibronectin-TG2 complex is also important to cell 
migration, adhesion, and growth (Verderio et al. 2004). The externalised TG2 
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activates cytokines such as TGF-β, interleukin-6, and tumour necrosis factor-α 
that further induces the expression of TG2 and further increases fibrosis 
formation (Fesus et al. 2002). The role of TG2 in liver cirrhosis (fibrosis) is 
closely related to extracellular TG2. Therapy specific to TG2 externalisation 
therefore can be a potential treatment for liver cirrhosis. 
1.2.6 TG2 externalisation and Coeliac disease 
TG2 on the surface of intestine mucosa cells plays an important role in the 
pathogenesis of Coeliac disease (Dieterich et al. 1997; Molberg et al. 1998). 
Coeliac disease is a malabsorbtion syndrome and characterised by small 
intestine villi atrophy due to ingestion of dietary glutens. Individuals with HLA 
DQ2 (majority) and DQ8 (minority) are predisposed to the development of 
Coeliac disease. TG2 is involved in generating T cell stimulatory gluten 
peptides through deamidation of specific glutamines. , TG2 catalyses the 
transamindation (crosslinking) or deamidation of specific glutamine residues in 
proteins or polypeptides (Figure 1.2-2). At lower pH and a higher concentration 
ratio of glutamine/polyamines, TG2 tends to deamidation rather than 
transamindation (Sollid 2002). TG2 is located mainly extracellularly in the 
subepithelial region and is also found in the brush border (Halstensen et al. 
1993). 
Coeliac disease patients on a gluten-containing diet produce immunoglobin A 
and G autoantibodies that are specific to TG2 binding gliadin. Gluten with 
resistance to luminal and brush-border enzymes is transported across the 
mucosal epithelium as polypeptides. Gluten peptides are deamidated by 
extracellular TG2 and recognised by CD4+ T cells in the lamina propria. The 
deamidated gluten peptides are presented to CD4+ T cells by HLA-DQ2 or 
-DQ8 molecules on the cell surface of antigen-presenting cells (Sollid 2002).  
The presence of immunoglobin A auto-antibodies against TG2 can be a 
screening and diagnostic tool for Coeliac disease in clinical practice (Dieterich 
et al. 1997).  In cultured T cells from adult human Coeliac lesions, T cells 
predominantly recognise deamidated gliadin epitopes that are formed in situ by 
endogenous TG2 and inhibition of TG2 activity with cyst amine can reduce 
T-cell proliferative responses to deamidated gluten digests (Molberg et al. 
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2001). The TG2 inhibitor, 2-[(2-oxopropyl)thio]imidazolium inhibitor L682777, 
can prevent T-cell activation in vitro by keeping gluten peptides in the 
non-deamidated state (Maiuri et al. 2005) . So far the only clinical effective 
treatment for Coeliac disease is gluten-free diet.  This is typically bland and 
not well accepted by patients. Treatments that target TG2 externalisation may 
decrease TG2 related deamidation of gluten and prevent the serious 
autoimmune response that leads to Coeliac disease.  
  
 
Figure 1.2-2 Enzymatic action of TG2 in Coeliac disease 
TG2 catalyses the transamindation (crosslinking) or deamidation of specific 
glutamine residues in proteins or polypeptides. In lowering the pH and by 
increasing the concentration ratio of glutamine substrates to polyamines, the 
propensity for deamidation compared with transamindation is increased. (Sollid 
2002) 
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1.2.7 TG2 externalisation and cancer 
Cancer cells are characterised by an insensitivity to growth signals and 
evasion of apoptosis. These are critical for cancer cells to proliferate and 
infiltrate the surrounding tissue (Hanahan et al. 2000). Anti-cancer drugs such 
as adriamycin, actinomycin D, mithrimycin and bleomycin are the major 
treatment choices for cancer as these cytotoxic agents can induce apoptosis in 
cancer cells. Drug resistance is critical for cancer cells to survive during 
cytotoxic drug treatment and thus allow metastasise to distance sites. TG2 has 
been reported as a pro-apoptotic and anti-apoptotic protein (Melino et al. 1994; 
Boehm et al. 2002; Piacentini et al. 2002). The anti-apoptotic function of TG2 
might be related to drug resistance of cancer cells. TG2 is linked to an 
increase of cytotoxic drug resistance in some types of cancer cells including 
ovarian cancer (Cao et al. 2008), melanoma (Fok et al. 2006), glioblastoma 
(Yuan et al. 2005) and pancreatic ductal adenocarcinoma (Verma et al. 2006). 
In breast cancer cells, increased TG2 is linked to an increase in drug 
resistance (Mehta 1994) with inhibition of TG2 reversing the drug resistance of 
breast cancer cells (Kim et al. 2006). Metastatic cancer cells can expressed 
high levels of TG2 (Fok et al. 2006; Verma et al. 2006) and thus TG2 can be a 
prognostic markers in some cancers. TG2's anti-apoptotic role can be 
explained by the activation of prosurvival signal transduction pathways 
mediated by Ras-ERK (Antonyak et al. 2003), phosphoinositide-3-kinase 
(PI3K/Akt) (Antonyak et al. 2002) and nuclear factor-kappa B (NF-κB) (Mann et 
al. 2006) through the binding of TG2 and integrin (Gaudry et al. 1999; Janiak et 
al. 2006; Song et al. 2007). Extracellular TG2 is critical for cell adhesion 
through the binding of integrin, fibronectin and syndecans (Jones et al. 1997; 
Verderio et al. 2003; Thomas-Ecker et al. 2007). TG2 related adhesion may 
also contribute to the anti-apoptotic role of TG2. Anoikis is a programmed cell 
death induced by cells detaching from the ECM. Expression of TG2 protects 
cells from anoikis by increasing cellular adhesion (Verderio et al. 2003). This 
suggests that TG2 externalisation may be important for the anti-apoptotic role 
of TG2. As some anticancer drugs contain amines such as adriamycin, and 
bleomycin can be substrates for TG2 (Russell et al. 1982), it is possible that 
extracellular TG2 consumes the anti-cancer drugs by crosslinking the drug 
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with ECM protein and thus decrease the anti-cancers potency. 
However, other studies suggested that increasing TG2 expression is 
associated with an increase of apoptosis (TG2 as a pro-apoptotic protein) in 
some types of cell such as cervix adenocarcinoma, neuroblastoma cells 
(Piacentini et al. 1991) and hepatoma (Fukuda et al. 1994). The pro-apoptotic 
role of TG2 can be explained by the activation of Bax protein signalling 
pathway (Yoo et al. 2012). It was suspected that the pro-apoptotic role of TG2 
may be dependent on the location of TG2 in the cell i.e. cytosolic TG2 (Fesus 
et al. 2005; Gundemir et al. 2009; Piacentini et al. 2011). 
Angiogenesis is also an important step in the development of cancer as it 
prerequisite to vascularise the primary tumour and migration into blood which 
is the first step in metastasis. Angiogenesis involves vascular endothelial cell 
migration, proliferation, interaction with smooth muscle cells and fibroblasts 
(reviewed in Kotsakis et al. 2007). The increase of TG2 externalisation in 
fibrosarcomas stabilised the ECM and lead to inhibition of angiogenesis and 
tumour growth (Johnson et al. 1994; Jones et al. 2006). Targeting TG2 
externalisation therefore might be a potential treatment for cancer metastasis. 
1.2.8 TG2 externalisation and neurodegenerative disease 
Neurodegenerative diseases including Alzheimer's disease, Parkinson's 
disease and Huntington's disease, are characterised by the accumulation and 
deposition of neurotoxic protein aggregates in the brain parenchyma or 
neurons. In Alzheimer's disease, the protein aggregates are composed of 
primarily amyloid-beta protein that deposits in the brain parenchyma as senile 
plaques. In Huntington’s disease, the accumulated protein aggregates as 
neurofibrillary tangles in neurons and is called cerebral amyloid angiopathy or 
tau protein (Selkoe 1991). In Parkinson's disease, the characteristic 
intracellular Lewy bodies and Lewy neurites are aggregates of α-synuclein 
protein aggregates (Polymeropoulos et al. 1997). In Huntington's disease, the 
aggregates of protein are huntingtin protein in the neuron (Leavitt et al. 2001). 
TG2 externalisation seems particularly relevant to the formation of senile 
plaques in Alzheimer’s disease. Senile plaques and cerebrovascular amyloid 
angiopathy are pathological features of brain parenchyma for Alzheimer’s 
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disease.  Both senile plaques and cerebrovascular amyloid angiopathy are 
formed by extracellular deposition of aggregated amyloid-beta (Selkoe 1991). 
Amyloid-beta protein is a 4 kDa proteolytic cleavage product (Glenner et al. 
1984) of the amyloid-beta precursor protein. Amyloid-beta may play a role in 
neuronal outgrowth in normal brain; however, amyloid-beta interacts with itself, 
forms neurotoxic, insoluble aggregates in the brain parenchyma as senile 
plaques and accumulates in vessel wall as cerebrovascular amyloid 
angiopathy in Alzheimer's disease (Selkoe 1991; Selkoe 2000). Amyloid-beta 
is a good substrate for TG2 (Ho et al. 1994) and TG2 can catalyse the 
formation of amyloid-beta polymers (Dudek et al. 1994) in vitro. This suggests 
that TG2 may initiate the aggregation of amyloid-beta in Alzheimer’s disease. 
TG2 is linked to the development and pathology of Alzheimer’s disease. TG2 
level and TG2 activity are elevated in the brain cortex of individuals with 
Alzheimer’s disease compared to normal individuals (Johnson et al. 1997). In 
the brain of patients with Alzheimer’s disease, staining for TG2 and 
TG-catalyzed cross-links demonstrates co-localisation with amyloid-beta in 
senile plaques and cerebrovascular amyloid angiopathy lesions (Zhang et al. 
1998; Wilhelmus et al. 2009). In an in vitro cell model of Alzheimer's disease, 
amyloid-beta toxicity towards neuroblastoma cells was reduced by inhibiting 
TG2 activity using TG inhibitor monodansyl cadaverine (Wakshlag et al. 2006). 
Taken together, inhibition of TG2 externalisation may provide a novel 
therapeutic target for Alzheimer’s disease. 
1.2.9 TG2 externalisation pathway 
Inhibition of TG2 activity could be a novel treatment in fibrosis. The major 
disadvantage of existing chemical TG inhibitors is the lack of specificity for 
TG2 that has limited the clinical usefulness of these compounds (Siegel et al. 
2007). Nine transglutaminases have identified so far. Chemicals that inhibit 
TG2 also inhibit other transglutaminase such as Factor XIII and TG1. Inhibition 
of factor XIII leads to a tendency to bleed and haemophilia like syndrome 
(Nijenhuis et al. 2004; Ishida et al. 2010). Inhibition of TG1 may result in 
parakeratosis and skin disease (Harrison et al. 2007). The activity of all TGs 
relies on the core domain. TGs have a 70-80% similarity across the  
 20 
 
transglutaminase family (Grenard et al. 2001) and as such small molecule 
inhibitors that specifically target 1 family member may be impossible to find. 
TG2 is a protein without a leader sequence (Grundmann et al. 1986; Ichinose 
et al. 1986). Other proteins without a leader sequence, however, still can be 
secreted to extracellular space include interleukin-1β, fibroblast growth factor 
(FGF-2), etc (Nickel et al. 2008). As mentioned above, the development of 
specific inhibitors for TG2 is difficult because of the sequence similarity 
between transglutaminases in the catalytic core region. Therefore, another 
possible way to interfere with TG2 activity in fibrosis may be to prevent TG2 
externalisation by interfering with its extracellular trafficking mechanism. 
However, the mechanism of TG2 externalisation is unknown. Understanding of 
TG2 externalisation pathway is the first step for any treatment that targets TG2 
externalisation.  
1.3 Protein synthesis and targeting 
Proteins are organic molecules made of amino acids in a linear chain joined by 
peptide bonds (Lodish 2007). The default pathway for proteins without any 
sorting sequence is staying in the cytosol and waiting for a targeting signal. For 
proteins with a leader sequence such as MMSFVSL in the N terminal domain, 
the default pathway is through ER, Golgi, plasma membrane, and extracellular 
environment (Berg 2002) (Figure 1.3-1). The leader sequence is removed from 
the mature proteins in the ER lumen (Rothman 1994). Vesicles formed on the 
surface of rough ER carry these proteins, bud off from the rough ER, and enter 
the Golgi complex where protein glycosylation and phosphylation is completed. 
Specific vesicles carry proteins and bud off the Golgi complex forming 
lysosomes, peroxisomes, or travel to the plasma membrane secreting into 
extracellular space (Pfeffer et al. 1987). TG2 has no leader sequence and 
cannot be transported classically through this route (Grundmann et al. 1986; 
Ichinose et al. 1986). 
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Figure 1.3-1 Traditional protein cell externalisation through 
endoplasmic reticulum (ER) and Golgi apparatus  
Proteins with a leader sequence that target extracellular environment are 
synthesised at ribosomes on the endoplasmic reticulum (ER) membrane. The 
secretory protein enters the ER lumen due to leader sequence targeting. The 
leader sequence is then removed & the secretory protein matured before entering 
the Golgi apparatus where protein modifications such as glycosylation and 
phosphorylation are completed. The secretory protein is transported into 
secretory vesicles and the proteins are released to extracellular space following 
the fusion of secretory vesicles and plasma membrane. 
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1.3.1 Non-traditional protein transport pathways 
Initially, it was thought that cells released unconventional secretary proteins 
following exposure to either stress or mechanical injury only (reviewed in 
McNeil et al. 1989). However, later studies clearly showed that unconventional 
protein secretion occurs not only during inflammation and angiogenesis but is a 
temperature-sensitive and energy-consuming process (Hughes 1999; Nickel 
2003). Interleukin-1β was one of the first identified extracellular proteins that did 
not contain a leading signal peptide (Rubartelli et al. 1990), although it is 
ultimately secreted via a lysosome route.  
Blocking the ER/Golgi-dependent secretary pathway does not inhibit secretion 
of unconventional secretary proteins (Nickel 2003; Nickel et al. 2008). Four 
possible mechanisms for unconventional secretory pathways have been 
proposed (Figure 1.3-2) (Nickel 2005). 1. Lysosomes secretion, 2. Exosomes 
secretion, 3. Plasma membrane blebbing, and 4. Direct molecular trap.  
In terms of cell morphology, the first two pathways may also involve a vesicle 
formation in the protein externalisation process. Some of the extensively 
studied unconventional secretory proteins such as interleukin-1β (IL-1β) and 
fibroblast growth factor 2 (FGF-2) can be involved in more than one secretory 
pathways based on the organelles involved in extracellular trafficking. 
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Figure 1.3-2 Possible unconventional protein secretary processes 
Proteins were synthesised by the ribosomes in the cytosol and externalised 
through 1) Lysosomes 2) Multivesicular bodies (MVBs). MVBs (also known as late 
endosomes) are part of endocytic membrane transport pathway in which early 
endosomes matured into late endosomes. The membrane of MVBs comes from 
plasma membrane or endoplasmic reticulum during endocytosis. MVBs and 
endosomes can direct fuse with plasma membrane and release the secretary 
protein into extracellular space. 3) Plasma membrane blebbing. Proteins are 
transported to and associate with the plasma membrane. The plasma membrane 
then protrudes outside of the cell and proteins are secreted when the protruding 
plasma membrane where by it separates from the cell. 4) Direct molecular trap by 
plasma membrane-resident transporters. Plasma membrane-resident transporters 
may “grip” the secretory proteins and move it through the membrane either by a 
conformational change in the transporter. (Nickel 2005) 
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1.3.1.1 Lysosomes secretion 
The major function for conventional lysosomes is degradation of proteins. The 
unconventional secretory lysosomes are similar to conventional lysosomes in 
that they are acidic and contain degradative proteins that degrade other 
proteins (Blott et al. 2002). Secretory lysosomes can directly fuse with plasma 
membrane and release the containing protein into the ECM such as the 
secretory lysosomes from cytotoxic T lymphocytes and melanosomes of 
melanocytes (Stinchcombe et al. 2004). This process can be involved in 
traditional protein secretion and unconventional protein secretion such as 
interleukin-1β (IL-1 β). IL-1 β is one of the most well-known secretory protein 
without a leader sequence and has been suggested it  can be externalised 
both through lysosomes (Rubartelli et al. 1990; Andrei et al. 1999) and plasma 
membrane blebbing (MacKenzie et al. 2001). The IL-1β positive vesicles in the 
cytoplasm are positive for cathepsin D (a classical marker for late endosomes) 
and Lamp-1 (a classical marker for lysosomes) (Andrei et al. 1999). IL-1β has 
no signal sequences and is modified by adding a mannose 6-phosphate moiety 
during biosynthesis in the trans-Golgi network (Andrei et al. 2004). The 
mannose 6-phosphate moiety is recognized by mannose 6-phosphate receptor 
on lysosomes and imports proteins into secretary lysosomes. The mannose 
6-phosphate receptors cycle between Golgi apparatus and lysosomes 
(Seelenmeyer et al. 2008). Mannose 6-phosphate receptor on lysosomes 
therefore can continuously import IL-1β from the trans-Golgi network. 
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1.3.1.2  Exosomes secretion 
Exosomes derived from cortical ER 
Exosomes are released from the cell by fusion with the plasma membrane 
allowing the secretion protein within the exosome to be released into the 
extracellular space. Examples of proteins secreted through this mechanism 
include increased sodium tolerance protein 2 (Ist2) (Aronov et al. 2007) and 
Galectin-3 (Brian Henderson 2005). Ist2 can be directly transported from 
cortical ER to plasma membrane through an exosome that is formed by the 
membrane of cortical ER or a direction fusion of ER membrane and plasma 
membrane (McNew et al. 2000). The cortical ER is different from the rough ER 
where synthesis of proteins occurs. It is located in the peripheral area of the 
 
Figure 1.3-3 Lysosomes secretion of interleukin 1 beta (IL-1β) 
After being synthesised at the ribosome, IL-1β enters trans-Golgi network where 
mannose 6-phosphate moiety (M6P moiety) is added. M6P moiety binds to 
mannose 6-phosphate receptor (M6P receptor) on  the lysosomes membrane. 
IL-1β therefore enters lysosomes and secreted to extracellular space after 
lysosomes fuse with the plasma membrane. 
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cytosol. Ist2 is synthesised by ribosomes in the cytosol and then recruited by 
the COPI coat on the cortical ER membrane which will subsequently bud 
vesicles from the cortical ER (Bednarek et al. 1995). The ER-located v-SNARE 
and plasma membrane coated t-SNARE (McNew et al. 2000) mediate the 
fusion of cortical ER membrane and plasma membrane. 
 
Exosomes derived from multivesicular bodies (MVBs) 
MVBs are involved in cell autophagy; a cellular self-eating process in a basal 
and an activated state induced by starvation. Traditionally, autophagy is 
associated with packaging damaged cell components into double-membrane 
vesicles (autophagosomes) and the contents of autophagosomes are 
 
Figure 1.3-4 Exosomes derived from cortical ER 
After being synthesised in ribosomes, Ist2 is recruited by COPI on cortical ER 
membrane. The cortical ER membrane budding forms an Ist2 containing exosome. 
The exosome fuses with plasma membrane through v-SNARE on exosome 
membrane and t-SNARE on plasma membrane. Ist2 is therefore released in 
extracellular space.(Nickel et al. 2008) 
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degraded by fusion with lysosomes. Recent research has suggested a novel 
role of autophagy in unconventional protein secretion by extracellular delivery 
(reviewed in Manjithaya et al. 2010). Acyl-coenzyme (Co) A binding protein 
(ACBP) is an example for protein secreted through autophagy (Duran et al. 
2010).  ACBP enters autophagosome after being synthesised at ribosomes in 
the cytosol and the ACBP enters MVBs after autophagosomes fuse with MVBs 
(Figure 1.3-5). ACBP is secreted into extracellular space following MVBs fusion 
with the plasma membrane. The same process can be involved in endocytosis 
which is a process where cells absorb molecules such as protein. In 
endocytosis, the absorbed protein was uptaken by the plasma membrane and 
form endosomes that are intracellular vesicles containing the absorbed protein. 
Endosomes can be divided into early and late endosomes in the process of 
endocytosis. Endosomes are fused with lysosomes normally in the process of 
endocytosis. Late endosomes are also known as MVBs and the secretory 
proteins in MVBs can be secreted extracellularly while the MVBs fuse with the 
plasma membrane (Russell et al. 2006). 
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1.3.1.3 Plasma membrane blebbing 
A bleb is an irregular bulge of plasma membrane on the cell surface. The 
formation of a bleb is caused by localised decoupling of the cytoskeleton from 
the plasma membrane (Charras et al. 2008). Plasma membrane blebbing is a 
result of an imbalance between the inner leaflet and outer leaflet of membrane 
phospholipids (Sims et al. 2001). Blebbing and subsequent shedding can occur 
in all cell types under stress conditions or apoptosis (Freyssinet 2003; Martinez 
et al. 2005). During apoptosis the cells cytoskeleton breaks up which results in 
the plasma membrane bulging upward (Charras et al. 2006). 
 
Figure 1.3-5 Exosomes derived from multivesicular bodies (MVBs) or 
endosomes 
Exosomes can be derived from MVBs in autophagy. The secretory protein enters or 
is packed by autophagosome. The autophagosome fuses with MVBs and forms 
exosomes. The exosomes fuse with plasma membrane and released the secretory 
protein in to the extracellular space. 
Exosomes can also be derived from endosomes that is part of endocytosis. The 
protein is taken up by endosomes which mature into early endosomes. The early 
endosomes subsequently develop into late endosomes that also known as MVBs. 
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It has been suggested that Galectin-3 and FGF-2 can be externalised through 
plasma membrane blebbing. Galectin-3 aggregates underneath the plasma 
membrane (Figure 1.3-6) using an N-terminal acylation motif and is released by 
membrane blebbing (Mehul et al. 1997). FGF-2 can also be released from cells 
through microparticles that are vesicles released from plasma membrane 
blebbing (Taverna et al. 2003). The microparticles from the plasma membrane 
contain the secretory proteins and other markers from the origin cells (Mallat et 
al. 2000). Plasma membrane blebbing from the cells with a high level of 
transglutaminase expression has been observed in fibroblasts (Gentile et al. 
1992), but the association between plasma membrane blebbing and TG2 
externalisation is unknown. 
Microparticles are plasma membrane vesicles released into the ECM by 
plasma membrane blebbing. Microparticles are usually smaller than one 
micron and express a panel of phospholipids and proteins specific to the 
original cells (reviewed in Leroyer et al. 2008). Microparticles in circulation 
have a prognostic role in clinical conditions. For example the use of 
leukocyte-derived microparticles to predict arthrosclerosis (Chironi et al. 2006) 
and endothelial cell original microparticles to predict to acute coronary 
syndrome (Mallat et al. 2000). These microparticles bear tissue factor and can 
be captured by thrombus associated platelets, which in turn initiate coagulation 
and fibrin formation (Furie et al. 2004). Factor XIII is a member of the 
transglutaminase family which like TG2 does not have a leader sequence. 
Factor XIII can be found in the platelet derived microparticles (Garcia et al. 
2005) but it is not clear if this indicates that Factor XIII is externalised through 
plasma membrane blebbing and microparticles. 
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Figure 1.3-6 Protein secretion by plasma membrane blebbing 
Secretory proteins in the cytosol are accumulated in the sub-plasma membrane 
area due to interaction with a specific plasma membrane binding protein. The 
secretory proteins enter blebs in the plasma membrane. The bulging plasma 
membrane is separated from plasma membrane of the cells and forms 
microparticles. The secretory proteins then released to extracellular space.  
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1.3.1.4 Direction molecule trap 
Some complexes on the plasma membrane can directly bind proteins near the 
membrane and transport these proteins out of the cell. Fibroblast growth factor 
2 (FGF-2) is one example of a protein that is directly transported to the cell 
surface (Nickel et al. 2008). Three hypothesis mechanisms of FGF-2 
translocation was proposed in the later works by Nickel et al (2008) (Figure 
1.3-7). (a) Cytoplasmic FGF-2 is recruited to the inner leaﬂet by binding to 
phosphatidylinositol 4,5 bisphosphate [PI(4,5)P2]. Heparan sulfate 
proteoglycans (HSPGs) on the cell surface and FGF-2 receptors inside the cell 
surface form a molecular trap that can bind FGF-2 and drive FGF-2 
translocation cross plasma membrane. In model (b) and (c), no specific 
receptor is needed for FGF-2 translocation. The interaction between FGF-2 
and PI(4,5)P2 generates a cholesterol-dependent lipid microdomain that opens 
 
Figure 1.3-7 Possible mechanism for direct molecular trap 
A specific protein transport channel (A) is located on the plasma membrane. 
Phosphatidylinositol 4,5 bisphosphate [PI(4,5)P2] recruit FGF-2 to the sub-plasma 
membrane area. Heparin sulphate proteoglycans (HSPG) grapes FGF-2 
accumulated at the sub-plasma membrane area and FGF-2 is pulled through the 
plasma membrane by HSPG. PI(4,5)P2 formed a hydrophilic pore on the plasma 
membrane (B) that allows FGF-2 to pass through the plasma membrane and 
HSPG is responsible for the net extracellular trafficking of FGF-2. PI(4,5)P2 binds 
FGF-2 and guide FGF-2 translocation through the plasam membrane (C). HSPG 
also responsible for the net extracellular trafficking of FGF-2. (Nickel et al. 2008) 
 32 
 
the plasma membrane (Temmerman et al. 2008) or results in penetration 
through the lipid bilayer (Milburn et al. 2003). In model (b) and (c) HSPG 
ensure the net extracellular transport of TG2. HSPG is essential for these three 
proposed possible mechanisms of FGF-2 transport because the deletion of the 
C-terminus of FGF-2 prevents FGF-2 from binding to HSPGs and subsequently 
translocation cross plasma membrane. (Zehe et al. 2006). Although a direct 
molecular trap has been suggested as a potential unconventional protein 
secretion pathway; however, no direct visualisation of a direct molecular trap 
had been reported in the literature. 
1.3.1.5 Transport binding partners 
In the possible unconventional protein transport mechanisms mentioned above, 
binding partners play an important role in the transport of protein secreted. For 
example, FGF2 is recruited by PI(4,5)P2 on the inner side of the plasma 
membrane and exported through a direct molecular trap or a transport channel. 
Ist2 is recruited by the COPI coat on the cortical ER membrane and secreted to 
extracellular space by the fusion of ER membrane and plasma membrane. A 
mannose 6-phosphate moiety is added to IL-1β such that it can be recognized 
by mannose 6-phosphate receptor on lysosomes and imported into secretary 
lysosomes. TG2 may also have binding partners that lead to its externalisation, 
but the binding partners for TG2 have not been identified.  
1.3.2 Possible pathways for TG2 extra-cellular trafficking 
The mechanism for TG2 trafficking out of cells is unknown.  As TG2 does not 
have a leader signal peptide, it can’t proceed via ER/Golgi dependent 
N-glycosylation (Gentile et al. 1991) and inhibition of ER/Golgi pathway did not 
prevent TG2 extracellular trafficking (Zemskov et al. 2011). So far, several 
possible routes have been hypothesised in the literature, but there remains no 
conclusive evidence for these. 
1.3.2.1 TG2 extracellular trafficking by fibronectin co-transport 
Fibronectin is one of the better substrates for TG2 crosslinking in the 
extracellular matrix. Evidence suggesting TG2 is co-transported with 
fibronectin came from two studies. Cell surface localisation of TG2 is 
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dependent on fibronectin and the deletion of fibronectin binding site (the first 6 
amino acids) of TG2 in the N-terminal β-Sandwich domain has been shown to 
decrease TG2 expressed on cell surface (Gaudry et al. 1999). These two 
studies both measured TG2 on the cell surface. It is not clear if the cell surface 
TG2 can represent TG2 extracellular externalisation. It is possible that 
fibronectin retained TG2 on the plasma membrane, but not TG2 in the ECM. 
As fibronectin is transported through the conventional pathway, it is possible 
that TG2 binds to fibronectin and is co-transported with fibronectin though the 
ER/Golgi pathway. However, considerably more evidence is needed to support 
this hypothesis such as the co-localisation of TG2/fibronectin with Golgi 
apparatus. TG2 is not always secreted with fibronectin and is not activated by 
the same factors as fibronectin. Therefore, co-transport with fibronectin does 
not completely explain TG2 externalisation. 
1.3.2.2 TG2 extracellular trafficking using Syndecan and heparan 
sulfate proteoglycans as co-receptors for TG2 
The heparan sulfate proteoglycans (HSPGs) on the cell surface modulates a 
wide range of extracellular protein ligands which affect angiogenesis, blood 
coagulation, and tumour metastasis. Several families of cell surface HSPGs 
including transmembrane syndecans and the glycosylphosphoinositide-linked 
glypicans bind extracellular ligands and enhance formation of their 
receptor-signalling complexes (Bernfield et al. 1999).  TG2 has some affinity 
for heparin sulphate and heparin that is an analogue of the chains of HSPGs 
(Scarpellini et al. 2009).  In addition, the binding of TG2 to heparin does not 
affect the catalytic activity of TG2, but protects TG2 from thermal unfolding and 
proteolytic degradation (Verderio et al. 2008). Heparitinase digestion of 
cell-surface heparin sulfate impairs both RGD-independent cell spreading and 
actin assembly mediated by fibronectin-bound TG2 (Verderio et al. 2003). As 
FGF-2 may externalise through molecular trapping formed by HSPGs complex, 
it is possible that TG2 may also be transported through similar HSPGs 
complexes given its affinity to heparin. The association between fibronectin and 
TG2 in previous studies (Gaudry et al. 1999) may be explained by the peptide 
similarity of heparin sulphate proteoglycans and fibronectin (Nickel et al. 2008; 
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Verderio et al. 2008). 
HSPGs belong to the syndecan family of cell-surface receptors. There are 
three main subclasses that may potentially interact with TG2 (Bishop et al. 
2007). Syndecans’ can activate cell growth and survival factors such as FGF-2, 
heparin-binding epidermal growth factor (EGF)-like growth factor (Kleeff et al. 
1998) and transforming growth factor-β (TGF-β) (Filmus et al. 2001). This may 
explain to role of HSPGs in cancer. Syndecan-4 (S4), in particular is involved in 
controlling adhesive function and the regulation of cell behaviour in response to 
the external environment (Morgan et al. 2007) and has been postulated as a 
co-receptor for TG2 (Telci et al. 2008; Scarpellini et al. 2009). The S4 
cytoplasmic domain binds phosphatidylinositol 4,5, biphosphate and directly 
activates protein kinase Ca (PKCa) to promote cellular spreading. 
1.3.2.3 TG2 extracellular trafficking via Autophagy 
So far no study has demonstrated that TG2 can be externalised through 
exosomes or lysosome secretion pathways. However, exosomes and 
lysosome secretion can be linked together through autophagy to potentially 
define a TG2 externalisation pathway. Cell surface TG2 can be internalised 
through the endocytic receptor, low-density lipoprotein receptor-related protein 
1, and degraded in lysosomes (Zemskov et al. 2007). Endocytosis is a 
different direction of protein transport from protein externalisation. Autophagy 
can turn endocytosis into a protein externalisation process through the fusion 
of lysosomes and MVBs. It is possible that lysosomes that contain undegraded 
TG2 fuse with plasma membrane and release TG2 into extracellular space. 
Endocytosis related late endosomes are involved in TG2 externalisation 
through a phospholipid delivery system (Zemskov et al. 2011). However, the 
overall process seems to be related to TG2 recycling rather than TG2 
externalisation per se. As cell surface TG2 must be externalised first before 
endocytosis, the primary pathway for TG2 externalisation remains unknown. 
TG2 has been associated with autophagy because over-expression of TG2 is 
related to drug resistance in cancer cells through the inhibition of TG2 on cell 
autophagy in pancreatic cancer cells (Akar et al. 2007). The ablation of TG2 
results in an increase of immature autophagosomes formation (D'Eletto et al. 
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2009). However, it is unknown if TG2 can be externalised through autophagy.  
If TG2 is externalised through autophagy, it is expected that the 
over-expression of TG2 should increase autophagy and ablation of TG2 
should result in a decrease of autophagy. Therefore, TG2 seems to be a 
regulator for autophagy rather than being externalised through this process. 
1.3.2.4 TG2 extracellular trafficking via plasma membrane blebbing 
and microparticles 
Plasma membrane blebbing from the cells with a high level of transglutaminase 
expressed has been observed in fibroblasts (Gentile et al. 1992), but the 
association between plasma membrane blebbing and TG2 externalisation is 
unclear. Other transglutaminase such as TG4 do not have a leader sequence 
(Grant et al. 1994) and can be externalised in rodent prostate through bleb-like 
structures (Seitz et al. 1990). Another member of transglutaminase without a 
leader sequence, Factor XIII, can be found in the platelet derived 
microparticles formed by plasma membrane blebbing (Garcia et al. 2005). 
Could plasma membrane blebbing and microparticles can be a potential 
externalisation pathway for TG2? 
1.3.3 Concluding remarks 
In summary, it is likely that TG2 is externalised through an unconventional 
protein externalisation pathway. Being able to target such a pathway could 
provide a highly specific means of lowering TG2 extracellular activity through 
locking TG2 in the cells.  Such an approach could be a potential treatment for 
CKD and fibrosis.  
To target TG2 externalisation, we must understand the externalisation pathway. 
Most of the research regarding TG2 cell export and extracellular function has 
been performed in fibroblasts; however, numerous studies on tissue Sections 
have shown that fibroblasts produce less TG2 than epithelial cells especially in 
diseased states.  Pilot studies from our own lab have clearly shown that 
fibroblasts fail to release transfected TG2, withTG2 simply accumulating in the 
cytosol until export is induced by cell stress (Fisher 1973). Fibroblasts 
therefore may not be an ideal cell in which to study TG2 externalisation as a 
clean system can never be achieved due to the need to stress cells for release. 
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In contrast, the extracellular TG activity is usually positively correlated to 
intracellular TG activity in renal tubular epithelial cells (Fisher et al. 2009) 
where TG2 is known to be elevated in CKD. Previous studies on 
unconventional cell export routes suggest TG2 may have a specific sequence 
within the TG2 molecule that is essential for its externalisation.  In most of the 
unconventional secretory proteins, another binding protein is subsequently 
needed to recruit the protein to be exported from the cell into the sub-plasma 
membrane area for plasma membrane blebbing, cortical ER for exosomes, 
lysosomes and MVBs.   
It is therefore highly likely that TG2 has a similar motif within it that is essential 
for its export and this motif binds to a protein or other type of molecule that 
forms the start of an externalisation pathway which may or may not dip into 
either the conventional export pathway or one of the described unconventional 
export pathways. 
The purpose of this thesis is therefore to try and identify which parts of TG2 are 
needed for its export, what this sequence may interact with and subsequently 
try and visualise how TG2 is moved out of the cell to ultimately provide early 
clues as to the TG2 extracellular trafficking pathway in tubular epithelial cells  
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Chapter 2  
Aims 
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Hypothesis I 
TG2 is trafficked to the cell surface by a novel mechanism that relies on specific 
amino acid motifs within the TG2 molecule. 
To test this hypothesis we aim to 
1. Use deletion and point mutation analysis of transfected TG2 into 
renal tubular epithelial cells and asses TG2 externalisation by 
measurement of intracellular and extracellular TG activity and TG2 
antigen in 3 Tubular epithelial cell lines.  
2. Initially identify which domain of TG2 any export sequence resides in 
by generating domain deletion mutants of TG2 by systematically 
removing each domain.   
3. Once a domain is highlighted use point mutation analysis to ascertain 
the specific sequence involved for TG2 to be exported.  
 
Hypothesis II 
TG2 externalisation is dependent on another intracellular protein that can bind 
to the specific export sequence in TG2. 
To test this hypothesis we aim to 
1. Apply a yeast two hybrid screen to identified candidate proteins that 
bind to the amino acid sequence that is critical to TG2 
externalisation.  
2. Confirm interaction between candidate proteins and TG2  by 
co-immunoprecipitation from cells endogenous proteins.  
3. Establish if the candidate proteins binding to the TG2 export 
sequence are critical to  TG2 externalisation by knockdown of the 
candidate proteins with siRNA. 
 
Hypothesis III 
TG2 externalisation followed one of the four possible unconventional protein 
secretion pathways. 
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To test this hypothesis we aim to 
1: Generate constructs of TG2 that carry a tetracysteine tag that can be 
visualised using FlAsH and ReAsH staining.   
2: Use chronological imaging to track TG2s movement with time post 
transfection and combine with co-localisation analysis of various cell 
organelles to provide clues as to the export mechanism.   
3: Apply a combination of fixed and live cell imaging techniques to generate 
3 dimensional cell maps to show TG2 cellular movement and extracellular 
trafficking.  This will be undertaken  using deconvolution microscopy with  
3D image rendering software. 
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Chapter 3 Materials and Methods 
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List of buffer 
10x PBS 2 g KCl, 2.4 g KH2PO4, 80 g NaCl, 21.6 g 
Na2HPO4 (7H2O) to 1000 ml  
3H putrescine incorporation 
assay reaction buffer 
25 mM CaCl2, 38.5 mM Dithiothreitol, 12.2mM 
3H Putrescine, 25 mg/ml N N’-Dimethylcasein 
BCA solution A 1% (w/v) bicinchoninic acid, 2% (w/v) sodium 
carbonate, 0.16% (w/v) sodium tartrate, 0.4% 
(w/v) sodium hydroxide, 0.95% (w/v) sodium 
hydrogen carbonate 
BCA solution B 4% (w/v) copper sulphate 
Colorimetric assay reaction 
buffer 
13.3 mM dithiothreitol, 6.7 mM CaCl2, and 10 
µM biotin-TVQQEL in 100mM Tris-HCl 
Halotag binding buffer 100mM Tris-HCl, 150mM NaCl, 0.01% 
IGEPAL®  CA-630, pH 7.6 
LB medium 10 g tryptone, 5 g yeast extract, 10 g NaCl in 
950 ml ddH2O, pH 7.0 
NP-40 cell lysis buffer 50 mM Tris-HCl, 150 mM NaCl, 1% (v/v) NP-40, 
pH 8.0 
Protease inhibitors 1 mM leupeptin, 1 mM benzamidine, 1 mM 
phenylmethylsulphonylfluoride (PMSF) in STE 
buffer 
SOC medium 20 g tryptone,5 g yeast extract, 0.5 g  NaCl, 
0.186 g KCl, 0.952 g MgCl2 in ddH2O to 1000 ml 
pH 7.4 
STE buffer 0.32 M sucrose, 5 mM Tris, 2 mM EDTA 
TBST 20 mM Tris, 150 mM Sodium Chloride, 0.1% 
(v/v) Tween 20, pH 7.6 
TE buffer 10 mM Tris-HCl, pH 8.0, 1 mM EDTA 
WB Reducing buffer 10 mM Tris (pH 6.8), 2.5% (w/v) SDS, 10% (v/v) 
glycerol, 0.02% (w/v) bromophen blue, 5% (v/v) 
β-mercaptoethanol 
WB Transfer buffer 39 mM glycine, 48 mM Tris, 20% (v/v) methanol 
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3.1 Molecular Biology techniques 
3.1.1 Plasmids and plasmid Systems 
3.1.1.1 TOPO Plasmids 
The TOPO group of vectors are designed to allow high speed, correct 
orientation insertion of cDNA into plasmids that then facilitate rapid switching of 
that sequence into other vectors based on using Gateway®  Cloning 
Technology (Figure 3.1-1). This provides a fast, room temperature cloning 
reaction with a high efficiency deliver the clone and maintains orientation. The 
insert DNA can be shuttled from one expression vector to another expression 
vector as needed. The pENTR/D-TOPO plasmid (Figure 3.1-2) (Invitrogen, UK) 
utilise a highly efficient, 5-minute cloning strategy ("TOPO®  Cloning") to 
 
Figure 3.1-1 Schematics of Gateway®  Cloning Technology 
Vectors contain attL (L1 & L2) sequences for recombination into any destination 
vector. The PCR products containing attB sequences (A) can be cloned into the 
pENTR/D-TOPO vector in the correct orientation. The PCR insert can also be 
cloned into any TOPO-adapted entry vector (B) or a traditional ligase reaction 
(C). Adapted from Invitrogen user manual. 
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directionally clone a blunt-end PCR product into a vector for entry into the 
Gateway®  System or the MultiSite Gateway®  System. Blunt-end PCR 
products clone directionally at greater than 90% efficiency, with no ligase, 
post-PCR procedures, or restriction enzymes required. The sequence of 
proteins can be cloned into this entry vector and transfer to other expression 
vectors using Gateway®  system. 
 
  
 
Figure 3.1-2 DNA map of pENTR/D-topo vector 
attL1 and attL2 sites: bacteriophage λ-derived recombination 
sequences that allow recombinational cloning of a gene of interest in 
the entry construct with a Gateway destination vector (Landy, 1989). 
TOPO cloning site allows rapid, directional cloning of the PCR 
product. The insert DNA sequence can be checked using T7 promoter 
and M13 reverse primer. Kanamycin resistance gene allows selection 
of the plasmid in E. coli. pUC origin of replication allows high-copy 
replication and maintenance in E. coli. 
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3.1.1.2 Tetra cysteine tagging mammalian expression plasmids 
Two vectors that add a 4 cysteine residues (ie a tetra cysteine tag) to the protein 
to be expressed have been used in this study. pcDNA6.2/nTC-Tag-DEST for 
N-terminal tagging and pcDNA6.2/cTC-Tag-DEST for C-terminal tagging 
(Figure 3.1-3)  (Invitrogen, UK) with a  tetracysteine tag (CCPGCC) were 
used in this study. Both vectors can be labelled with the green-fluorescent 
FlAsH-EDT2 reagent or the red-fluorescent ReAsH-EDT2 reagent. The main 
advantages of tetracysteine tag is that it is very small will have little effect on 
protein externalisation or movement through the cell and that FlAsH and 
ReAsH reagents can be used in live cells. Double staining with FlAsH and 
ReAsH can be used for tracking TG2 externalisation chronologically as once 1 
die has bound to the tag, the other can not. Therefore for example a protein 
synthesised in 24 hours can be labelled green with FlAsH, so that any new 
protein synthesised say between 24 to 48 hours can be labelled with ReAsH – 
thus older protein appears green and newer red. 
 
  
 
Figure 3.1-3 DNA map of N- and C-terminal tetracysteine tag vectors 
Human cytomegalovirus (CMV) allows efficient, high-level expression of the 
recombinant protein. The gene of interest  was cloned into attR1 and attR2 site 
that can be transcripted using T7 promoter. A V5 epitope was also fused with 
protein of interest and tetracysteine tag can be detected using FlAsH (green) 
and/or ReAsH reagent. Cells with stable expression of proteins can be selected 
using blasticidin resistance gene. 
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3.1.1.3 HaloTag Mammalian expression vector 
pFC14K HaloTag®  CMV Flexi®  Vector is a HaloTag fusion vector. HaloTag can 
be used to immobilise the protein of interest using resin or magnetic beads. 
 
  
 
Figure 3.1-4 DNA Map of pFC14K HaloTag®  CMV Flexi®  Vector 
expression of C-terminal-tagged HaloTag®  fusion proteins in mammalian cells. 
Once expressed, the HaloTag®  fusion protein may be used for cell imaging of 
protein localization or trafficking in conjunction with the fluorescent HaloTag®  
Ligands. In addition, the HaloTag®  fusion protein can be purified or pulled down 
as a complex with its protein partners such as TG2. 
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3.1.2 Polymerase Chain Reaction (PCR) 
3.1.2.1 Basics of PCR 
The polymerase chain reaction is a technique that amplify a single or a few 
copies of a piece of DNA across several orders of magnitude and generate 
thousands to millions of copies of a particular DNA sequence (Bartlett et al. 
2003). 
3.1.2.2 PCR general protocol 
Phusion high-fidelity DNA polymerase (Finnzymes, Finland) was used for all 
PCR reactions. 50 µl of a PCR reaction mix was made by mixing the 
following in order: 35.5 µl distilled water, 10 µl of 5x Phusion HF buffer, 1 μl 
of 10 mM dNTPs, 0.5 μl of 50 μM forward primer, 0.5 μl of 50 μM reverse 
primer, 10 ng of template DNA, 1.5 μl of DMSO, and 0.5 μl of Phusion DNA 
polymerase and making up to 50 µl with ultrapure endonuclease free water. 
The PCR reaction was run using a thermocycler (gene cycler, Bio-rad, UK) 
with the following settings: 1 cycle of 98ºC for 30 seconds, 35 cycles of 
(98ºC for 10 seconds, 55ºC for 30 seconds, and 72ºC for 30 seconds), and 
72ºC for 10 minutes. 
3.1.3 Insertion of PCR products into vector 
All PCR products was purified using a PCR clean-up system (A9281, Promega) 
and cloned into an entry vector (pENTR™/D-TOPO® ) using the 
pENTR™/D-TOPO®  Cloning kit (K2400-20, Invitrogen). 2 µl of PCR product 
obtained from the PCR reaction was mixed with 1 µl salt solution, 1µl 
pENTR™/D-TOPO vector (15 ng/μl), 4 µl sterile water and incubated for 5 
minutes at room temperature. 2 µl of this cloning reaction was then mixed with 
competent TOP10 E. coli (C4040-03, Invitrogen) and incubated on ice for 30 
minutes followed by 30 seconds of heat-shock at 42ºC, 250 µl of SOC (Super 
Optimal Broth) medium (20 g tryptone,5 g yeast extract, 0.5 g  NaCl, 0.186 g 
KCl, 0.952 g MgCl2 in ddH2O to 1000 ml pH 7.4) was added to the E. coli and 
the tube was shaken horizontally (200 rpm) at 37ºC for 1 hour on an orbital 
shaker (Kika Labortechnik KS250 basic). 100 µl of the transformation was 
spread on a LB plate containing 50 µg/ml kanamycin and incubated overnight 
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at 37ºC. Colonies forming (ie containing the kanamycin resistance gene) were 
picked the next day and grow in 10 ml LB medium containing 50 µg/ml 
kanamycin overnight at 37°C on an orbital shaker. 850 µl of this culture was 
added to 150 µl of sterile glycerol, mixed by vortexing and stored at -80°C. The 
remainder of the culture was used to prepare a small scale plasmid preparation 
(Section 3.1.9) to verify successful transformation. 
3.1.4 Preparation of Competent Cells 
A glycerol stock of the JM109 strain of E.coli was streaked on a LB [1% (w/v) 
bactotryptone, 0.5% (w/v) yeast extract, 1% (w/v) sodium chloride, pH 7.0] agar 
plate and the plate incubated at 37°C overnight. A colony was transferred to 5 
ml of LB media and the culture incubated at 37°C with shaking at 250 rpm for 3 
hours on an orbital shaker (Kika Labortechnik KS250 basic). The culture was 
transferred to 200 ml LB media and incubated overnight with shaking at 300 
rpm until an absorbance of 0.6 at 600 nm. The culture was kept on ice for 15 
minutes, divided into four 50 mL sterile centrifuge tubes, and centrifuged at 
2,500 g for 10 minutes in 4°C. The cells were resuspended in 15 ml pre-cooled 
0.1 M calcium chloride by gentle pipetting, left on ice 15 minutes, and 
centrifuged at 2,500 g for 10 minutes in 4°C. The cells were suspended in 4 ml 
pre-cooled 0.1 M calcium chloride/15% (v/v) glycerol, and left on ice for 4 hours. 
The cells were dispensed in 50 µL aliquots and frozen at -80°C. 
3.1.5 LR Recombination for the transfer of sequences in D-TOPO 
vectors to expression vectors  
The LR Recombination reaction was used to transfer the cDNA insert (Gentile 
et al. 1991) from the entry vector to the expression vector. Gateway®  LR 
Clonase®  enzyme mix contains a proprietary blend of Int (Integrase), IHF 
(Integration Host Factor) and Xis (Excisionase) enzymes that catalyze the in 
vitro recombination between an entry clone (pENTR/D-TOPO containing TG2 
or TG2 mutants flanked by attL sites) (Figure 3.1-5) and a destination vector 
(containing attR sites, pcDNA6.2/nTC-Tag-DEST or pcDNA6.2/cTC-Tag-DEST) 
to generate the expression clone (Figure 3.1-6). 
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LR recombination reaction was performed using LR clonase II enzyme mix 
(11791-020, Invitrogen). 100 ng of the vector obtained from the previous 
section in entry vector: pENTR/D-TOPO (Figure 3.1-5) was mixed with 100 ng 
of expression vector (pcDNA6.2/nTC-Tag-DEST or pcDNA6.2/cTC-Tag-DEST) 
(Figure 3.1-6), 6 µl TE buffer, pH 8.0 and incubated at 25ºC for 1 hour. 1 µl of 
Proteinase K solution (to degrade native proteins) was added to each reaction 
and the reaction was incubated for 10 minutes at 37ºC. 1 µl LR recombination 
reaction was then transferred to 50 µl of competent JM109 E. coli and 
incubated on ice for 30 minutes followed by a 45 seconds of heat-shock at 
42ºC and then placed on ice for 2 minutes, 250 µl of SOC medium was added 
to the E. coli and the tube was shaken horizontally (200 rpm) at 37ºC for 1 hour 
on an orbital shaker (Kika Labortechnik KS250 basic). 100 µl of the 
transformation was spread on a LB plate containing 100 µg/ml ampicillin and 
incubated overnight at 37ºC. The ampicillin resistant colonies were picked the 
next day and grown in 10 ml LB medium containing 100 µg/ml ampicillin 
overnight at 37°C on an orbital shaker with shaking at 200 rpm. 850 µl of this 
 
Figure 3.1-5 DNA map for D-TOPO entry vector with different TG2 
constructs 
D-TOPO entry vector containing full length human TG2 (TG2), TG2 with the 
β-sandwich domain deleted (-bsw), TG2 with β-barrel 2 domain deleted (-b2), TG2 
with both β-barrels removed (-b1b2),TG2 with the β-sandwich domain and β-barrel 
2 removed (-bwb2) and the core domain of TG2 (core). 
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culture was added to 150 µl of sterile glycerol mixed by vortexing and stored at 
-80°C. The remainder of the culture was used to prepare a small scale plasmid 
preparation (Section 3.1.9) to verify successful transformation. 
3.1.6 Site-directed mutagenesis 
The QuickChange Site-Directed Mutagenesis kit with Pfu turbo polymerase 
(Stratagene, UK) was used as per manufacturer’s instructions. The reaction 
was prepared by mixing 5 μl 10× reaction buffer, 20ng pcDNA6.2/ 
cTC-Tag-DEST containing full length TG2, 125 ng forward primer, 125ng 
reverse primer (Chapter 5.3), 1 μl dNTP mix and ddH2O to a final volume of 50 
μl. Then 1 μl PfuTurbo DNA polymerase (Stratagene, UK) was added to the 
mix. The PCR reaction was run using a thermocycler (gene cycler, Bio-rad, UK) 
with the following settings: segment 1: 1 cycle of 95ºC for 30 seconds, segment 
2: 12 cycles of (95ºC for 30 seconds, 55ºC for 1min and 68ºC for 16minutes). 
Segment 2 was adjusted according to the type of point mutations: 12 cycles 
were used for 1 point mutation and 18 cycles for two point mutations. The 
 
Figure 3.1-6 DNA map for pcDNA6.2/cTC-Tag dest with different TG2 
constructs 
pcDNA6.2/cTC –tag-dest vector containing full length human TG2 (TG2), TG2 with 
the β-sandwich domain deleted (-bsw), TG2 with β-barrel 2 domain deleted (-b2), 
TG2 with both β-barrels removed (-b1b2),TG2 with the β-sandwich domain and 
β-barrel 2 removed (-bwb2) and the core domain of TG2 (core). 
 50 
 
reaction was placed on ice for 2 minutes. 1 µl of Dpn I restriction enzyme was 
added in each PCR reaction and mixed by pipetting. After spin down the 
reaction mix, the reaction was incubated at 37°C for 1 hour to digest the 
parental supercoiled dsDNA. 1 µl of the Dpn I-treated DNA was added to 50 µl 
JM109 E. coli and incubated on ice for 30 minutes followed by a 90 seconds of 
heat-shock at 42ºC and then placed on ice for 2 minutes, 250 µl of SOC 
medium was added to the E. coli and the tube was shaken horizontally (200 
rpm) at 37ºC for 1 hour on an orbital shaker (Kika Labortechnik KS250 basic). 
100 µl of the transformation was spread on a LB plate containing 100 µg/ml 
ampicillin and incubated overnight at 37ºC. The colonies were picked on the 
next days and grown in 10 ml LB medium containing 100 µg/ml ampicillin 
overnight at 37°C on an orbital shaker with shaking at 200 rpm. 850 µl of this 
culture was added to 150 µl of sterile glycerol mixed by vortexing and stored at 
-80°C. The remainder of the culture was used to prepare a small scale plasmid 
preparation (Section 3.1.9) to verify successful transformation. As β-sandwich 
domain is critical for TG2 externalisation (Section 4.3), point mutation of amino 
acid Asp94 and/or Asp97 to Ala (Hang et al. 2005) was used to determine to 
effect of aa 88-106 (2nd fibronectin binding site in β-sandwich domain) on TG2 
externalisation (Section 5.3). 
Table 3.1-1 Primers for deletion and point mutations 
 Constructs Forward primer Reverse primer 
-7a Remove first 7 
aa of 
β-sandwich 
domain 
CACCGAGAGGTGTGATCT
GGAGCT 
AAATCCGCCCCGGTTACTA
CTGT 
f1 88WTATVVAQQ
DCTLSLQLTT106 
CAGCCACCGTGGTGGCC
CAGAAAGACTGCAC 
GTGCAGTCTTGCTGGGCC
ACCACGGTGGCTG 
f2 88WTATVVDQQ
ACTLSLQLTT106 
TGGTGGACCAGCAAGCCT
GCACCCTCTCGCT 
AGCGAGAGGGTGCAGGC
TTGCTGGTCCACCA 
f3 88WTATVVAQQ
ACTLSLQLTT106 
CAGCCACCGTGGTGGCC
CAGCAAGCCTGCACCCTC
TCGCT 
AGCGAGAGGGTGCAGGC
TTGCTGGGCCACCACGGT
GGCTG 
f1: single point mutation of Asp94 to Ala, f2: single point mutation of Asp97 to Ala , f3: a 
two point mutation of TG2 at Asp94& Asp97 to Ala 
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3.1.7 Construction of pFC14K vector containing TG2 fragments 
In results (Chapter 5.3) a TG2 export amino acid export sequence was 
identified. To generate a protein of this export sequence that can be 
immobilised a HaloTag label was used.  HaloTag labelled proteins can then 
be pulled out by using HaloTag magnetic beads separated using SDS-PAGE 
and then examined by western blotting, silver staining or mass spectrometry.  
Here the β-sandwich domain, the TG2 export motif spanning amino acids 
88-106 within the β-sandwich domain identified in Chapter 5.3 and the TG 
catalytic core were placed into a HaloTag vector. 
Constructs using TG2 cDNA (Gentile et al. 1991) were generated by PCR 
(Section 3.1) using suitable primer pairs. The PCR products were inserted into 
the HaloTag plasmids using the Flexi enzyme blend system (SgfI and PmeI, 
R1851, Promega). 250 ng of PCR product was digested with 4 µl Flexi enzyme 
blend and 4 µl 5X Flexi digest buffer at 37ºC for 30 minutes. Meanwhile, 2 µl 
pFC14K (HaloTag 7) CMV flex (G9661, Promega, UK) vector (Figure 3.1-7) 
was digested with 2 µl Flexi enzyme blend and 2 µl 5X Flexi digest buffer in 12 
µl nuclease-free water at 37ºC for 30 minutes. The enzyme was inactivated by 
20 minutes incubation at 65ºC. The ligation of PCR product and pFC14K 
 
Figure 3.1-7 DNA map for pFC14K HaloTag®  CMV Flexi®  Vector 
pFC14K HaloTag CMV Flexi vector containing the β-sandwich domain (bsw), the 
TG2 export motif aa 88-106 (motif) or the core domain of TG2 (core) 
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vector was performed by mixing 10 µl 2X Flexi ligase buffer, 5 µl digested 
vector, 100 ng of digested PCR product & 1 µl T4 DNA ligase. The reaction 
was incubated at room temperature for 1 hour and 1 µl reaction mix was 
transferred to JM109 competent cells. The JM109 E. Coli was incubated on ice 
for 30 minutes followed by a 45 seconds of heat-shock at 42ºC and then 
placed on ice for 2 minutes, 250 µl of SOC medium was added to the E. coli 
and the tube was shaken horizontally (200 rpm) at 37ºC for 1 hour on an orbital 
shaker (Kika Labortechnik KS250 basic). 100µl of the transformation was 
spread on a LB plate containing 50 µg/ml kanamycin and incubated overnight 
at 37ºC. Discrete colonies were picked the next day and grown in 10 ml LB 
medium containing 100 µg/ml kanamycin overnight at 37°C on an orbital 
shaker at 200 rpm. 850 µl of this culture was added to 150 µl of sterile glycerol 
mixed by vortexing and stored at -80°C. The remainder of the culture was used 
for a small scale plasmid preparation (Section 3.1.9) to verify successful 
transformation. 
3.1.8 Sub cloning and propagation of bacterial colonies 
A single colony of transformed bacteria was picked from agar plates and used 
to inoculate 10 ml of LB medium containing 50 µg/ml of ampicillin or kanamycin 
depending on the resistance carried by the transforming vectors. The culture 
was incubated at 37°C overnight with shaking at 250 rpm. 850 µl of this culture 
was added to 150 µl of sterile glycerol, mixed by vortexing and stored at -80°C. 
The remainder of the culture was used in a small scale plasmid preparation to 
verify successful transformation. The identity of all cDNA constructs was 
confirmed by DNA sequencing (Core Genomic Facility of the University of 
Sheffield) using a T7 Promoter primer following restriction mapping. 
3.1.9 Small scale plasmid preparation 
Small scale plasmid preparation was performed using the Wizard Miniprep 
DNA Purification System (Promega). 10 ml of cells were centrifuged at 2,500 g 
(Fisons MSE) for 15 minutes, supernatant removed and the cell pellet 
suspended in 250 µl cell resuspension solution by pipetting. Cells were lysed in 
250 µl of cell lysis solution and mixed by inverting the tube 4 times. 10 μl of 
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alkaline protease solution was added in the lysate, mixed by inverting the tube 
4 times, and incubated for 5 minutes at room temperature. The bacterial lysate 
was neutralised by 350 µl of neutralisation solution and centrifuged at 5,000 g 
for 10 minutes at room temperature. In the meantime, plasmid DNA purification 
units were prepared by inserting one spin column into one 2 ml collection tube 
for each sample. The cleared lysate was transferred to the prepared spin 
column by decanting and centrifuged for 1 minute. The spin column was 
washed twice, firstly with 750 µl then 250 µl of column wash solution and 
centrifuged at maximum speed for 1 minute. The spin column was transferred 
to a sterile 1.5 ml tube and the DNA was eluted by the addition of 100 µl 
nuclease-free water followed by centrifugation at 10,000 g for 1minute.  
3.1.10 Large scale plasmid preparation 
Large scale plasmid preparation was performed using the PureYield Plasmid 
Maxiprep System (Promega). 200 ml of bacterial cells culture overnight were 
centrifuged at 5,000 g (Beckman J25) at room temperature for 10 minutes. 
After removal of the supernatant, the cell pellets were completely resuspended 
in 12 ml cell resuspension solution. The cells were lysed in 12 ml cell lysis 
solution, neutralised using 12 ml neutralisation solution, and centrifuged at 
5,000 g (Jouan A14) at room tempature for 15 minutes. A column stack was 
assembled by placing a blue PureYield™ clearing column on the top of a white 
PureYield™ maxi binding column. The assembled column stack was placed 
onto the vacuum manifold and the clarified supernatant applied to the DNA 
binding column after passage through a clearing column. The binding column 
was washed with 5 ml of endotoxin removal wash and 20 ml of column wash. 
After the membrane of the binding column was dry, the binding column was 
placed into a new 50 ml disposable centrifuge tube and the DNA was eluted by 
adding 1 ml nuclease-free water and centrifuging at 1500 g for 1 min. 
3.1.11 Agarose gel electrophoresis 
All DNA was separated on a 1% (w/v) agarose gel prepared in 1× TAE buffer 
[40 mM Tris, 0.1% (v/v) glacial acetic acid, 1 mM EDTA, pH8.0]. Ethidium 
bromide was added to the gel at a final concentration of 0.5 µg/ml prior to 
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pouring. 2 µg of DNA (5 µl) was mixed with 1 µl of 6X DNA loading dye 
(Promega) and the mixture was loaded onto the gel. 8µl of BenchTop 1 Kb DNA 
ladder (Promega) was loaded and the gel was electrophoresed at 100 V (Model 
1000/500 Power Supply, Biorad) until the bromophenol blue front had run 3/4 of 
the length of the gel. The DNA was visualised on a transilluminator and the 
image was documented using Kodak EDAS 290 Electrophoresis 
Documentation System (Kodak DC 290 Zoom Digital Camera, light shroud, 
and Kodak_1D software). 
3.1.12 Restriction Mapping of DNA Construct inserted into vectors 
To confirm that the various TG2 constructs used were inserted in the correct 
orientation in vectors post ligation, restriction mapping of DNA construct was 
performed for every entry and expression vectors. The restriction site and the 
size of fragment after digestion were calculated for each construct in its correct 
orientation (Table 3.1-2 &  
Table 3.1-3). 5 µg of plasmid DNA was digested with 6 units of restriction 
enzyme at 37°C for 2 hours and run on a 1% (w/v) agarose gel (Section 3.1.11). 
The identity of all cDNA constructs was confirmed by DNA sequencing (Core 
Genomic Facility of the University of Sheffield) using a T7 Promoter primer and 
TK poly A Reverse primer following restriction mapping.  
Table 3.1-2 Restriction mapping of TG2 in TOPO and Entry plasmids  
Construct 
D-TOPO pcDNA6.2 
Enzyme/Buffer Fragment 
(Reverse) 
Enzyme/Buffer Fragment 
(Reverse) 
tg NotI/XbaI/D 604/4040 
(1483/3161) 
NotI/EcoRV/D 1330/6634 
(748/7216) 
-bsw PvuI/XbaI/D 2187/2028 
(734/3481) 
SmaI/EcoRV/M 2705/4830 
(2061/5474) 
-b2 PvuI/Tth111I/C 1748/2632 
(1274/3106) 
SmaI/EcoRV/M 1668/6076 
(2516/5208) 
-b1b2 PvuI/BstX1/D 1851/2145 
(985/3011) 
NotI/EcoRV/D 1330/5950 
(68/7212) 
-bwb2 NotI/StuI/D 962/2977 
(420/3719) 
NotI/EcoRV/D 913/6346 
(421/6838) 
core PvuI/NaeI/M 1851/2145 
(985/3011) 
NotI/EcorV/D 901/5950 
(68/6789) 
-7a NotI/XbaI/D 583/4040 
(1483/3140) 
NotI/EcoRV/D 1309/6634 
(748/7195) 
Restriction enzymes, buffers, and predicted DNA fragment sizes for restriction 
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mapping of the following TG2 sequences (Gentile et al. 1991) in TOPO and entry 
vectors tg: full length of TG2 cDNA, -bsw: TG2 with β-sandwich domain missing, -b2: 
TG2 with β-barrel 2 missing, -b1b2: TG2 with both β-barrels missing, -bwb2: tg with 
β-sandwich and barrel 2 domains missing, core: tg core domain, M: multi-core buffer 
 
Table 3.1-3 Restriction mapping of TG2 in tagging plasmids 
Construct Enzyme/buffer Fragment 
Halotag7-bsw BstX I/ Not I/ buffer D 1584/3880 
Halotag7-core EcoR V/ Not I/ buffer D 1541/4510 
Halotag7-motif BstX I/ Not I/ buffer D 1491/3619 
pGBKT7-motif BstX I, buffer D 2273/5071 
LT-Myc Hind III, buffer D 1182/5136 
Motif-HA Pst I, buffer H 1396/4082 
Restriction enzymes, buffers, and predicted DNA fragment sizes for restriction 
mapping of the following TG2 sequences in various tag vectors. Halotag7-bsw: 
β-sandwich domain with HaloTag, Halotag7-core: core domain with HaloTag, 
Halotag7-motif: motif 88-106 with HaloTag, pGBKT7-motif: pGBKT7 vector containing 
motif 88-106, LT-Myc: origin binding domain of large T antigen protein with Myc tag, 
Motif-HA: motif 88-106 with HA tag 
3.2 Cell Culture 
3.2.1 Cell lines 
Opossum proximal tubule cells (OK cells) (Malstrom et al. 1987) and NRK-52E 
tubular epithelial cells (de Larco et al. 1978) were obtained from the European 
Cell Culture Collection.  MDCK II cells were a gift from N. Simmons (University 
of Newcastle, Newcastle, UK) and NRK-49F renal fibroblasts were a gift from 
Dr. Jill Norman (UCL, London). 
3.2.1.1 Validate the renal tubular epithelial cell lines 
To validate if the cells used in this study are tubular epithelial cells, electron 
microscopy images were obtained (With the assistance of Mr Bart Wagner, 
Histopathology, NGH) with classical characteristics of microvilli and 
microvesicles (Figure 3.2-1). 
To confirm all cells used retained the characteristics of tubular epithelial cells 
(TECs), markers for tubular epithelial cells including β-catenin and E-cadherin 
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were used. OK, NRK52E and MDCKII cells were incubated with anti-β-catenin 
antibodies and anti-E-cadherin antibodies followed by FITC secondary 
antibodies (Section 3.4.14). NRK49F (fibroblast) cells were used as negative 
controls. β-catenin and E-cadherin were highly expressed in OK (Figure 3.2-2 
A&B), NRK52E (Figure 3.2-2.C&D) and MDCKII (Figure 3.2-2 E&F) cells in a 
pericellular pattern. The green fluorescence is mainly found between cells 
because β-catenin and E-cadherin are markers for cell junctions. In contrast, 
β-catenin and E-cadherin green fluorescence was localised in the cytosol in 
NRK49F fibroblasts (Figure 3.2-2 G&H). This result confirmed that cell lines 
used in this study had the typical characteristics for tubule epithelial cell. 
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Figure 3.2-1 Electron microscopy images of tubular epithelial cells 
(TECs) 
Transmission electron microscopy images for microvilli and microvesicles in TECs 
including OK (A), NRK52E (B) and MDCK II (C) cells 
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Figure 3.2-2 β-catenin and E-cadherin staining in renal tubular 
epithelial cells (TECs) 
β-catenin and E-cadherin staining (green) in OK (A,B), NKR52E (C,D) 
and MDCKII cells (E, F) showed a peri-cellular distribution that is the cell 
junction. β-catenin and E-cadherin stains in NRK49F (G, H) fibroblast are 
localised in the cytosol. The cell nucleus was stained with DAPI in blue 
 
 59 
 
3.2.2 Cell culture media 
OK cells were cultured in Dulbecco’s Modified Eagles Medium (DMEM) 
containing 584 mg/L L-glutamine, 5% (v/v) heat inactivated foetal calf serum, 
100 IU/ml penicillin, and 100 µg/ml streptomycin. 
NRK-52E, MDCKII, and NRK-49F cells were cultured in Dulbecco’s Modified 
Eagles Medium (DMEM) containing 584 mg/L L-glutamine, 10% (v/v) heat 
inactivated foetal calf serum, 100 IU/ml penicillin, and 100 µg/ml streptomycin. 
All cultures were maintained at 37ºC and in a humidified atmosphere of 5% CO2 
in air. 
3.3 Transfection of tubular epithelial cells (TEC) 
3.3.1 Lipofectin 
1 × 105 Cells were seeded into a 6-well plate and allowed to attach overnight at 
37°C after which they reached about 60% confluency. 10 µl of lipofectin reagent 
(Invitrogen, UK) was diluted in 100 µl of Opti-MEM reduced serum medium 
(Invitrogen, UK) and incubated at room temperature for 45 minutes. 2 µg of 
vector was diluted in 100 µl of Opti-MEM medium. The lipofectin and DNA 
solutions were combined and incubated at room temperature for 15 minutes. 
Meanwhile, cells were washed once with 2 ml of Opti-MEM medium. 0.8 ml of 
Opti-MEM medium was added to the DNA and lipofectin complexes, and added 
to the cells. The cells were incubated at 37°C overnight. Media was removed 
and replaced with complete media. The cells were incubated at 37°C for a total 
of 48 hours before analysis. 
3.3.2 Lipofectamine 2000 or LT1 
2×105 Cells were seeded into a 6-well plate and allowed to attach overnight at 
37°C after which they reached about 90% confluency. 4 µg of DNA and 10 µl of 
Lipofectamine 2000 (11668-027, Invitrogen, UK) or LT1 (MIR 2300, Geneflow, 
UK) was diluted in 50 µl of Opti-MEM reduced serum medium (Invitrogen, UK) 
separately with 5 minutes of incubation at room tempature. The Lipofectamine 
2000/LT1 and DNA mix were combined and incubated at room temperature for 
20 minutes. The DNA and Lipofectamine 2000/LT1 complexes were added to 
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the cells with 0.9 ml of Opti-MEM medium. The cells were incubated overnight. 
The Opti-MEM medium was replaced with complete media after a overnight 
incubation and the cells were incubated at 37°C for a total of 48 hours before 
analysis. 
3.3.3 Transfection using nucleofection  
1 × 106 harvested cells were resuspended in 100 µl Ingenio electroporation 
solution (Geneflow, UK) containing 5 µg of DNA (or with 8 µg of siRNA) and 
transferred to a 0.4 cm cuvette. The cuvette was inserted in nucleofector 
(Nucleofector I device, Amaxa, UK). The optimal programs were A-20 for OK 
cell, L-05 for MDCK II cell line and X-01 for the NRK-52E cell line. The cells 
were rinsed in complete culture media, transferred to 6-well culture plate and 
incubated at 37°C for 48 hours before analysis. 
3.3.4 Optimise transfection protocols in renal epithelial cells 
To determine the relative levels of transfection using different transfection 
methods (lipofectin, lipofectamine 2000, LT-1 & Amaxa Nucleofector), the 
transfection efficiency for each method in each cell line was determined by the 
measurements of both TG activity and the percentage of cells positive for 
fluorescently labelled TG2 following transfection of pcDNA6.2/cTC-Tag-dest 
vector containing full length TG2 cDNA (Gentile et al. 1991). The percentage 
of green fluorescent positive was calculated from the number of cells with 
FlAsH positive (see Section 3.4.14) compared to the total cell number in 10 
randomly selected fields using a 10x objective lens. 50% of OK cells were 
positive for green fluorescent protein using lipofectin, lipofectamine 2000, LT1 
reagent (Figure 3.3-1 A). The percentage of green fluorescent positive was 
slightly higher for OK cells transfected by nucleofection (program A-20) (Figure 
3.3-1 A). There was no difference between with Amaxa solution V and Ingenio 
solution. The transfection efficiency for NRK52E and MDCK II cells using 
lipofectin was 20%. The transfection efficiency increased to 50% using 
lipofectamine and LT1 reagents (p=0.01, t-test). Nucleofector with amaxa 
solution V or Ingenio solution (program X-01 for NRK52E and L-05 for MDCKII 
cells) further increased the transfection efficiency to 60% (p=0.03 and 0.05) 
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compared to lipofectamine 2000 and LT1 (Figure 3.3-1 C&E). 
A significantly increase in TG activity was found in OK cells transfected with 
TG2 tetracysteine tag vector using lipofectin, lipofectamine 2000, LT1 and 
nucleofector protocols. The TG activity increase 20 folds for OK cells 
transfected with nucleofector compared to the cells without transfection (Figure 
3.3-1 B). For NRK52E (Figure 3.3-1 D) and MDCKII (Figure 3.3-1 F) cells 
transfected with TG2 tetracysteine tag vector using lipofectin reagent, no 
significant differences in TG activity compared to cells without transfection can 
be detected. This can be explained the endogenous TG2 of the cells or the 
expression of pcDNA6.2/cTC-Tag-dest vector in a protein level. Transfection 
with lipofectamine 2000 and LT1 reagent resulted in a 5 to 10 fold increase in 
TG activity (p=0.02). Transfection using nucleofector method resulted in a 10 to 
15 fold increase of TG activity comparing to the cells without transfection 
(p=0.05 compared to LT1 and lipofectamine 2000). 
As transfection using the nucleofector with the Ingenio solution showed similar 
transfection efficiency and TG activity to that of Amaxa solution V, 
nucleofection with Ingenio solution with program A-20 for OK, X-01 for 
NRK52E and L-05 for MDCKII cells was used in the study. 
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Figure 3.3-1 Comparison of Transfection efficiencies using different 
transfection reagents 
OK, NRK52E and MDCKII cells transfected with TG2 tetracysteine tag vectors  
pcDNA6.2/cTC-Tag-dest vector containing full length TG2 cDNA using different 
transfection methods were analysed 48 hours post transfection. The percentage 
of fluorescently positive cells in 10 random 100X fields was calculated in OK (A), 
NRK52E (C) and MDCKII (E) cells. Total TG activity (B) measured by 3H 
putrescine incorporation assay (section 3.4.5) using different transfection 
methods was used to evaluate transfection efficiency in tubular epithelial cells. wt: 
cells without transfection, LP: lipofectin, LM: lipofectamine, LT1: LT1 reagent N1: 
Amaxa solution V, N2: Ingenio solution. Data represents mean ±SEM, n=5, 
*:p<0.05 
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3.3.5 Stable transfection in NRK 52E cells 
The vector we chose to use for stable expression of various TG2 constructs 
was the pcDNA 6.2 cTC-Tag vector. This contains the blasticidin resistance 
gene. Therefore to determine the dose of blasticidin required for the selection 
of stably transfected NRK52E cells, a blasticidin cell survival curve was 
generated against increasing does of blasticidin. No wild type NRK52E cells 
can survive in a 5 µg/ml blasticidin for more than 2 days or in 2 µg/ml 
blasticidin for more than 5 days (Figure 3.3-2). 5 µg/ml of blasticidin followed 
by 2 µg/ml blasticidin after 5 days was used for the selection of stably 
transfected cells. 
  
 
Figure 3.3-2 Cell survival curve according to blasticidin doses 
Cells were trypsinised using 1x trypsin/EDTA, then resuspended in 10 ml of 
medium and counted using a hemocytometer. Cells counts according to 0-5 µg/ml 
of blasticidin in the media up to 7 days were recorded. 
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3.3.6 Selection of cell lines to study TG2 extracellular trafficking 
To explorer the mechanism of TG2 externalisation, using a cell in which 
increasing intracellular TG2 has a direct effect on the amount of TG2 exported 
is highly preferable as it means no further stimulus (or confounding factor) is 
required. The total TG activity of the cell lysate (the amount of TG2 inside the 
cells) (Figure 3.3-3 A), extracellular TG activity (the amount of TG on cell 
surface) (Figure 3.3-3 B) and TG activity in the culture media (the amount of 
TG2 outside the cells) (Figure 3.3-3 C) were measured in response to 
increasing amounts (5, 10, 15, 20 µg) of tetracysteine tag vector with full length 
TG2 cDNA was transfected in 5 cell lines. The extracellular TG activity and TG 
activity in the medium showed no changes in NRK49F and 1097 cells 
according to the different levels of TG2 inside the cells (Figure 3.3-3). This 
suggested that TG2 transport in NRK49F and 1097 cells were not correlated to 
the amount of TG in the cells. OK, NRK52E and MDCKII cells had a clear 
correlation between of transported TG2 and the amount of TG2 in the cells. 
Therefore, OK, NRK52E and MDCKII cell lines were selected for studying TG2 
externalisation.  
 65 
 
 
 
Figure 3.3-3 Select cell line for studying TG2 externalisation 
TG activity in the cell lysate (A) (the amount of TG2 in the cells), extracellular TG 
activity (B) (the amount of TG2 on cell surface/ outside the cell) and TG activity in 
the medium (C) (the amount of TG2 outside of the cells) for OK, NRK52E, 
MDCKII, NRK49F, 1097 cells in response to transfection with a different amounts 
of tetracysteine tag TG2 expression vector pcDNA6.2/cTC-tag-DEST (0, 5, 10, 
15 and 20 µg). Data represent mean±SEM, n=5 
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3.4 General and Biochemical Techniques 
3.4.1 Preparation of cell lysates 
Cells were trypsinised using 2x trypsin-EDTA solution (Invitrogen, UK) (2% v/v) 
for 5 minutes at 37ºC. These were resuspended in the same volume of 
complete media and centrifuged at 400 g (Fisons MSE) for 5 minutes at room 
temperature. The media was removed and cells centrifuged at 400 g (Jouan 
A14 microfuge) for 2 minutes to produce a cell pellet. After the removal of 
excess media, cells were resuspended in 100 μl of STE buffer (0.32M sucrose, 
5mM Tris, 2mM EDTA) containing protease inhibitors [1 mM leupeptin, 1 mM 
benzamidine and 1 mM phenylmethylsulphonylfluoride (PMSF)] (Sigma, UK). A 
cell lysate was produced by sonicating (Qsonica sonicator 3000) the cells for 
3×5 seconds at 40kHz, 25% amplitude on ice. For immunoprecipitation, the 
cells were lysed using NP-40 cell lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 
1% (v/v) NP-40, pH 8.0) with protease inhibitors added before use 
(11836170001, Roche, UK).  
3.4.2 Preparation of media samples 
Cells were grown to confluency, the media removed and replaced with 400µl of 
serum free culture medium into each well in a 6-well plate. The medium was 
collected and centrifuged at 10,000 g in a Jouan A14 microfuge for 10 minutes. 
The supernatant was used for analysis. To determine the time at which the 
most TG activity (measured as showed in section 3.4.4) was present in the 
medium once fresh medium is added, at 48 hours post transfection of a TG2 
expression vector, serum free medium was added and incubated for 2, 4, 6, 8, 
10, 12 and 16 hours at 48 hours post transfection. Peak TG activity is seen 
after 4 to 6 hours (Figure 3.4-1) that is consistent with the half-life of TG2 
(Fesus et al. 1989) and thus 4 hours was used for all subsequent study. 
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3.4.3 Protein knock-down by siRNA 
The cells were co-transfected with 5 µg of plasmid DNA plus either 300 nM of 
nonsense siRNA or the selected siRNA with TG2 cDNA using the Amaxa 
Nucleofection using the optimised program for the expression vector. The 
siRNA used included anti-fibronectin 1 siRNA (s130401, Applied Biosystems, 
UK), anti-tapasin siRNA (sc42938, Santa Cruz biotechnology, UK), 
anti-translocon-associated proteins siRNA (sc63149, Santa Cruz biotechnology, 
UK) and anti-large T antigen siRNA (applied Biosystems, UK). The selected 
siRNA consist of five target-specific 19-25 nt siRNA. 
The TG activity of the cell lysates, extracellular TG activity, antigen and TG 
activity in the culture medium were measured 48 hours after transfection.  The 
knock down of fibronectin in the cell lysate was determined by fractionation of 
the cell lysate on a 7.5% (v/v) SDS-PAGE gel in reducing buffer followed by 
western blot analysis for fibronectin. The knock down of LTA, tapasin and 
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Figure 3.4-1 TG activity in serum free culture medium incubation for 
0-16 hours 
48 hours post transfection, the culture medium was replaced with 400µl of serum 
free medium and incubated for 0-16 hours. The TG activity of the culture medium 
was measured in OK, NRK52E and MDCKII cells. TG activity in culture medium 
can be measured in 4 & 6 hours of incubation. Data are expressed as mean±SEM, 
n=5 
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translocon-associated proteins in the cell lysate was also determined by 
western blot analysis but using 10% (v/v) SDS-PAGE gels.  
3.4.4 Total transglutaminase activity by colorimetric assay 
Total TG activity was measured by the incorporation of Biotinylated TVQQEL 
peptide into casein as described by Trigwell (Trigwell et al. 2004). A 96-well 
plate was pre-coated with casein at 1 mg/ml in 50mM sodium carbonate and 
kept overnight at room temperature. The next day, the casein solution was 
discarded and the wells were washed with distilled water. 250 µL of blocking 
solution [0.1% BSA (w/v) in 50 mM sodium carbonate] was added into every 
well and incubated at 37°C for 1 hour. After 3 wash of distilled water, 150 µL of 
reaction buffer (13.3 mM dithiothreitol, 6.7 mM CaCl2, and 10 µM 
biotin-TVQQEL in 100 mM Tris-HCl) were added in each well. The reaction was 
started by adding 50 µL of cell lysates into each well and incubated for 1 hour at 
37°C. After 3 wash of distilled water, 200 μl of 1 in 5000 diluted 
Extravidin-peroxidase in blocking solution was added into every well and 
incubated 1 hour at 37°C. After 3 wash of distilled water, the extravidin binding 
is revealed by adding 200 μl of 3,3’,5,5’ tetramethyl benzidine (TMB) solution to 
each well. The colour was developed after 5-15 minutes at room temperature 
and the colour development was stopped by adding 50 μl of 2.5 M H2SO4. The 
resulting colour was then read in an ELISA plate reader (Labsystems Multiskan 
Ascent) using Genesis Software (version 3.05) at 450 nm. A standard curve 
(Figure 3.4-2) was obtained using Guinea pig liver transglutaminase (T006. 
Zedria) (0.0001, 0.0025, 0.005, 0.01, 0.025 and 0.05 IU per well) showing a 
linear response between 0.0001 and 0.05 IU. The expression of total TG 
activity was calculated in unit of TG activity/mg of protein. 
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3.4.5 Total transglutaminase activity by 3H putrescine incorporation 
assay 
In the presence of Ca2+, active transglutaminase uniquely incorporates 
3H-putrescine into N’N-dimethylcasein forming a radioactive trichloroacetic acid 
(TCA)-insoluble material capable of being detected by scintillation counting.   
50 µl of cell lysate was added to 50 µl of reaction solution (Table 3.4-1).  A 
background control in which calcium was replaced with EDTA was used to 
determine non-enzymatic incorporation. Samples and controls were incubated 
at 37ºC for up to 60 minutes. At set time points (0, 20, 40, and 60 minutes) after 
initiation of the reaction, 10 µl aliquots in duplicate were removed from the 
tubes and dotted on to 1 cm2 Whatman 3MM filter paper. The filter papers were 
immediately dropped into 10% (w/v) TCA to stop the reaction and precipitate 
protein. This was followed by a further wash with 10% (w/v) ice cold TCA for 10 
minutes, 5% (w/v) ice cold TCA 3 times for 5 minutes, 100% (v/v) ethanol for 5 
minutes and drying. To determine efficiency of counting, a 10 µl aliquot was 
 
Figure 3.4-2 Standard curve for colorimetric assay 
A standard curve of total TG activity measured by colorimetric assay using 
Guinea pig liver transglutaminase (T006, Zedria).The A450nm and TG2 
activity data forms a linear correlation between 0.0001 to 0.05 IU.  
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dotted on to two filter paper squares and not washed. These two filter papers 
represent the total counts in the samples. Filter papers were allowed to air dry 
before being placed in 2 ml of Ultima Gold Liquid scintillation fluid (Packard) 
and radioactive incorporation measured by scintillation counting on a Rack 
Beta liquid scintillation counter (Packard Instruments, UK). The gradient 
(change in cpm per hour) was calculated which was subsequently used to 
calculate TG activity. Values were corrected for protein and expressed as nmol 
of putrescine incorporated per hour (unit of activity per mg of protein: IU/mg 
protein). A cell lysate was prepared using sonicating in 100 μl of STE buffer 
(Section 3.4.1.) 
Table 3.4-1 Constituents of a TG activity assay reaction solution 
Per sample Per control 
Reagent Volume Reagent Volume 
25 mM CaCl2 5 µl 100 mM EDTA 5 µl 
38.5 mM Dithiothreitol 5 µl 38.5 mM Dithiothreitol 5 µl 
12.2 mM 3H Putrescine 5 µl 3H 12.2 mM Putrescine 5 µl 
25 mg/ml N 
N’-Dimethylcasein 
10 µl 25 mg/ml N 
N’-Dimethylcasein 
10 µl 
Total volume 25 µl Total volume 25 µl 
12.2mM 3H Putrescine was made by mixing 1ml of 59.8mM Putrescine in 1.05M 
Tris-HCl pH 7.4 and 2ml 3H putrescine (1:2), CaCl2, N N’-Dimethylcasein and 
dithiothreitol were made in 50mM Tris-HCl pH 7.4, EDTA was made in 1.05M Tris-HCl 
pH 7.4.  
3.4.6 Measurement of Total TG activity using 3H putrescine 
incorporation assay and colorimetric assay 
The 3H putrescine incorporation assay is more sensitive and the gold standard 
assay for Total TG activity measurement; however, the 3H putrescine 
incorporation assay is very expensive and is complicated by the need to use 
radioactive isotopes. To determine if the colorimetric assay can provide similar 
data and thus replace the 3H putrescine incorporation assay, we measured 
total TG activity using both the 3H putrescine and colorimetric assay of the cell 
lysates from OK, NRK52E and MDCKII cells transfected with 5 domain 
deletion mutants of TG2: TG2 lacking the β-sandwich domain (-bsw); the 
 71 
 
β-barrel 2 domain (-b2); both β-barrel domains (-b1b2); the TG2 core domain 
(core). Total TG activity increased by 5-10 folds in transfected cells compared 
to wild type (non-transfected control) in both the 3H putrescine (Figure 
3.4-3A-C) and colorimetric assay (D-F). All the mutants of TG2 were equally 
active for TG activity in OK (Figure 3.4-3 A&D), NRK52E (B&E) and MDCKII 
cells (Figure 3.4-3 C&F) irrespective of the assay used.  As both 3H 
putrescine and colorimetric assay can detect baseline TG activity (wt) and 
distinguish the difference of TG activity between transfected cells and 
non-transfection control (wt), the colorimetric assay was used for all 
measurement for total TG activity in this study as cheaper, quicker and free of 
isotopes. 
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3.4.7 Cell surface biotin-cadaverine incorporation 
Extracellular TG activity was measured by the incorporation of biotinylated 
cadaverine into fibronectin described by Jones et al (Jones et al. 1997). A 
 
Figure 3.4-3 Total TG activity in the cell lysate using 3H putrescine and 
colorimetric assay 
Total TG activity in the cell lysate of OK, NRK52E and MDCK II cells was measured 
48 hours post transfection with tetracysteine tag vectors containing TG2 
constructs. tg: full length TG2 cDNA, -bsw: TG2 with β-sandwich domain missing, 
-b2: TG2 with barrel 2 domain missing, -b1b2: TG2 with barrel 1&2 missing, core: 
core domain only, wt: non-transfection control. Data represents mean values 
±SEM. *: p<0.05, n=5 
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96-well plate was pre-coated with 100 µl of 5 µg/ml plasma fibronectin (Sigma) 
in 50 mM Tris buffer (pH 7.4) and kept at 4°C overnight. The next day, the 
fibronectin solution was discarded and the wells were washed with PBS. Cells 
were harvested using 2 mM EDTA in PBS for 10 minutes at room temperature 
and pelleted by centrifugation at 400g (Fisons MSE) for 5 minutes. Cells were 
resuspended in 10 ml serum-free DMEM medium and counted using a 
haemocytometer.   
8×104 cells in 100 µl serum-free DMEM containing 0.1 mM biotinylated 
cadaverine (Molecular Probes, Netherlands) per well were plated and 
incubated for 1 hour at 37°C. Negative controls were serum free culture 
medium with biotinylated cadaverine. The reaction was stopped by two washes 
of 5 mM EDTA in PBS. The cells were lysed using 100 µl of a detergent solution 
consisting of 0.1% (w/v) sodium deoxycholate in PBS & 5 mM EDTA with 20 
minutes of incubation at room temperature. EDTA was added to inhibit any TG 
activity released from lysed cells. The supernatant was removed and used to 
determine the amount of cellular protein using the BCA assay (Section 3.4.13). 
The remaining fibronectin layer was washed three times with PBS. The wells 
were blocked with 3% (w/v) bovine serum albumin (BSA) in PBS for 30 minutes 
at 37°C and incubated with a 1:5000 dilution of extravidin horse radish 
peroxidase (HRP) conjugate (Sigma) for 1 hour at 37°C. Incorporated 
biotinylated cadaverine was revealed using 0.01% (w/v) 
3,3’,5,5’-tetramethylbenzidine (TMB) (Sigma) in 50 mM  phosphate / citrate 
buffer (50 mM dibasic sodium phosphate, 25 mM citric acid, pH 5.0).  The 
resulting colour was then read in an ELISA plate reader (Labsystems Multiskan 
Ascent) using Genesis Software (version 3.05) at 450 nm. The standard curve 
(Figure 3.4-4) was obtained using Guinea pig liver transglutaminase. 
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3.4.8 Extracellular TG2 antigen measurement using the modified 
ELISA 
The amount of extracellular TG2 antigen was quantified using a modified 
quantitative ELISA adapted from the one described by Achyuthan et al 
(Achyuthan et al. 1995). 8×104 cells per well were prepared as above and 
plated into a fibronectin coated 96-well plate as previously described. Cells 
were allowed to incubate in serum-free DMEM for 2 hours at 37°C before being 
washed twice with PBS and lysed using 100 µl per well of 0.1% (w/v) 
deoxycholate in PBS containing 5 mM EDTA at room temperature for 20 
minutes. The supernatant was removed and used for quantification of cellular 
protein. The remaining fibronectin layer containing TG2 was washed three 
times with PBS. Wells were then blocked with 3% (w/v) BSA in PBS for 30 
minutes at 37°C and incubated with a 1:500 dilution of anti-TG2 mouse 
monoclonal antibody cub 7402 (Neomarkers, USA) at 4°C overnight.  
Samples incubated without cub 7402 were used as negative controls. The wells 
were washed 3 times with PBS containing 0.1% (v/v) Tween 20 and incubated 
 
Figure 3.4-4 Standard curve for the extracellular TG activity assay 
The standard curve was obtained using Guinea pig liver transglutaminase 
showing a linear response between A450 nm and 0.0001 to 0.01 IU of 
transglutaminase on cell surface. 
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with a 1:1000 dilution of HRP conjugated goat anti-mouse IgG (Dako, Denmark) 
at 37°C for 1 hour.  Following 3 washes with PBS/Tween, TMB was added and 
the resulting colour was then read in an ELISA plate reader (Labsystems 
Multiskan Ascent) using Genesis Software (version 3.05) at 450nm. The 
standard curve (Figure 3.4-5) was obtained using Guinea pig liver 
transglutaminase. 
 
3.4.9 HaloTag®  protein measurements 
HaloTag protein®  was measured using ELISA according to manufacturer’s 
instructions. 50μl of cell lysate or culture medium was plated into 96-well plate 
and incubated at 37°C for 1 hour. After three washes of 1% (w/v) of BSA, rabbit 
anti-HaloTag pAb (G9281, Promega, UK) at 1:500 was added in each well and 
incubated for 1 hour at 37°C. Following three washes of 1% (w/v) BSA, 
anti-rabbit immunoglobulins/HRP at 1:1000 was added and incubated for 1hr at 
 
Figure 3.4-5 Standard curve for extracellular TG2 antigen 
assay 
The standard curve was obtained using Guinea pig liver 
transglutaminase showing a linear response between A450 nm and 
0.0001 to 0.01 IU of extracellular TG2 antigen. 
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37°C. The anti-HaloTag protein pAb and anti-rabbit immunoglobulins/HRP 
binding was revealed by TMB and read at 450 nm. 
3.4.10 Immunoblotting 
SDS-Polyacrylamide Gel Electrophoresis (PAGE): Gel preparation  
20 ml of a 10% (v/v) polyacrylamide resolving gel was made up by mixing 7.9 
ml ddH2O, 6.7 ml 30% (w/v) acrylamide mix (Geneflow, UK), 5 ml 1.5 M Tris (pH 
8.8), 200 µl 10% (w/v) SDS and 200 µl of fresh 10% (w/v) ammonium persulfate, 
de gassing and then 8µl N,N,N’,N’-tetramethylethylenediamine (TEMED) to 
initiate polymerisation. The mixture was poured into the assembled glass plates 
(Mini-PROTEAN II System, Biorad) and the gel allowed to set at room 
temperature. 10 ml of a 5% (v/v) polyacrylamide stacking gel was made up by 
mixing 6.8 ml ddH2O, 1.7ml 30% (w/v) acrylamide solution, 1.25 ml 1M Tris (pH 
6.8), 100 µl 10% (w/v) SDS, 100 µl 10% (w/v) ammonium persulfate and 10 µl 
TEMED. The mixture was poured on top of the set resolving gel and allowed to 
set for 30 minutes. 20 µg of cell lysate in no more than 10 µl was mixed with 10 
µl reducing buffer [10 mM Tris (pH 6.8), 2.5% (w/v) SDS, 10% (v/v) glycerol, 
0.02% (w/v) bromophen blue, 5% (v/v) β-mercaptoethanol] and boiled for 5 
minutes. Samples were immediately loaded and separated by SDS-PAGE at 
100 V till the blue dye reached the bottom of the gel. 
Western blotting 
The gel was removed from the gel tank and soaked in transfer buffer [39 mM 
glycine, 48 mM Tris, 20% (v/v) methanol] for 15 minutes. 8 pieces of 3 MM filter 
paper and 1 piece of Hybond C nitrocellulose membrane (Amersham Life 
Science) were cut to the same size as the gel and also socked in transfer buffer.  
Western blotting was performed using a Trans-Blot SD Semi-dry Transfer Cell 
(Biorad). 4 pieces of filter paper were placed on to the anode plate and bubbles 
removed. The nitrocellulose membrane was placed on the filter paper block 
and the gel was then positioned onto the membrane with bubbles removed 
again prior to the placement of the second block of 4 pieces of filter paper on 
the top to form a sandwich. The cathode plate was placed on the top of the gel 
and the electrode pins connected. Proteins in the gel were electroblotted onto 
the membrane for 30 minutes at 15V. Transfer of proteins from the gel to the 
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membrane was checked by staining the membrane with 0.1% (w/v) Ponceau S 
solution (Sigma). The western blot was blocked at room temperature for 1.5 
hours with 5% (w/v) non-fat dry milk in TBST [20 mM Tris, 150 mM Sodium 
Chloride, 0.1% (v/v) Tween 20, pH 7.6] and probed overnight at 4°C with the 
primary antibody in TBST (Table 3.1-2). Following 3 washes with TBST, primary 
antibody was revealed with a secondary antibody. Protein bands were 
visualised using an ECL chemiluminescent detection system (Geneflow, UK). 
Blots were exposed to Kodak BioMax ML film for approximately 6 seconds, 
developed in GBX developer (Kodak) and fixed in GBX fixer (Kodak) for 2 
minutes at room temperature. The appropriate length of exposure was 
assessed from the resulting films. 
3.4.11 Immobilisation of HaloTag®  fusion proteins on HalolinkTM 
magnetic beads 
HaloLinkTM magnetic beads (G9311, Promega, UK) were used to immobilise 
and analyse HaloTag® fusion proteins including the β-sandwich domain, the 
TG2 export motif aa88-106 and the core domain (Section 3.1.7). To identify 
proteins that bind to the TG2 export motif aa88-106, cell lysates from NRK52E 
cells transfected with HaloTag®  containing the TG2 export motif aa88-106, 
β-sandwich domain and core domain were immobilised using HaloLinkTM 
magnetic beads. Proteins that bind to the TG2 export motif aa88-106 are also 
immobilised and can be visualised by SDS PAGE using silver staining. The 
bands present in cells transfected with the TG2 export motif aa88-106 and 
β-sandwich domain that also contains the export motif, but not on the core 
domain construct indicate proteins specifically binding to the TG2 export motif. 
These bands can be cut out and further analysed by mass spectrometry to 
identify amino acid sequences. of proteins that bind to the TG2 export motif 
aa88-106. 
Cell lysates from NRK52E cells were prepared as described in Section 3.4.1 
using NP-40 cell lysis buffer at 48 hours post transfection.  HaloLinkTM 
magnetic beads were equilibrated with 3 washes of 200µl binding buffer 
(100mM Tris-HCl, 150mM NaCl, 0.01% IGEPAL®  CA-630 pH 7.6). 50µl of cell 
lysate was added to the equilibrated HaloLinkTM magnetic beads and mixed by 
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inversion on a tube rotator at 4°C for 1 hour. The magnetic beads were 
captured by placing the tube on a magnetic stand and supernatant was 
removed. After 3 washes of 200 µl binding buffer, the “TG2 export motif 
88-106-candidate protein complex” was released with 20 µl of Factor Xa 
Protease (V5581, Promega) buffer (5 µg Factor Xa Protease in 20 mM 
Tris-HCl, 0.1 M NaCl, pH 7.4) at room temperature for 1 hour. The magnetic 
beads were captured by placing the tube on a magnetic stand and supernatant 
was analysed by SDS-PAGE. 
3.4.12 Silver stain 
SDS-polyacrylamide gels were fixed with 40% (v/v) Methanol & 12% (v/v) 
glacial acetic acid at 4ºC overnight. After decanting off the fixing solution, the 
gels were washed with 30% (v/v) ethanol three times. The gels were sensitised 
in 0.02% (w/v) sodium thiosulphate for 90 seconds followed by three washes of 
deionised water. The gels were stained with 0.2% (w/v) silver nitrate & 0.02% 
(v/v) formalin for 20 minutes. After three washes of deionised water, the gels 
were developed in 3% (w/v) sodium carbonate, 0.05% formalin and 0.000005% 
(w/v) sodium thiosulphate until the stained protein band becoming clearly 
visible. After two washes with deionised water, the staining was stopped using 
0.5% (v/v) glycine. 
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Table 3.4-2 List of antibodies used for immunoblotting 
Primary antibodies Dilution Secondary 
antibodies 
Dilution 
Mouse anti-transglutaminase 2 antibodies 
cub7402 (ab2386, Abcam, UK) 
1:750 Anti-mouse 
IgG-HRP (P0447, 
Dako, UK) 
1:1000 
Mouse anti-fibronectin antibodies (Ab6328, 
Abcam, UK) 
1:1000 Anti-mouse 
IgG-HRP 
1:1000 
Rat anti-large T antigen (ab18187, Abcam, 
UK) 
1:1000 Anti-rat IgG-HRP 
(ab7097, Abcam, 
UK) 
1:5000 
Goat anti-tapasin antibodies (sc11473, 
Santa Cruz biotechnology, UK) 
1:1000 Anti-goat IgG-HRP 
(P0449, Dako, UK) 
1:2000 
Goat anti-translocon-associated proteins 
antibodies (sc54414, Santa Cruz 
biotechnology, UK) 
1:1000 Anti-goat IgG-HRP 1:2000 
Mouse anti-β-actin (ab8226, Abcam, UK) 1:1000 Anti-mouse 
IgG-HRP 
1:1000 
3.4.13 Quantitation of total protein by bicinchoninic acid assay 
Total protein was determined in cell lysates using the bicinchoninic acid assay.  
A standard curve was prepared of 0, 0.4, 0.8, 1.2, 1.6, 2.0 mg/ml BSA in distilled 
water. A volume of 1ml of BCA working solution [25 parts solution A (1% (w/v) 
bicinchoninic acid, 2% (w/v) sodium carbonate, 0.16% (w/v) sodium tartrate, 
0.4% (w/v) sodium hydroxide, 0.95% (w/v) sodium hydrogen carbonate): 1 part 
solution B (4% (w/v) copper sulphate)] was added to samples and standards. 
All tubes were vortexed prior to incubation at 37oC for 30 minutes. 200 μl of 
standards and samples were pipetted in duplicate into a 96 well plate and the 
optical density read at 600 nm on a 96 well plate reader (Labsystems Multiskan 
Ascent). 
3.4.14 Immunofluorescent staining 
3.4.14.1 Optimisation of cell fixation 
To optimise cell fixation of the subsequent procedures, cells were fixed using 
the following fixation solutions: 
1. Ice cold methanol for 20 minutes (methanol) 
2. Ice cold acetone for 20 minutes (acetone) 
3. 50% (v/v) methanol and 50% (v/v) acetone for 20 minutes (M+A) 
4. 4% (w/v) paraformaldehyde in PBS, pH 7.2 for 1 hour (PFA) 
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5. Bouin’s solution for 1 hour (Bouin) 
6. 1% (v/v) glutaraldehyde in PBS pH 7.2 for 2 hours (Glutaraldehyde) 
7. 50% (v/v) ethanol, 5% (v/v) glacial acetic acid, 4% (v) 
paraformaldehyde in ddH2O for 20 minutes (FAA) 
Cells were transfected with a pcDNA6.2/cTC-Tag-DEST plasmid containing full 
length TG2. 48 hours post transfection, the cells were stained with organelle 
light orange ER (red) (Section 3.4.14.7) and FlAsH (green) for the tagged TG2. 
The images for the cells fixed with methanol, acetone and 4% 
paraformaldehyde (PFA) were similar in the fluorescent signals intensity and 
coverage for ER and TG2 (Figure 3.4-6). The details for ER (red) and TG2 
staining (green) can be observed. Some co-localisation of ER and TG2 
staining was found around the cell nucleus (blue). The image for cells fixed 
with 1% (w/v) glutaraldehyde was associated with a higher background signal 
of FlAsH and Organelle light in the cytosol that makes it difficult to identify 
organelles from TG2 stains. The images for the cells fixed with Bouin’s solution 
and methanol+acetone (M+A) were similar and showed less detailed for the 
structure of the organelles compared to the image obtained from acetone, 
methanol and PFA fixation. ER should be visible as a membrane structure that 
runs round the cell nucleus and cytosol. However, most of the images obtained 
showed a dot pattern and more linear structure can be visualised in the cells 
fixed using PFA. PFA therefore was selected as standard fixation method in 
this study. 
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Figure 3.4-6 TG2 and ER fluorescent images of cells fixed using 
different solution 
Cells stained with Organelle-light ER (red) and FlAsH-TG2 (green) fixed using A. 
pure methanol, B. acetone, C. Bouin’s solution, D.1% (v/v) glutaraldehyde, E. 
50%(v/v) methanol & 50% (v/v) acetone F. 4% (w/v) paraformaldehyde (PFA), 
G.50% (v/v) ethanol, 5% (v/v) glacial acetic acid, 4% (w/v) paraformaldehyde 
(FAA). H. Wild type NRK52E cells without ER and FlAsH stain 
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3.4.14.2 Mounting reagents 
Mowiol mounting solution 
2.4 g of Mowiol 4-88 (sigma) was mixed with 6 g of glycerol by stirring. 6 ml of 
ddH2O was added and left stirring for 2 hours at room temperature. 12 ml of 
0.2 M Tris-HCl (pH 8.5) and 4 mg of sodium azide was added into the mix. 
After incubation at 60°C for 10 minutes, the mix was centrifuged at 5,000 g for 
15 minutes and undissolved solids were removed. 0.1% (w/v) 
p-phenylenediamine solution (prepared separately and protect from light) was 
added to the Mowiol solution before use (1:9). 
Other mounting reagents used include ProLong®  Gold antifade reagent 
(P36930, Invitrogen, UK) and VECTASHIELD HardSet Mounting Medium 
(H-1400, vector laboratories, UK). 
3.4.14.3 Optimisation of mounting reagents 
VECTASHIELD HardSet mounting medium with 4’, 6 diamidino-2-Phenylindole 
(DAPI) was associated with a high blue background signal. ProLong®  Gold 
antifade reagent (Invitrogen) and Mowiol mounting solution with DAPI (final 
concentration 0.5 µg/ml) provides a similar antifade effect on fluorescence. 
Mowiol mounting solution has the advantage of hardening at room 
temperature and is cheaper. Mowiol mounting solution with DAPI was used in 
this study. 
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Figure 3.4-7 Fluorescent images using different mounting reagents 
NRK52E cells VECTASHIELD HardSet mounting medium with DAPI (A) 
ProLong®  Gold antifade reagent (B) and Mowiol mounting solution with DAPI 
(C). The cell nucleus was blue using DAPI. 
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3.4.14.4 FlAsH and ReAsH staining 
The FlAsH and ReAsH-EDT2 staining was performed using the TC-FlAsH™ 
TC-ReAsH™ II In-cell Tetracysteine Tag Detection Kit (T34563, Invitrogen, 
UK). 
After the removal of culture media, the cells were washed once with 2ml of 
Opti-MEM. 1ml of labelling solution (2.5 µM FlAsH-EDT2 or ReAsH-EDT2 
reagent in Opti-MEM) was added in each well. The plate was incubated for 30 
minutes at 37ºC while protected from light. For dual labelling the cells were 
washed once with BAL buffer, followed by the complete growth medium, and 
incubate at 37ºC for the desired amount of time. The labelling procedure was 
repeated with the second labelling solution. 
3.4.14.5 Validation of FlAsH and ReAsH staining 
To validate FlAsH and ReAsH staining, NRK52E cells were transfected with a 
suitable tetracysteine tag vector or non-tetracysteine tag vector such as, 
pCIneo-hTG (Huang et al. 2004).  48 hours post transfection the cells were 
incubated with either FlAsH or ReAsH reagents before visualisation. Clear 
green (FlAsH) and red (ReAsH) fluorescent signals were found in the cells 
transfected with tetracysteine tag vector (Figure 3.4-8) and little back ground 
fluorescent signals were found in the cells transfected with non-tetracysteine 
tag vector confirming that tetracysteine tag staining technology was suitable to 
these cells. 
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Figure 3.4-8 Validation of tetracysteine tag staining 
NRK52E cells transfected with tetracysteine tag vector followed by incubation with 
FlAsH (A) or ReAsH (B) reagents 48 hours after transfection. Cells transfected with 
pCIneohTG that is a non-tetracysteine vector containing TG2 cDNA incubated with 
FlAsH (C) and ReAsH (D) reagent. The cell nucleus was stained with DAPI in blue. 
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3.4.14.6 Immunofluorescent staining 
Cells were grown on sterilised microscopy glass cover slips to an optimal 
confluence and harvested after 3 washes of PBS. The cover slip was fixed with 
4% (w/v) PFA and blocked with blocking buffer [3% (w/v) BSA, 0.1% (w/v) 
Tween 20 in PBS, pH 7.4] at room temperature for 1 hour. The cover slip was 
incubated with the selected primary antibody with an optimal dilution in 
blocking buffer at 4°C over night (Table 3.4-3). After 3 washes of blocking 
solution, the cover slip was incubated with the selected secondary antibody 
with an optimal dilution in blocking buffer at 37°C for 1.5 hours (Table 3.4-3). 
After three washes of PBS, the cover slip was mounted with Mowiol mounting 
solution with or without with DAPI (0.5 µg/ml) (Vector Laboratories, UK) and 
allowed to set in the dark. 
To visualise TG2 transport, NRK52E cells were grown on sterilised microscopy 
slide cover slips and incubated with 2.5 μM FlAsH-EDT2 reagent (Invitrogen, 
UK) for 30 minutes at 37°C to stain TG2. After this, the cover slip was rinsed in 
PBS and fixed with 4% (w/v) PFA. For co-localisation dual immunofluorescent 
staining was performed using the following antibodies at a 1:300 dilution;  
monoclonal anti-human collagen IV (C1926, Sigma, UK); rabbit polyclonal 
human calnexin (endoplasmic reticulum) (C4731, Sigma, UK); monoclonal 
anti-Golgi 58K protein (G2404, Sigma, UK) & monoclonal anti-LAMP2 
(lysosomes) (SAB1402250, Sigma, UK).  Secondary antibodies were 
polyclonal anti-rabbit IgG-TRITC (T5268, Sigma, UK) and anti-mouse 
IgG-TRITC at 1:500 (T5393, Sigma, UK). Cell organelle staining, cell markers 
and antibodies used in this study are listed in Table 3.4-3. Images were 
acquired on an Olympus BX-61 microscopy using Cell^F software. FlAsH, 
ReAsH, FITC, TRITC, DAPI, OFP (orange) filters were used according to the 
fluorochrome used. 
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Table 3.4-3 List of antibodies and reagents used for immunofluorescent 
staining 
Primary antibody (dilution) Dilution Secondary antibody 
(dilution) 
Dilution 
Cell Junction 
   
Mouse anti-β-Catenin  (610154, BD 
Transduction laboratories, UK) 
1:300 Anti-mouse IgG-TRITC 
(T5393, Sigma, UK) 
1:500 
Mouse anti-E-Cadherin (610182, BD 
Transduction laboratories, UK) 
1:300 Anti-mouse IgG-TRITC 1:500 
Apical 
   
Texas Red-X phalloidin (T7471, Invitrogen, 
UK) 
1:100   
Basolateral 
   
Mouse anti-collagen IV (C1926, Sigma, UK) 1:100 Anti-mouse IgG-TRITC 1:500 
Endoplasmic reticulum 
   
Rabbit anti-calnexin (C4731, Sigma, UK) 1:100 Anti-rabbit IgG-TRITC 
(T5268, Sigma, UK) 
1:500 
Organelle Lights™ ER-OFP (O36223, 
Invitrogen, UK) 
   
Golgi apparatus 
   
Mouse anti-Golgi 58K (G2404, Sigma, UK) 1:300 Anti-mouse IgG-TRITC 1:500 
Organelle Lights™ Golgi-OFP (O36224, 
Invitrogen, UK) 
   
Lysosome 
   
Mouse anti-LAMP2 (SAB1402250, Sigma, 
UK) 
1:100 Anti-mouse IgG-TRITC 1:500 
Plasma membrane 
   
Organelle Lights™ PM-CFP (O36216, 
Invitrogen, UK) 
   
CellMask™ Orange plasma membrane 
(C10045, Invitrogen, UK) 
1:1000   
Proteins 
   
Mouse anti-transglutaminase 2 antibodies 
cub7402 (ab2386, Abcam, UK) 
1:300 Anti-mouse IgG TRITC 
(T2402, Sigma, UK) 
Anti-mouse IgG FITC 
(F0257, Sigma, UK) 
Anti-mouse IgG FITC 
(ab7064, Abcam, UK) 
1:200 
 
 
1:200 
TG2 FlAsH-EDT2 or ReAsH-EDT2 reagent 1:1000   
Rat anti-large T antigen (ab18187, Abcam, 
UK) 
1:300 Anti-rat IgG-TRITC 
(ab7094, Abcam, UK) 
1:500 
Goat anti-tapasin antibodies (sc11473, 
Santa Cruz biotechnology, UK) 
1:100 Anti-goat IgG-TRITC 
(T7028, Sigma, UK) 
1:300 
Goat anti-translocon-associated proteins 
antibodies (sc54414, Santa Cruz 
biotechnology, UK) 
1:100 Anti-goat IgG-TRITC 
(T7028, Sigma, UK) 
1:300 
Mouse anti-β-actin (ab8226, Abcam, UK) 1:300 Anti-mouse IgG-TRITC 1:500 
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3.4.14.7 Organelle light staining 
Organelle lightTM ER and Golgi stains were obtained from Invitrogen. 
Organelle lightTM reagents contain baculovirus that upon entry into mammalian 
cells, directs the expression of autofluorescent proteins that are localized to 
specific organelles via a signal peptide. Organelle lightTM ER targets 
calrecitulin and KDEL (ER retention signal). Organelle lightTM Golgi targets 
Golgi-resident enzyme (N-acetylgalactosaminyltransferase 2). The 
advantages of using organelle lights to visualise cell structures include it can 
be used in live cell imaging and double labelling of organelles. 
1 × 105 Cells were seeded into a 6-well plate and allowed to attach overnight at 
37°C. Culture medium was removed and 550 µl of Organelle light solution (200 
µL of Organelle Lights™ reagent mixed with 350 µL Dulbecco’s Phosphate 
Buffered Saline (D-PBS) without Ca2+ or Mg2+) was added in the well. The cells 
were incubated at room temperature in the dark for 3 hours with gentle rocking. 
The Organelle light solution was removed, replaced with culture medium 
containing 1x enhancer and the plate was incubated at 37°C for 2 hours. After 
the enhancer was removed, the cells were incubated at 37°C overnight and 
were ready for imaging. 
3.4.14.8 Validation of organelle light fluorescent signal 
To validate the fluorescent signals obtained from organelle light reagents, cells 
treated with organelle light reagents were compared to the stains obtained 
from anti-calnexin antibodies (C4731, Sigma) for ER and anti-Golgi 58K 
(O36224, Invitrogen) for Golgi apparatus. The fluorescent signals obtained 
from NRK52E cells stained with organelle light ER were predominately 
accumulated around the cell nucleus and some of the fluorescent signals in a 
reticular shape were found at the peripheral of the cytosol (Figure 3.4-9 A). 
Similar pattern of fluorescent signals distribution was found in the cells stained 
with anti-calnexin antibodies followed by anti-rabbit IgG-TRITC (B) confirming 
the Organelle light ER was picking up the ER. 
Organelle light Golgi stained predominately around the cell nucleus with little 
fluorescent signals in the cytosol and followed a pattern consistent with Golgi 
apparatus sitting on ER. A similar distribution of Golgi apparatus was also 
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found in the cells stained with anti-Golgi 58K antibodies but with a slightly 
higher back ground fluorescent signals in the cytosol. This confirms that the 
organelle light stains for Golgi apparatus are fit for NRK52E cells. Organelle 
light ER and Golgi stains were selected because as an easy and fast option in 
this study.  
  
 
Figure 3.4-9 Comparison of organelle light stain for endoplasmic 
reticulum and Golgi apparatus with classical immunofluorescent 
staining of ER and Golgi markers 
NRK52E cells were stained with organelle light ER (A) and anti-calnexin antibodies 
for ER (B) showing membrane like structure around the cell nucleus and in the 
cytosol. Organelle light Golgi apparatus (C) and anti-Golgi 58K antibodies for Golgi 
apparatus (D) showed a high density structure around the cell nucleus indicated by 
white arrows. The cell nucleus was stained with DAPI in blue 
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3.4.14.9 CellMaskTM plasma membrane staining 
Cells were grown on a cover slip or in a 6-well plate for an optimal time. After 
three washes of PBS the cover slip was incubated with CellMaskTM plasma 
membrane stain (2.5 µg/ml) in PBS for 5 minutes at 37°C. The cover slip or 
plate can be visualised or fixed with PFA after three washes of PBS.  
3.4.14.10 Optimisation of CellMaskTM plasma membrane staining 
Incubating CellMaskTM plasma membrane reagent for 5minutes at 37ºC on live 
cells followed by 1-3 washes of PBS or medium was recommended in the 
instruction manual for CellMaskTM plasma membrane reagent. However, the 
fluorescent signal was not only present on plasma membrane but was also 
found in the cytosol when applied to tubular epithelial cells (Figure 3.4-10 A). 
This makes it difficult to observe the position of intracellular components by 
co-localisation as well as determine when something is outside the cell 
membrane. We tested a series time of incubation times to try and optimise the 
procedure and found that 30 seconds of incubation with the CellMaskTM 
reagent at room temperature followed by 3 washes of PBS showed the best 
fluorescent signal on plasma membrane with little background in the cytosol 
(Figure 3.4-10B) that is useful in observation of protein trafficking in 2D 
images. 
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Figure 3.4-10 NRK52E cell stained with CellMaskTM plasma 
membrane 
NRK52E cells were incubated with CellMaskTM plasma membrane reagent 
for 5 minutes at 37ºC followed by 1 wash of PBS (A) and 30 seconds at room 
temperature followed by 3 washes of PBS (B). A short incubation with more 
PBS washes provides a better observation of plasma membrane between 
cells in a 2D image. The cell nucleus was stained with DAPI in blue 
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3.4.15 Deconvolution microscopy 
Deconvolution is a computational image processing technique for improving 
the contrast and resolution of digital images captured from the fluorescent 
microscopy. The image information like the size of each pixel and information 
about the particulars of the optics are given to the computer-based program, an 
algorithm excludes “out of focus” blur and reassigns “out of focus” light to its 
proper location. The characterisation of out-of-focus light is based on the 3D 
image of a point source of light called point-spread function (PSF). Each PSF 
can be localized using 3D coordinates (X, Y, Z; XY correspond to the 
focal-plane coordinates and Z corresponds to the direction of focal-plane axial 
coordinates). After mathematical calculation of the PSF results in a focused 
light source with a X,Y,Z coordinates that enable the generation of a 3D 
reconstruction image. Deconvolution microscopy has the advantages of 
generating clear image from multiple-focal plane and at very low light levels. 
The 3D images generated by deconvolution microscope are crucial in this study. 
Many of the fluorescent signals were localised on top of or below the cell 
nucleus and many apparent co-localised proteins were actually not in the 
same focal plane. When one sees “green” TG2 around cell nucleus in 
conventional fluorescent microscopy, it is impossible to know if the TG2 is 
secreted in rough ER that is near the cell nucleus, translocated to sub-plasma 
membrane. We can visualise the exact location of TG2 using the tetracysteine 
tag in three-dimensional images using deconvolution microscopy and with 3D 
imaging rendering of the deconvolved data. Cells were grown on sterilised 
microscopy cover slips and visualised 48 hours post transfection or till an 
optimal confluence was reached.  Plasma membrane, FlAsH and/or ReAsH 
reagents and organelle light staining were applied as described in Section 
3.4.14.9 , Section 3.4.14.4 and Section 3.4.14.7 respectively. The cells were 
fixed after 3 washes of PBS and immunofluorescent staining (Section 3.4.14.6) 
applied as needed. Images were acquired on an Olympus BX-61 microscope 
using Cell^F software using a 100X objective lens with immersion oil 
(Numerical aperture 1.2). The Z-stock images were acquired every 0.2µm and 
the thickness of the cells were determined by the plasma membrane stains or 
DAPI for the cell nucleus (20-25 sections were taken). Where applicable 
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images were deconvolved using Autoquant X2 (Media Cybernetics, Silver 
Spring, MD, USA) with the specific setting to the acquired image stacks (X, Y, Z 
spacing, emission wavelength of the fluorescence, refractive index of the 
immersion oil and the point spread function ( detailed in Section 3.4.16.1). 
Deconvolution algorithm settings were 20 iterations with a low noise level. The 
deconvoluted images were then 3D-rendered using Imaris (Bitplane AG, Zurich, 
Switzerland). A 3D blend model that shows the fluorescent signals or a 3D 
cartoon model that is the volume calculated from fluorescent signals obtained 
(Figure 3.4-11). The volume and the percentage of co-localisation of 
fluorescent signals can be also measured in the software as needed. 
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Figure 3.4-11 Three dimensional model generated using Imaris 
software 
NRK52E cells transfected with pcDNA6.2/cTC-Tag-dest vector containing full 
length TG2 cDNA were stained green with FlAsH 24 hours post transfection 
and red with ReAsH 48 hours post transfection. The 3D blend image of 
fluorescent signals (A) and a cartoon image (B) based on the calculation of 
volume for each fluorescent signals. The volume of fluorescent signals less 
than the threshold intensity are not shown. The cartoon image (B) provides a 
better observation of the co-localisation of fluorescent signals. The image 
shows the basal side of the cell (basement membrane) upwards. TG2 
synthesised in the last 24 hours (red) is located around the cell nucleus and 
where as TG2 synthesised in 24-48 hours (green) accumulates at basal side of 
the cells. The cell nucleus is stained with DAPI in blue. 
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3.4.16 Optimisation of image acquiring for deconvolution microscopy 
3.4.16.1 Point spread function for different fluorescent 
A point spread function (PSF) is a mathematical function that describes 
distortion in terms of the pathway a theoretical source of light takes through the 
observed samples. Such a light source contributes a small area of fuzziness to 
the final image. The PSF of the z-stack image obtained from 0.1 µm 
fluorescent beads is shown in Figure 3.4-12 A in XY, XZ and Y plane. By 
correcting such an image based on a theoretical PSF an undistorted image 
can be obtained (Figure 3.4-12 B), however because the 0.1 µm fluorescent 
beads used are smaller than the limitation of the objective lens and camera, 
the green and red fluorescence from the bead are refracted differently and 
thus appear separated and spread. A perfect objective lens would be able to 
focus all light (red, green and blue) in the same spot; however, it is impossible 
to make perfect objective lens. Therefore signals obtained from three colour 
channels overlap but not in the same spot and thus need to be further 
corrected for the properties of the lens to generate a true image (Figure 3.4-12 
C). Therefore to properly generate a high resolution image a PSF must use an 
algorithm that determines both the source and path of light through a sample 
 
Figure 3.4-12 A point spread function for the objective lens 
The point spread function was obtained from 0.1 µm fluorescent beads (A) and after 
correction for PSF (B). As the size of the beads is smaller than the limitation of the 
objective lens, the real 3D image of a bead should look like (C). The difference 
between (B) and (C) comes from the refraction of the different fluorescent wave 
lengths through the lens. 
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and have a objective lens correction. This allows an accurate deconvoluted 
image (Figure 3.4-12 C) allowing accurate co-localisation of three fluorescent 
colours (red, green and blue) in all 3 planes. 
3.4.16.2 Nyquist rate 
The image acquisition spacing in a Z-axis is another important factor in 
deconvolution microscopy.  Too larger spacing (1 or 2 µm) may loose the 
detail of the fluorescent signals and thus not able to distinguish the location of 
two fluorescent signals. Equally too small spacing such as 0.1 µm means 20 to 
30 images are required to cover the thickness of the cell and fluorescence is 
lost because of photobleaching at the end of image acquisition. The three 
fluorescent signals (red, green and blue) have different wavelengths and thus 
have different ideal acquisition spacing in Z-axis. The location of the 
fluorescent molecule in the Z-axis is not accurate in a large Z-axis spacing 
because the differences are caused by the differences of wavelengths. 
Nyquist rate was used to determine the optimal spacing of Z-stack. Nyquist 
rate was calculated based on the type of microscopy, numerical aperture, 
excitation and emission wavelength of fluorescents and lens medium refractive 
index. A 0.2 µm acquisition space for Z-stock image for three fluorescents (red, 
green and blue) was used. A spacing less than 0.2 µm makes it impossible to 
distinguish the real Z-position of the fluorescence. The difference in Z-position 
can be caused by the different wave length of different fluorescents, for 
example a red and green fluorescent signal can be focused in different plane 
but are in fact on the same Z-position. 
3.4.17 Live cell imaging 
TG2 is mainly localised at the basal side of the cell where it attaches to the 
basement membrane. It is difficult to observe TG2 externalised through the 
plasma membrane using statics images and thus live cell imaging was used. 
Images were acquired on an Olympus IX81 inverted microscopy with a 
incubator chamber using a Hamamatsu Orca camera and SimplePCI 
(Hamamatsu) software.  Cells were grown in a 6-well plate as described in 
Section 3.2. The culture medium was replaced with 1ml of serum free 
Dulbecco's Modified Eagle Medium (D-MEM) without phenol red (21063-029, 
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Invitrogen). The focus plane was sat using phase contrast images and the 
fluorescent signals obtained using the specific filter with an automatic 
acquisition every 1 minute for 200 minutes. The focus plane was automatically 
re-set after 10 images had been acquired. The images acquired were exported 
to AVI or WMV video files using Imaris as needed. The imaging was performed 
48 hours after transfection at 37ºC for an optimal period of time. 
3.4.17.1  Optimisation of live cell imaging acquisition 
To visualise TG2 externalisation in TECs, the maximum duration of live cell 
imaging that can be acquired before cell apoptosis or any other morphological 
changes occur was determined using wild type NRK52E cells stained with 
CellMaskTM plasma membrane (red) (Section 3.4.14.9).  Cells were placed on 
an Olympus IX81 microscopy with incubation at 37ºC for 4 hours. The images 
were acquired every 5 minutes with a maximum of 240 minutes. Images were 
displayed every 40 minutes from 0 minute to 200 minute (Figure 3.4-13 A-F) 
showing morphological changes over time. 
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Figure 3.4-13 NRK52E cells with plasma membrane staining 
visualised for 200 minutes 
To determine the maximum duration of live cell imaging, NRK52E cells with 
CellMaskTM plasma membrane stains (images acquired every 20 seconds) were 
shown at 0 minute (A), 40 minutes (B), 80 minutes (C), 120 minutes (D), 160 
minutes (E) and 200 minutes (F). The cell shrank with time and detached from the 
culture plate after 200 minutes. 
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3.4.17.2 Optimisation of fluorescent signals for live cell imaging 
Antifade reagents such as sodium azide and p-phenylenediamine are toxic to 
cells and thus antifade reagents cannot be used in live imaging. To determine 
optimal duration for fluorescent imaging and total images before 
photobleaching of the fluorochrome, NRK52E cells were labelled with FlAsH 
reagent and visualised for a different interval and duration for example 1) every 
10 seconds for 40 minutes, 2) every 20 seconds for 60 minutes, 3) every 1 
minute for 40 minutes and 60 minutes, 4) every 2 minutes for 60 minutes, 120 
minutes. The time of photobleaching was determined by the back ground 
fluorescent signals by an inability to distinguish the fluorescent signal in the 
cell and background (Figure 3.4-14). 
The fluorescent signal can last for 80minutes using acquisition of one 
fluorochrome (green or red) with an interval of 20 seconds or 40minutes with 
an interval of 10 seconds. 
To visualise TG2 externalisation using tetracysteine tag with FlAsH or ReAsH 
stain in live cell imaging, an acquisition time of 40 to 60 minutes with 20 
seconds interval was used.  
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Figure 3.4-14 Live fluorescent signal fading with time 
NRK52E cells were transfected with pcDNA6.2/cTC-Tag-dest vector containing full 
length TG2 cDNA (Gentile et al. 1991) & stained with FlAsH reagent before being 
visualised to determine the maximum time of live cell imaging. The time was 
determined using the differences of the cytosol and back ground fluorescent 
signals. The images are FITC merged with phase contrast at 0 minute (A) that 
cytosol fluorescent signal is different from back ground (white arrow). At 60 
minutes (B) that the fluorescent signal at the peripheral of the cell was not different 
from back ground fluorescent (white arrow). 60 minutes is the maximum time for 
live cell imaging with phase contrast and FlAsH. 
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3.5 Yeast two hybrid screen 
Yeast two hybrid (Y2H) screening was performed using Matchmaker Gold 
Yeast Two-hybrid System (Cat. No. 630489, Clontech, UK). In a Matchmaker 
GAL4-based two-hybrid assay (Figure 3.5-1), a bait protein is expressed as a 
fusion to the Gal4 DNA-binding domain (DNA-BD), while libraries of prey 
proteins are expressed as fusions to the Gal4 activation domain. As bait and 
library (prey) fusion proteins interact, the DNA-BD and AD are brought into 
proximity to activate transcription of four independent reporter genes (AUR1-C, 
ADE2, HIS3, and MEL1). AUR1-C is an antibiotics (Aureobasidin A) resistance 
gene in yeast. Y2H Gold is unable to synthesise histidine and adenine, the 
expression of ADE2 and HIS3 allow the cells to grow on histidine and/or 
adenine minimal medium. MEL1 encoded α-galactosidase that is an enzyme 
occurring naturally in many yeast strains and turn the yeast blue in the 
presence of the chromagenic substrate X-α-Gal. The yeast two hybrid assay 
can be used to identify novel protein interactions, confirm putative interactions 
and define interacting domains. In this study, we used Y2H library screen to 
indentify proteins that bind to the TG2 export motif aa88-106. 
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3.5.1 Construct of pGBKT7 vector with motif 88-106 
The TG2 export motif aa88-106 was cloned into the pGBKT7 DNA-BD vector 
(630443, Clontech, UK) (Figure 3.5-2) between Nde I and ECoRI restriction 
sites. The PCR products were generated with the  primers as detailed (Table 
3.5-1) using a standard PCR protocol (Section 0.). 50 ng pGBKT7 DNA-BD 
vector and 50 ng of PCR product was digested using Nde I (R6801, Promega, 
UK) and ECoRI restriction enzymes (R6017, Promega) in buffer D at 37°C for 
1 hour followed by 10 minutes incubation at 65°C to inactive the restriction 
enzyme. DNA ligation was performed by combining 2µl 10X T4 DNA ligase 
buffer, the pGBKT7 DNA-BD vector, the PCR product, T4 DNA ligase (M0202, 
New England BioLabs, UK) with nuclease-free water to 20 µl.  This was 
incubated at room temperature for 20 minutes. 5 µl of the reaction mix was 
used to transform 50 µl JM109 E. Coli (Section 3.1.8.). The identity of all cDNA 
 
Figure 3.5-1 Principle of the two-hybrid principle 
Two proteins are expressed separately, one (a bait protein) fused to the Gal4 
DNA-binding domain (BD) and the other (a prey protein) fused to the Gal4 
transciptional activation domain (AD). Thus activation of the reporters (AUR1-C, 
ADE2, HIS3, and MEL1) only occurs in a cell that contains proteins which 
interact and bind to the Gal4-responsive promoter in Y2HGold Yeast Strain. 
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constructs was confirmed by DNA sequencing (Core Genomic Facility of the University 
of Sheffield) using a T7 Promoter primer following restriction mapping. 
 
Table 3.5-1 Primers for pGBKT7 vector containing The TG2 export motif 
cDNA 
 Forward primers Reverse primers 
Y2H-motif CTCGTACATATGGGTGGTGAGC
TGCAGCGA 
CTCGTAGGATTCGGACAGCCA
CCGTGGTGG 
 
 
3.5.2 Preparation of competent yeast cells 
Y2H Gold yeast and Y187 yeast was streaked on a Yeast Extract Peptone 
Dextrose Adenine (YPDA) agar plate with 3 days of incubation at 30ºC. A 
colony (diameter 2 mm) was inoculated into 3 ml YPDA medium. After 
 
Figure 3.5-2 DNA map for pGBKT7 vector containing the 
TG2 export motif cDNA 
pGBKT7 vector containing the transport motif amino acid sequence 
88-106 of TG2 
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incubation at 30ºC with shaking at 250 rpm for 8 hours, 5 μl of the culture 
medium was transferred to 50 ml of fresh YPDA in a 250 ml flask. The flask was 
incubated with shaking for 16 hours until the OD 600 nm reached 0.2. The cells 
were then centrifuged at 700 g for 5 minutes at room temperature. The 
supernatant was discarded and the cell pellet was resuspended in 100 ml of 
fresh YPDA medium. The 100 ml of YPDA culture was incubated at 30ºC for 4 
hours until the OD 600 nm reached 0.4 and was divided into two 50 ml sterile 
Falcon conical tubes. The cells were centrifuged at 700 g for 5 minutes at room 
temperature. The supernatant was discarded and the pellet was resuspended 
in 30 ml sterile deionised H2O. The cells were centrifuged at 700 g for 5 minutes 
at room temperature and the supernatant was discarded. The cell pellets were 
resuspended 1.5ml of 1.1x TE/LiAc. The cells were transferred to two 1.5ml 
eppendorf tubes and centrifuged at 10,000 g for 15 seconds.  The supernatant 
was discarded and the cell pellets were resuspended in 600 μl of 1.1xTE/LiAc. 
3.5.3 Transformation of competent yeast cells 
The followings were combined in a pre-chilled sterile 1.5ml tube for a 
small-scale experiment (control experiment and testing bait for autoactivation 
and toxicity) or a 15 ml tube for library screening. 
Table 3.5-2 Constituents and Procedure for competent yeast cells 
transformation 
 Small-Scale Library-Scale 
Pre-chilled, sterile tube 1.5 ml tube 15 ml tube 
Plasmid DNA 100 ng 10 μg 
Yeast maker carrier DNA 5 μl 20 μl 
Competent cells and gently mix 50 μl 600 μl 
PEG/LiAC and gently mix 500 μl 2.5 ml 
Incubate at 30ºC 30 min 45 min 
DMSO 20 μl 160 μl 
Place the tube in a 42ºC water bath 15 min 20 min 
Centrifuge to pellet yeast cells 10,000 g 15 sec 700 g 5 min 
Remove the supernatant and resuspend the cells in YPD 
Plus Medium  
1 ml 3 ml 
Incubate at 30ºC with shaking (200 rpm) 30 min 90 min 
Centrifuge to pellet yeast cells 10,000 g 15 sec 700 g 5 min 
Discard the supernatant and  resuspend the pellet in 0.9% 
(w/v) NaCl solution  
1 ml 15 ml 
3.5.3.1 Plating and determination of transformation efficiency 
100 μl of cells were spread at a dilution of either 1/10 or 1/100 onto a 100 mm 
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selection medium plate containing the appropriate selection medium (SD/-Trp 
medium for pGBKT7 vector, SD/-Leu medium for pGADT7 vector and 
SD/-Leu/-Trp medium for co-transformations of pGBKT7 and pGADT7). The 
plates were incubated upside down at 30ºC for 3 days. The transformation 
efficiency was calculated as following: 
Transformation efficiency=cfu x suspension volume (ml) / Volume plated (ml) x 
amount of DNA (μg). (Multiply by 10 and 100 for 1/10 and 1/100 dilutions 
respectively)   
3.5.4 Two-Hybrid library screening with yeast mating 
After testing for autoactivation and toxicity for the bait construct, a 2 mm colony 
of bait strain was inoculated into 50 ml of SD/-Trp liquid medium. The culture 
was incubated at 30ºC with shaking (200 rpm) for 20 hours until the OD 600 nm 
reached 0.8. After centrifugation to pellet the cells (1,000 g for 5 minutes at 
room temperature) and removal of the supernatant, the pellet was resuspended 
to a density of 1x108 cells per ml in SD/-Trp medium (5ml). The library strain 
(630481, Clontech, UK) and the medium of bait strain were combined in a 
sterile 2L flask. 45 ml of 2x YPDA medium containing 50 μg/ml kanamycin was 
also added to the flask. The flask was incubated at 30ºC for 20 hours with slow 
shaking (40 rpm). A drop of the culture was checked under a phase contrast 
microscopy (40x) for the presence of the zygotes. The culture was centrifuged 
at 1,000 g for 10 minutes to pellet cells and resuspended in 10ml 0.5x YPDA 
(with 50 μg/ml kanamycin) medium. The final total volume of the cells with 
medium was 11.5 ml. To calculated the mating efficiency 100 μl of the 1/10, 
1/100, 1/1000 and 1/10,000 dilutions of the mated culture medium was spread 
on 100 mm agar plates (SD/-Trp, SD/-Leu and SD/-Leu/-Trp) and incubated at 
30ºC for 3 days. The remainder of the mated culture was spread 100 μl per 100 
mm DDO/A plate (SD/-Leu/-Trp agar containing 125 ng/ml Aureobasidin A 
(630466, Clontech, UK)) and incubated at 30ºC for 3 days. The mating 
efficiency was calculated as followings: 
The viability of the prey library (number of cfu/ml on SD/-Leu plate) and bait 
(number of cfu/ml on SD/-Trp plate) was measured. The strain (bait or prey) 
with the lower viability is the limiting partner. The viability of diploids was the 
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number of cfu/ml on SD/-Leu/-Trp plate. Mating efficiency= number of cfu/ml of 
diploids / number of cfu/ml of limiting partner x 100%. All colonies from the 
previous step was picked and grew on QDO/A (SD/-Ade/-His/-Leu/-Trp and 
125ng/ml Aureobasidin A) agar plate. 
3.5.5 Confirmation of positive interaction 
3.5.5.1 Extracting yeast plasmids 
E.Z.N.A. yeast plasmid kit (D3376-02, Omega Bio-Tek, UK) was used to extract 
yeast plasmid. A yeast colony from the previous section was inoculated in 5mL 
SD/-Leu liquid medium and incubated at 30°C overnight. The yeast culture was 
centrifuged at 5,000 g for 5 minutes at room temperature. The supernatant was 
discarded and the cells were resuspended in 480 μl buffer SE containing 
2-mercaptoethanol and 40 μl lyticase solution by vortexing for 1 minute. After 
incubation at 30°C for 30 minutes, the cells were pelleted by centrifuging at 
4,000 g for 5 minutes at room temperature. The cell pellet was resuspended 
with 250 μL buffer YP I, followed by 50 mg glass beads and vortex at for 5 
minutes. The supernatant was transferred to a new 1.5 mL eppendorf tube, 250 
μl YP II was added and gently mixed by inverting 5 times. After 5 minutes 
incubation at room temperature, 350 μl YP III was added to the lysate and 
gently mixed by inverting 5 times until a flocculent white precipitate formed. The 
cell lysate was centrifuged at 10,000 g for 10 minutes at room temperature. The 
clear supernatant was aspirated and added to a clean HiBind DNA mini column 
(treated with equilibration buffer) assembled in a 2 ml collection tube. The 
lysate passed through the column by centrifugation for 1 minute at 10,000g at 
room temperature.  The flow-through liquid was discarded and the column was 
washed with 500 μl of buffer HB followed by centrifuge for 1 minute at 10,000 g. 
The flow-though was discarded and the column was washed with 700 μl DNA 
twice. The empty column was centrifuged at 13,000 g for 2 minutes to dry the 
column. The column was placed into a clean 1.5 ml eppendorf tube and 50 μl 
elution buffer (10 mM Tris, pH 8.5) added to the column. After incubation for 1 
minute at room temperature, the DNA was eluted by centrifugation at 13,000 g 
for 1 minute. The plasmid was amplified by transforming JM109 E. Coli and 
selecting bacteria incorporating the vector with 100 µg/ml ampicillin LB plate.  
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3.5.5.2 Confirmation of genuine positive interactions 
Genuine interactions were confirmed using a small-scale transformation 
procedure by co-transforming 100 ng of the paired vector pGBKT7/bait + prey/ 
pGADT7 or empty pGBKT7 + prey/pGADT7 into Y2H gold competent cells. 100 
μl of 1/10 and 1/100 dilutions of the co-transformed cells were spread on DDO 
(Double dropout medium: SD/–Leu/–Trp) and QDO/A plates (Quadruple 
Dropout, SD/–Ade/–His/–Leu/–Trp with Aureobasidin A). The plates were 
incubated at 30°C for 3 days. A genuine positive interaction was seen by 2 mm 
colonies on DDO/A and QDO/A plate from pGBKT7/bait + prey/ pGADT7 mix 
and no colony on DDO/A and QDO/A plate from empty pGBKT7/bait + prey/ 
pGADT7.  
The prey/pGADT7 vector was then sent for sequencing by Sheffield University 
Core Sequencing service to identify the protein of interest. 
3.5.6 Reverse transcription Polymerase Chain Reaction (RT-PCR) 
The results from Y2H library screen generated a list of candidate sequences 
that interacted with the TG2 export motif aa88-106. These candidate proteins 
were screened based on literature review to identify proteins that may have a 
profile that could possibly be involved in protein externalisation. Selected 
candidate proteins should also be expressed in TECs as TG2 externalisation 
in TECs was being studied (Section 7.3). RT-PCR was therefore used to 
identify the presence of the candidate proteins from yeast two hybrid screening. 
3.5.6.1 RNA extraction 
Tubular Epithelial Cells (TECs) were scraped from a confluent 100 mm petri 
dish in 1 ml trizol and disrupted by sheer stress induced by a 25-gauge 
hypodermic syringe needle. The trizol/cell lysate was transferred into a 1.5 ml 
eppendorf tube. After incubation for 5 minutes at room temperature, 250 μl of 
chloroform was added to the eppendorf tube and the eppendorf tube was 
shaken vigorously for 10 seconds. The eppendorf tube was incubated for a 
further 5 minutes at room temperature and then centrifuged at 10,000 g for 5 
minutes. Three layers in the tube include top layer: clear aqueous, middle layer: 
white precipitated DNA & bottom layer: pink organic phase (protein). The 
aqueous phase was carefully aspirated and placed in a new 1.5 ml eppendorf 
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tube. 550 μl of isopropanol was added to the aqueous phase and mixed by 
pipetting. After 5 minutes of incubation at room temperature, the eppendorf 
tube was centrifuged 13,000 g for 20 minutes at 4°C. A barely visible pellet was 
left at the base of the eppendorf tube after the removal of isopropanol. 1 ml of 
75% (v/v) EtOH in DEPC treated H20 was added to the tube and mixed gently. 
After centrifugation at 10,000 g for 5 minutes, the pellet was left to air-dry after 
the EtOH was removed. 20 μl DEPC treated TE buffer was added to the RNA 
pellet. The RNA was diluted in 1/40 (1.2 μl in 48.8 μl of TE buffer) and the 
absorbance of RNA was measured at 260 nm. An absorbance of 1 unit at 260 
nm corresponds to 40 µg of RNA per ml. 
3.5.6.2 DNase treatment 
2 μg of RNA from the previous section was mixed with 1 μl of RQ1 Rnase free 
DNase (M6101, Promega, UK), 2 μl of DNase 10x reaction buffer, 6 μl of 
DEPC-treated H2O and 0.5 μl of Rnase inhibitor (N2111, Promega, UK). The 
mix was incubated at 37°C for 15 minutes, and then 65°C for 20 minutes to 
deactive the DNase in a thermal cycler before being placed on ice. 
3.5.6.3 Reverse transcription of RNA 
Reverse transcription was performed using RETROscript kit (AM1710, Ambion, 
UK). The DNase treated RNA from the previous step was mixed with 2 μl of 
random primer, 2 μl of 10x RT buffer, 4 μl of dNTP mix, 1 μl of RNase inhibitor, 1 
μl of MMLV-RT and nuclease-free water to 20 μl. The reaction was incubated at 
44°C for 1 hour and the reverse transcriptase was inactivated by heating at 
92°C for 10 minutes. The DNA was amplified with PCR (Section 3.1) using 
designed primers (Table 3.5-3). The absorbance of PCR products was 
measured at 260 nm. 
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Table 3.5-3 Primers for reverse transcription polymerase chain reaction 
(RT-PCR) 
Protein Forward Reverse 
Size 
(BP) 
Iduronate 2-sulfatase 
GCTTGTTGCTAGGC
TTCTT 
TCAGAATCGACAAAA
TAGAGT 
1458 
large neutral amino 
acids transporter small 
subunit 1 
CCCGAGGGCGAAG
GCGTGAC 
GCAGGATCCATTTG
GGCTTGTTTT 
1357 
Neurobeachin-like 
protein 2 
GTTGTGGCTGCTCT
ACTACG 
GTTCAAGTGGAGGA
TATGTAGAGA 
972 
Voltage-dependent 
calcium channel subunit 
alpha-1A 
ATGGCCCGCTTTGG
AGA 
GCCGTGCCCCGCGT
AGTAACCATT 
1035 
Voltage-dependent 
L-type calcium channel 
subunit alpha-1C 
GCCTTCGCTCAGCC
ATCCACA 
CTGCAGTTCACAAAA
GGTAA 
1386 
Tapasin 
GCTTCTTCCCCTGCT
CGTC 
AGGCCCAAAAGGAG
AAAAGCAGAC 
1278 
Translocon-associated 
protein gamma 
CTTCAGGATTTCAGC
CGCAACC 
CCAGTAGACAAGAG
GGCGATGAG 
500 
 
3.5.7 Co-immunoprecipitation 
Cells were harvest from a confluent 100 mm petri dish and lysed in 100 μl cell 
lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1% IGEPAL, pH 8.0) after 
centrifuge at 80 g in room temperature. 1 μg of selected antibody was added to 
the cell lysates and the tube incubated with rotation for 1 hour at 4°C. 50 μl of 
Dynabeads protein G (100.04D, Promega, UK) was added into the tube and 
incubated with rotation for 10 minutes at room temperature. The tube was 
placed on the magnet and the supernatant was removed. After 3 washes of 200 
μl PBS, the antigen complex was eluted using reducing buffer and 
electrophoresed on SDS-polyacrylamide gels. Gels were western blotted and 
immunoprobed for the protein suspected of binding the protein targeted by the 
pull down antibody (Table 3.5-4). 
Table 3.5-4 List of antibodies use for co-immunoprecipitation studies 
Primary antibodies Dilution 
Secondary 
antibodies 
Dilution 
Mouse anti-transglutaminase 2 antibodies 
cub7402 (ab2386, Abcam, UK) 
1:750 Anti-mouse HRP 
(ab97040, Abcam, 
1:5000 
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UK) 
Rat anti-large T antigen (ab18187, Abcam, 
UK) 
1:1000 Anti-rat HRP 
(ab7097, Abcam, 
UK) 
1:5000 
Goat anti-tapasin antibodies (sc11473, 
Santa Cruz biotechnology, UK) 
1:1000 Anti-goat IgG-HRP 
(P0449, Dako, UK) 
1:2000 
Goat anti-translocon-associated proteins 
antibodies (sc54414, Santa Cruz 
biotechnology, UK) 
1:1000 Anti-goat IgG-HRP 1:2000 
 
3.6 Statistical Analyses 
Data analyses were performed using unpaired Student’s t-test or one-way 
ANOVA with a Bonferroni post hoc test as appropriate. A value of p<0.05 was 
considered as statistical significant. All analysis was performed with GraphPad 
Prism (GraphPad software Inc, California, USA). 
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Chapter 4 Determination of which 
TG2 domain is critical for its 
extracellular trafficking using 
deletion analysis 
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4.1 Introduction 
While there is extensive evidence for TG2 export from the cell and its 
extracellular functions in TECs (Fisher 1973; Basile et al. 1998; Skill et al. 2004; 
Fisher et al. 2009), there is very little data detailing how TG2 is moved out of 
the cell or in fact which parts of TG2 are used in this process (Aeschlimann et 
al. 2000; Grenard et al. 2001; Skill et al. 2004; Jones RA 2005; Fisher et al. 
2009). While the fibronectin binding domain of the β-sandwich has been 
reported to be involved in TG2 export from fibroblasts (Gaudry et al. 1999; 
Hang et al. 2005), it is unknown if this could be applicable to other cell types.  
Further, the nature of the previous studies does not fully confirm the role of this 
fibronectin domain and it remains a possibility the authors were simply 
measuring TG2 association at the cell surface from damaged cells rather than 
export per se. 
To address this a series of deletion mutants of TG2 (Gentile et al. 1991) were 
prepared (Section 3.1.3) and inserted into the pCDNA6.2/cTC-Tag-DEST 
mammalian expression vector (Section 3.1.5) The constructed vectors were 
then transfected into OK, NRK52E and MDCK II cells renal tubular epithelial 
cells (TECs) using nucleofection with Ingenio solution (Section 3.3.3) with total 
TG activity & TG2 antigen of the cell lysate, extracellular TG activity, 
extracellular TG2 antigen and TG activity in culture medium measured 48 
hours after transfection. Expression vectors containing the full length TG2 
cDNA (tg), TG2 without β-sandwich domain (-bsw), TG2 without β-barrel 2 (-b2), 
TG2 without both β-barrels (-b1b2), TG2 with β-sandwich and barrel 2 domain 
missing (-bwb2) and the core domain of TG2 (core) (Figure 4.1-1) were used 
for this study to identify the TG2 domain required for TG2 export. The 
constructed vectors were transfected into OK, NRK52E and MDCK II cells 
renal tubular epithelial cells (TECs) using the nucleofection with Ingenio 
solution as described in section 3.3.3. Total TG activity and TG2 antigen of the 
cell lysate, extracellular TG activity, extracellular TG2 antigen and TG activity in 
culture medium were measured 48 hours after transfection. 
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4.2 Generation of TG2 Domain deletion cDNA by PCR 
All constructs were prepared by PCR using the human TG2 cDNA as a 
template (Gentile et al. 1991) using the primers detailed in   
 
Figure 4.1-1 TG2 mutants for deletion analysis 
Five TG2 mutants were constructed to determine which domain of TG2 is critical 
for TG2 externalisation. Full length TG2 (tg) (Gentile et al. 1991), TG2 with 
β-sandwich domain missing (-bsw), TG2 with β barrel 2 missing (-b2), TG2 with 
β-barrel 1 &2 missing (-b1b2), TG2 with β-sandwich & β barrel 2 domain missing 
(-bwb2) and TG2 with β-sandwich, β barrel 1 & 2 domains leaving just the core 
domain (core). 
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Table 4.2-1. All TG2 constructs were transferred from pENTR/D-TOPO®  vector 
to mammalian pcDNA6.2/cTC-Tag-dest and transfected into TECs as 
described in Section 3.1.5. 
After having identified the domain that is essential for TG2 externalisation, a 
point mutation analysis was used to determine the sequences in the domain 
that is critical for TG2 externalisation. 
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Table 4.2-1 Primers for deletion analysis 
 Forward primers Reverse primers 
tg CACCATGGCCGAGGAGCTGGTCTT AAATCCGCCCCGGTTACTACTGT 
-bsw CACCATGCTGTGTACCTGGACTCG AAATCCGCCCCGGTTACTACTGT 
-b2 CACCATGGCCGAGGAGCTGGTCTT AAAGTAGAGGTCCCTCTCAGCCA 
-b1b2 CACCATGGCCGAGGAGCTGGTCTT AAAGTTCGCCCTTGTGAAGGCCT 
-bwb2 CACCATGCTGTGTACCTGGACTCG AAAGTAGAGGTCCCTCTCAGCCA 
core CACCATGCTGTGTACCTGGACTCG AAAGTTCGCCCTTGTGAAGGCCT 
Forward primers were designed by adding CCAC at 5-end of the insert sequences. 
Reverse primers were designed by adding AAA at the 5-end of the insert sequences. 
Full length TG2 (tg), TG2 with β-sandwich domain missing (-bsw), TG2 with β barrel 2 
missing (-b2), TG2 with β-barrel 1 &2 missing (-b1b2), TG2 with β-sandwich & β barrel 
2 domain missing (-bwb2) and TG2 with β-sandwich, β barrel 1 & 2 domains leaving 
just the core domain (core), removal of first 7 amino acid of N-terminal β-sandwich 
domain (-7a). 
4.3 Deletion Analysis - Total TG by activity and antigen in the cell 
lysate 
To establish if all the TG2 domain deletion mutants were both equally 
transfected into the cell and had equal TG activity, the total TG activity in the 
cell lysates and total TG2 antigen was measured 48 hours post transfection.  
 
Figure 4.2-2 DNA map for pENTR/D-TOPO®  vector 
pENTR/D-TOPO entry vector containing full length TG2, TG2 with the 
β-sandwich domain deleted (-bsw), TG2 with the β-barrel 2 domain deleted (-b2), 
TG2 with β-barrel 1 & barrel 2 domain deleted (-b1b2), TG2 with the β-sandwich 
and barrel 2 domain deleted (-bwb2), or the core domain of TG2 (core). 
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TG2 protein in each cell lysate was determined by western blot (Figure 4.3-1 
A-C) using β-actin as a loading control.  TG2 was probed for using mAb 
cub7402 (ab2386, Abcam, UK) that targets the catalytic core which is present 
in each construct.  This detected a band of molecular weight 75 kDa for full 
length TG2 (tg), 61 kDa for TG2 with β-sandwich domain missing (–bsw), 66 
kDa for TG2 with β barrel 2 missing (–b2), 52 kDa for TG2 with β barrel 1 & β 
barrel 2 missing (–b1b2), 51 kDa for TG2 with β-sandwich domain and β barrel 
2 missing (–bwb2) and 38 kDa for the core domain (core) in OK (Figure 4.3-1 
A), NRK52E (Figure 4.3-1 B) and MDCKII cells (Figure 4.3-1 C) respectively.  
All constructs appeared to be equally expressed within each cell line. 
TG activity in the cell lysates (Figure 4.3-1 D-F) also increased equally (approx 
5-fold) for all constructs within each cell line. This confirmed comparable 
transfection efficiency and that all domain deletions retained TG activity. 
Subsequently TG2 transport could be tracked using extracellular TG activity 
assays. 
 117 
 
  
 
Figure 4.3-1 TG2 levels following domain deletion 
OK, NRK52E and MDCK II renal epithelial cells were transfected with the following 
constructs 1) full length tissue transglutaminase (tg), 2) TG2 with β-sandwich domain 
deleted (-bsw), 3) TG2 with the barrel2 deleted (-b2),  4) TG2 with β-barrel 1 and 
β-barrel 2 domains deleted (-b1b2), 5) TG2 with both β-sandwich and β-barrel 2 
domains deleted (-bwb2) and finally 6) TG2 catalytic core (core). Western blots for 
TG2 in cell lysates post transfection are shown in A-C and total TG activity in cell 
lysates (D-F). wt: non-transfection control. Data represents mean values ±SEM, n=5, 
*= p<0.05 
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4.4 Deletion analysis – Extracellular TG activity 
Extracellular TG2 activity was measured 48 hours post transfection using a 
biotin-cadaverine incorporation (Section 3.4.7). An increase in extracellular TG 
activity was readily detectable in the extracellular environment after 
transfection with full length TG2 (tg, Figure 4.4-1 A-C), with activity increased 
between 3 & 4 fold in all 3 cell lines transfected. Similarly, cells transfected with 
TG2 cDNA with β-barrel 2 (-b2) and both β-barrel 1 & β-barrel 2 domains 
missing (-b1b2) had the same levels of extracellular TG activity to that of full 
length TG2 in all 3 cell lines suggesting that β-barrel domains played no role in 
TG2 externalisation. However, when cells were transfected with constructs in 
which the β-sandwich domain was missing (ie -bsw, -bwb2 , and just core), 
extracellular TG activity was similar to that in cells that had not been transfected. 
This suggests that the transfected deletion mutant of TG2 is not being trafficked 
and that β-sandwich domain is crucial for TG2 transport. 
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Figure 4.4-1 Extracellular TG activity following domain deletion 
OK, NRK52E and MDCK II renal epithelial cells were transfected with full length 
TG2 (tg), TG2 mutants including TG2 with β-sandwich domain deleted (-bsw), 
TG2 with the barrel 2 deleted (-b2), TG2 with β-barrel 1 and β-barrel 2 domains 
deleted (-b1b2), TG2 with both β-sandwich and β-barrel 2 domains deleted 
(-bwb2) and TG2 catalytic core only (core).wt: non-transfected control. 
Extracellular TG activity was measured 48 hour post transfection. Data 
represents mean values ±SEM, n=5, *= p<0.05 
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4.5 Measurement of TG2 in culture medium 
It is possible that removing a domain may not be affecting TG2 transport, but 
simply its ability to localise to the cell surface or extracellular matrix which 
extracellular TG activity assay used predominantly measure. Experiments 
were therefore repeated taking measurements of TG antigen using western 
blot (Figure 4.5-1 A-C) and activity (Figure 4.5-1 D-F) in the culture medium to 
ensure TG2 was not “floating” away post transport. In all 3 tubular epithelial 
cells, only the full length TG2 and mutant TG2s with barrel domains had been 
deleted (-b1 and –b1b2, Figure 4.5-1 A-C) was detected in culture medium 
with the same molecular weight as in the cell lysate: 66 kDa for TG2 with β 
barrel 1 missing (–b1) and 52 kDa for both β barrels missing (–b1b2). The TG2 
fraction found in the medium (Figure 4.5-1 E-F) mirrored measurements of 
extracellular TG activity using a modified cell ELISA (Figure 4.4-1 A-C). None 
of the constructs with β-sandwich domain missing (-bsw, -bwb2 and core) were 
detected in the medium as constructs with barrel domains missing. 
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Figure 4.5-1 TG activity and Antigen in culture medium following 
domain deletion 
OK, NRK52E and MDCK II renal epithelial cells were transfected with full length TG2 
(tg), TG2 mutants including TG2 with β-sandwich domain deleted (-bsw), TG2 with 
the barrel 2 deleted (-b2), TG2 with β-barrel 1 and β-barrel 2 domains deleted 
(-b1b2), TG2 with both β-sandwich and β-barrel 2 domains deleted (-bwb2) and TG2 
catalytic core only (core).wt: non-transfected control. TG2 antigen and TG activity in 
culture medium was measured 48 hour post transfection pcDNA6.2/cTC-Tag-dest 
vector containing full length TG2 cDNA or pcDNA6.2/cTC-Tag-dest vector containing 
TG2 mutants. Data represents mean values ±SEM, n=5, *= p<0.05 
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4.6 Proportion of TG2 on cell surface and TG2 in the culture 
medium 
In this study, we measured extra- and intra-cellular TG activity to determine 
TG2 externalisation. The result showed significant different between TG2 
mutants and full length of TG2. However, we do expect this would lead to an 
increase in intracellular TG activity in cells transfected with the TG2 lacking the 
β-sandwich domain as it would be retained in the cell. However the data of 
TG2 in the cell failed to demonstrate this. Subsequently to address this, the 
total amount of TG2 in each compartment was calculated (Figure 4.6-1), which 
while not statistically significant, did suggest that TG2 was being retained. This 
data can be explained by the proportion of TG2 measured on cell surface 
(extracellular TG activity) and TG activity in the medium which is only 5% of 
the TG activity in the cell lysate. Thus the differences can be observed by 
transforming the unit expressed as TG activity IU/mg of protein into TG activity 
per well. The extracellular TG levels compared to intracellular TG levels are 
relatively small. So if only 5% of transfected TG2 is retained, it will not have a 
huge affect on intracellular TG2 as only 5% of the total TG2 transfected, but it 
has a dramatic affect on TG2 detectable outside of the cells, where TG2 is 
barely detectable. TG2 in the culture medium was measured up to 16 hours 
(section 3.4.2) and the half-life of TG2 is 8 hours, the barely detectable TG2 in 
the culture medium can not be explained by the degradation TG2.  
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4.7 Chronologically labelling of TG2 with time post transfection 
TG2 with the β-sandwich domain deleted cannot be externalised. 
Consequently the differences in TG2 movement in the cell between full length 
TG2 and mutant TG2 (-bsw) can provide clues to its extracellular trafficking. To 
visualise TG2 movement, NRK52E cells transfected with 
pcDNA6.2/cTC-Tag-DEST containing either full length of TG2 or mutant TG2 
(-bsw, β-sandwich domain missing) were visualised 24, 48, 72 and 96 hours 
after transfection by staining with FlAsH reagent. The plasma membrane of the 
cells was stained red using CellMaskTM plasma membrane reagent and the 
cell nucleus stained blue with DAPI. Most of the synthesised TG2 (green) in 24 
hours (tg2) was found around the cell nucleus (Figure 4.7-1 A-C) that is likely 
 
Figure 4.6-1 Total TG activity in cell lysate and medium expressed as TG 
activity per well 
TG activity in cell lysate and TG activity in culture medium were measured in OK, 
NRK52E and MDCKII cells 48 hours post transfection with pcDNA6.2/cTC-tag-DEST 
vector containing full length of TG2 cDNA (tg), TG2 with β-sandwich domain missing 
(-bsw), TG2 with barrel2 domain missing (-b2), TG2 with barrel 1 and barrel 2 missing 
(-b1b2), β-sandwich and barrel 2 domain missing (-bwb2) and the core domain of TG2 
(core). The unit of TG activity was expressed as Unit per well. wt: non-transfected cells. 
Data represents mean±SEM, n=5, *:p<0.05.  
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within rough ER and some TG2 localised in the cytosol (Figure 4.7-1 C). The 
FlAsH stains for mutant TG2 (-bsw) followed the same pattern (Figure 4.7-1 
D-F) at 24 hours. Wild type TG2 was accumulated in a vesicle shape structure 
by 48 hours post transfection with some extracellular TG2 vesicles seen (white 
arrow, Figure 4.7-1 G-I). In contrast, FlAsH labelled mutant TG2 missing the 
β-sandwich was also in a vesicle shape structure, but clearly retained within 
the cytosol, often just inside the plasma membrane (Figure 4.7-1 J-L). 
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Figure 4.7-1 FlAsH staining for TG2 in NRK52E cells 24 and 48 hours 
post transfection 
NRK52E cells were transfected with pcDNA6.2/cTC-Tag-dest vector containing full 
length TG2 cDNA (tg2) or mutant TG2 (-bsw, β-sandwich domain missing). FlAsH 
stains for TG2 (A-C & G-I, tg2) and mutant TG2 (D-F & J-L, -bsw) was carried out 
at 24 (A-F) and 48 (G-L) hours post transfection. TG2 accumulated extracellularly 
in a vesicle shape structures are indicated by white arrows at 48 hours post 
transfection. Mutant TG2 (-bsw) are localised in vesicle shaped structures in the 
cytosol indicated by yellow arrows (J&L). Plasma membrane (PM) was stained red 
with CellMaskTM plasma membrane and the cell nucleus stained blue with DAPI. 
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By 72 (Figure 4.7-2 A-C) and 96 hours post transfection (Figure 4.7-2 G-I) most 
TG2 is on cell surface (white arrows). Little TG2 remains around the cell 
nucleus or in the cytosol. Mutant TG2 (-bsw) at 72 (Figure 4.7-2 D-F) and 96 
hours (Figure 4.7-2 J-L) post transfection accumulated in the peripheral cytosol 
in the sub-plasma membrane area in a vesicle shape. This is consistent with 
the finding in section 4.5 that the mutant TG2 with the β-sandwich domain 
missing) cannot be externalised. 
In summary, TG2 is synthesised in the cytosolic ribosomes, accumulated 
around the cell nucleus within in 24 hours and moved to the peripheral part of 
the cells. TG2 begins to be exported by 48 hours post transfection. By 72 
hours most of the visible TG is outside the cell and appears associated with 
the cell surface. TG2 without the β-sandwich domain cannot be externalised 
stays in the cytosol in a sub-plasma configuration.  
 127 
 
  
 
Figure 4.7-2 FlAsH stains for TG2 in NRK52E cells 72 and 96 hours post 
transfection 
NRK52E cells were transfected with tetracysteine tag vector containing either full 
length TG2 (tg2) or mutant TG2 (-bsw, β-sandwich domain missing). FlAsH labelled 
TG2 were localised on the plasma membrane surface at 72 & 96 hours post 
transfection (A & G, white arrows). Mutant TG2 that cannot be externalised was 
accumulated in the near the plasma membrane (D & J). Plasma membrane (PM) 
was stained red with CellMaskTM plasma membrane and the cell nucleus stained 
was stained blue (B, E, H, K). The merge images suggested the location of 
intracellular and extracellular TG2 (C, F, I, L). 
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4.8 Visualisation of externalised TG2 
Given the diffuse nature of the CellMaskTM plasma membrane stain, to confirm 
that full length TG2 was finding its way into the extracellular space, while TG2 
missing the β-sandwich domain was unable to do so, the cell periphery was 
visualised with phase contrast microscopy. This was then merged with FlAsH 
labelled TG2 as in the previous section at 48 hours post transfection. Two 
different distribution patterns were observed in the cells transfected with full 
length TG2 (Figure 4.8-1 A) or mutant TG2 (-bsw, β-sandwich domain deleted) 
(Figure 4.8-1 B). The green TG2 was found between cells (yellow arrow) for 
full length TG2, but the mutant TG2 was found just in the cytosol (white arrow, 
A & B). 
  
 
Figure 4.8-1 Extracellular and intracellular TG2 using immunofluorescents 
NRK52E cells stained with pcDNA6.2/cTC-Tag-dest vector carrying either full length TG2 
cDNA (A) or TG2 with β-sandwich domain deleted (B) were stained with FlAsH (green). 
The fluorescent images were merged with phase contrast image to show the extracellular 
and intracellular compartments. The extracellular TG2 is indicated with yellow arrow and 
intracellular TG2 is indicated with white arrow. 
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Unfortunately the merging of phase contrast images that have a white 
background with fluorescent signal in the cytosol raising questions about 
differences in the amount of TG2 or TG2 lacking the β-sandwich remaining in 
cells. To address this the plasma membrane was stained red with CellMaskTM 
plasma membrane reagent (Section 3.4.14.10). Wild type cells (wt) picked up 
no FlAsH stain for TG2 with the plasma membrane staining a deep red (Figure 
4.8-2 A). A green TG2 fluorescent signal was found in extracellular space 
(yellow arrow) and cytosol (white arrow) in cells transfected with full length 
TG2 (+tg2) (Figure 4.8-2 B) with the plasma membrane being seen as yellow / 
orange due to the co-localisation of FlAsH labelled TG2 (green) and the red 
plasma membrane staining. Only intracellular TG2 was found in the cells 
transfect with TG2 lacking the β-sandwich domain (+tg2-bsw) with the plasma 
membrane appearing identical to that of the untransfected cells as no TG2 was 
being exported across the plasma membrane (Figure 4.8-2 C). This clear cell 
junction for CellMaskTM plasma membrane only clearly displayed in very 
confluent cells, therefore cannot applied to chronological visualisation study.  
  
 
Figure 4.8-2 Visualisation of extracellular TG2 
NRK52E cells transfected with tetracysteine tag containing full length TG2 (B, +tg2) 
or mutant TG2 (C, +tg2-bsw) were visualised 48 hours post transfection. The plasma 
membrane stained red using CellMaskTM plasma membrane reagent. Extracellular 
green TG2 (yellow arrows) was observed in the cells transfected with full length TG2 
(B) but only intracellular TG2 was found in the cells transfected with mutant TG2 
(+tg-bsw). The plasma membrane was orange colour because of the co-localisation 
of green full length TG2 and red plasma membrane stains. In contrast, the plasma 
membrane was red in wild type NRK52E cells (A, wt) that is similar to the plasma 
membrane in the cells transfected with mutant TG2 (C). Cell nucleus was stained in 
blue with DAPI. 
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4.9 Discussion 
In this study, mutant TG2 constructs with each of the 3 non-catalytic domains 
individually or doubly deleted were generated and transfected into three 
tubular epithelial cells (TECs). As the catalytic activity of TG2 relies on the core 
domain alone, all TG2 mutants retained TG activity and thus extracellular TG 
activity levels, as well as antigen, can be used to access TG2 externalisation. 
The expression of TG2 was similar across the three different types of TECs 
used as well as between the different TG2 mutant constructs using the 
optimised nucleofection protocols. 
Measurements of intra- and extra-cellular TG activity can be compared 
between different TG2 mutants and different cell lines. Despite having the 
same TG levels inside the cell, TG2 mutants with the β-sandwich domain 
deleted (either alone or with a barrel domain also deleted), only had the same 
extracellular TG levels as wild type cells conclusively proving that the 
β-sandwich is critical to TG2 extracellular trafficking. Cells transfected with 
TG2 where β-barrel 2 deleted or TG2 with both β-barrel deleted had the same 
extracellular TG levels as cells transfected with full length TG2 proving that the 
β-barrels are not required for TG2 cell export. TG2 externalisation was further 
confirmed by using FlAsH staining of tetracysteine tagged TG2 and mutant 
TG2. Full length TG2 and TG2 with the β-sandwich domain deleted were 
synthesised in the ribosomes around the cell nucleus and moved peripherally 
to the plasma membrane. Full length TG2 can be found both on cell surface 
and in the extracellular space 48 hours post transfection, whereas TG2 
missing the β-sandwich could not be externalised and accumulated under the 
plasma membrane in vesicle shaped structures. 
The β-sandwich domain contains many binding sites including heparin 
(Verderio et al. 2008), integrin (Akimov et al. 2000; Telci et al. 2008) and 
fibronectin (Gaudry et al. 1999), it is therefore possible that even if TG2 was still 
exported it can’t be measured efficiently using the extracellular TG activity 
assay as this assay is far less efficient if the TG2 is not on the cell surface or in 
the ECM. Removal of the β-sandwich could prevent direct ECM or cell surface 
association. We therefore measured TG activity in the medium and TG2 
antigen in the medium to guard against misinterpretation of the data. This 
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showed that TG activity was not increased in the culture media when the 
β-sandwich was removed in contrast to full and barrel deletion TG2. This 
finding confirms that the deletion of β-sandwich domain stops TG2 
externalisation. The role of β-sandwich domain in TG2 externalisation has been 
raised in previous studies (Verderio et al. 1998; Gaudry et al. 1999; Akimov et al. 
2000; Herman et al. 2006) and thus our findings in renal tubular epithelial cells 
are consistent with that in Swiss 3T3 fibroblasts (Verderio et al. 1998; Gaudry et 
al. 1999), WI-38 fibroblasts, human erythroleukemia cells (Akimov et al. 2000), 
and breast cancer (MCF-7) cells (Herman et al. 2006). 
Initially TG2 was localised in just the cytosol around the cell nucleus. Despite 
TG2 having a well described nuclear presence it is likely that early TG2 is just 
TG2 being synthesised in the cytosolic ribosomes and accumulated around 
the cell nucleus in 24 hours post transfection. TG2 then moved to the periphery 
of the cells between 24-48 hours and extracellular TG2 can be visualised 48 
hours post transfection. Mutant TG2 that cannot be externalised followed the 
same pathway – like wild type TG2 it is synthesised in the cytosolic ribosomes 
at 24 hours post transfection, move to the periphery of the cell and 
accumulated in a vesicle shape structure 24-48 hours post transfection. More 
studies such as co-localisation of TG2 and lysosomes or multivesicular bodies 
(MVBs) (Zemskov et al. 2011) may provide information for the involvement of 
lysosomes or MVBs in TG2 externalisation. So far, no plasma membrane 
blebbing was observed in images using fixed cells. Plasma membrane 
blebbing is not likely to be involved in TG2 externalisation based on the plasma 
membrane stains used in this chapter. 
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Chapter 5 Which part of the 
β-sandwich domain is required for 
TG2 externalisation? 
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5.1 Introduction 
In the previous chapter, it was demonstrated that β-sandwich domain is critical 
for TG2 externalisation, while β-barrel 1, β-barrel 1 and the core domain are 
not involved in TG2 externalisation. Extracellular TG2 can be visualised 48 
hours post transfection while TG2 missing the β-sandwich domain cannot be 
externalised and is retained in the cytosol in a vesicle structure. Examination of 
the literature to assist in identifying the functional sequence within β-sandwich 
domain responsible for export highlighted a previous report by Griffin and 
colleagues (Gaudry et al. 1999) on TG2 trafficking suggested that a fibronectin 
site encompassing the first 7 amino acids (Figure 5.1-1) of the TG2 β-sandwich 
domain was crucial for TG2 presenting on the cell surface. They co-localised 
TG2 and fibronectin on the cell surface using confocal microscopy in stably 
transfected Swiss 3T3 cells with a tetracycline induced TG2 expression. The 
interaction of TG2 and fibronectin was determined using a GTP binding 
TG2-β-galactosidae fusion protein in transiently transfected COS-7 fibroblasts. 
However, this study was at odds with data generated in Sheffield were it was 
noted that renal fibroblasts would accumulate transfected TG2 in the cytosol 
rather than secreting TG2 into extracellular environment and subsequently the 
amount of TG2 fibroblasts would export remained constant irrespective of 
intracellular TG2 levels unless the cells was stressed. There was therefore 
concern that these studies in 3T3 fibroblasts may be resulting from cell 
damage and TG2 association with fibroblasts rather than controlled export. As 
renal tubule cells readily export TG2 with a relationship between TG2 
production and that exported, this experiment was repeated in three renal 
tubule epithelial cells. 
Another fibronectin binding site-the sequence 88-106 in β-sandwich domain 
was reported by Belkin et al (Hang et al. 2005) using surface plasmon 
resonance that measured association/dissociation of fibronectin and TG2. 
However, no studies regarding TG2 externalisation was done in their study on 
this additional fibronectin binding site and given the link proposed by Griffin 
and colleagues determine if this site could be involved in TG2 export was a 
logical progression. To do this, intra- and extra-cellular TG activity was 
measured following transfection with TG2 containing mutations of this 
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fibronectin binding site (Asp94 from D to A, Asp97 from D to A and both Asp94, 
Asp97 from D to A) as in their study (Figure 5.1-1).  
5.2 Deletion of first 7 amino acids to remove a fibronectin binding 
site in the β-sandwich domain 
The pcDNA 6.2/cTC-tag-DEST vector containing human TG2 cDNA with the 
first 7 amino acids of β-sandwich domain missing was generated. The mutant 
TG2 (tg-7a) retained full TG activity (Figure 5.2-1 A & B) and transfected with 
equal efficiency in 3 different cell lines. As the construct (tg-7a) retained full TG 
activity, externalisation of TG2 can be tracked using TG activity. The 
extracellular TG activity and TG activity found in the medium was the same for 
wild type TG2 (tg) and TG2 lacking the fibronectin binding site at amino acid 
1-7 (Figure 5.2-1 D and E). A western blot for TG2 in culture medium was also 
performed (Figure 5.2-1 C) to confirm this result. This also showed that wild 
type and TG2 lacking this fibronectin binding site was equally exported from 
the cell. Therefore the deletion of first 7 amino acids failed to prevent TG2 
export and as such this potential fibronectin binding site is not important in TG2 
export in tubular epithelial cells. 
 
Figure 5.1-1 Location of point mutations in β-sandwich domain of TG2 
Point mutation analysis include: removal of first 7 amino acid in N-terminal 
β-sandwich domain (red) and the motif 88-106 (yellow) with Asp94 and/or Asp97 to 
Ala  
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Figure 5.2-1 Intracellular and extracellular TG following the removal of 
the amino acid 1-7 fibronectin binding site 
OK, NRK52E and MDCK II renal epithelial cells were transfected with full length 
TG2 (tg) or mutant TG2 lacking the first 7 amino acid of β-sandwich domain 
missing that constitute a fibronectin binding site (tg-7a,). Western blots for TG2 in 
cell lysate 48 hours post transfection are shown in A and TG2 in medium are 
shown in B. Total transglutaminase activity in cell lysates (C), extracellular TG 
activity (D) and TG activity in culture medium (E) was measured, wt indicates 
non-transfection control. Data represents mean values ± SEM, n=5, *: p<0.05 
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5.3 Affect of mutating a second fibronectin binding site in TG2 
The primers for generating point mutation TG2 constructs (Table 3.1-1) were 
designed as previous described (Hang et al. 2005). The second fibronectin 
binding site (88WTATVVDQQDCTLSLQLTT106) in the β-sandwich domain of 
TG2  reported in the literature (Hang et al. 2005), had not been implicated in 
TG2 trafficking. Given the precious work of Gaudry et al (1999) a logical step 
was to determine if this fibronectin binding site was involved in TG2 
extracellular trafficking. Subsequently we introduced a 2 point mutations (Asp94 
& Asp97) in this binding domain that had previously been shown to disable it’s  
binding to fibronectin (Hang et al. 2005). Constructs containing either 1 or both 
mutations were equally expressed in each of the 3 TECs lines used (Figure 
5.3-1 A-C). This construct had the same level of TG activity in the cell lysate to 
wild type TG2 (Figure 5.3-1 D-F). Therefore TG2 externalisation could be 
tracked using both extracellular TG activity and antigen. 
 137 
 
  
 
Figure 5.3-1 Intracellular TG2 levels following point mutation 
OK, NRK52E and MDCK II renal epithelial cells were transfected with 
pcDNA6.2/nTC-tag-DEST vectors containing either 1) full length TG2 (tg), 2) single 
point mutation of Asp94 to Ala (f1), 3) single point mutation of Asp97 to Ala (f2), or 4) a 
two point mutation of TG2 at Asp94& Asp97 to Ala (f3), wt indicates  non-transfection 
control.  Western blots for TG2 in cell lysate 48 hours post transfection are shown 
in A-C and TG2 in medium are shown in D-F. Data represents mean values ±SEM.  
n=5, ** p<0.01, *p<0.05) 
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Single mutation of either Asp94 (f1)or Asp97 (f2) into Ala significantly decreased 
extracellular TG activity and TG activity in the culture medium by 50% (p<0.05), 
while two point mutation of Asp94 and Asp97 returned TG2 export to basal levels 
(p<0.01) (Figure 5.3-2 A-C). 
 
Figure 5.3-2 Extracellular TG activity following point mutation 
Extracellular TG activity was measured using a modified cell ELISA incorporating 
biotin labelled cadaverine into fibronectin following transfection with 
pcDNA6.2/cTC-tag-DEST vector containing either 1) full length TG2 (tg), 2) TG2 
with a single point mutation of Asp94 to Ala (f1), 3) TG2 with a single point mutation 
of Asp97 to Ala (f2), or 4) TG2 with a two point mutation of TG2 at Asp94& Asp97 to 
Ala (f3), wt indicates non-transfection control. Data represents mean values ±SEM.  
n=5, ** p<0.01, *p<0.05) 
 139 
 
This was further confirmed by measuring extracellular TG2 antigen (Figure 
5.3-2 A-C) and TG activity in medium (Figure 5.3-2 D-F). One point mutation of 
Asp94 or Asp97 to Ala decreased 50% of TG externalisation and two point 
mutations completely prevent TG2 externalisation. This indicates this second 
fibronectin binding domain is critical for TG2 trafficking in tubular epithelial cells. 
 
Figure 5.3-3 TG2 in medium following point mutation 
A western blotting immunoprobed for TG2 and measurement of TG activity in the 
culture medium were measured following transfection with 
pcDNA6.2/nTC-tag-DEST vector containing either 1) full length TG2 (tg), 2) TG2 
with a single point mutation of Asp94 to Ala (f1), 3) TG2 with a single point mutation 
of Asp97 to Ala (f2), or 4) TG2 with a two point mutation of TG2 at Asp94& Asp97 to Ala 
(f3), wt indicates non-transfection control. Data represents mean values ±SEM.  
n=5, ** p<0.01, *p<0.05) 
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5.4 TG2 Co-transport with fibronectin 
As the sequence 88 to 106 is a fibronectin binding site, it is possible that TG2 
in TECs is simply co-transported with fibronectin in the same way as proposed 
by Griffin in fibroblasts, but with a different fibronectin binding site. To assess 
this, we knocked down fibronectin using co-transfection of anti-fibronectin 
siRNA with full length TG2 (tg-f) into three TECs lines. Fibronectin knockdown 
was in excess of 80% compared to cells transfected with non-sense siRNA 
(tg-ns) using volume densitometry analysis by western blot analysis (Figure 
5.4-1 A) and β-actin was used as a loading control. Fibronectin knockdown had 
no effect on TG activity in the cell lysate. The cells co-transfected with 
anti-fibronectin siRNA and TG2 had same TG activity in cell lysate as the cells 
co-transfected with nonsense siRNA and TG2 did (Figure 5.4-1 B). The 
measurement of extracellular TG activity, antigen and TG activity in culture 
medium was identical irrespective of fibronectin knockdown (Figure 5.4-1C-E). 
Therefore, TG2 externalisation appears to be independent of cell-secreted 
fibronectin and thus TG2 is not co-transported with fibronectin. 
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Figure 5.4-1 Intra and extra-cellular TG2 levels following fibronectin 
knockdown 
OK, NRK52E and MDCK II renal epithelial cells were co-transfected with TG2 plus 
either anti-fibronectin siRNA (tg-f) or non-sense siRNA (tg-ns). Western blot (WB) 
was immunoprobed for fibronectin were used to show basal fibronectin level in the 
cell lysate 48 hours after transfection (A) with β-actin as a loading control. Volume 
density measurements as a percentage of the fibronectin knockdown against cells 
transfected with non-sense siRNA are shown below the blot. Total TG activity in 
cell lysates (B), extracellular TG activity (C), extracellular TG2 antigen (D) and TG 
activity in culture medium (E) was measured, wt indicates non-transfection control. 
Data represents mean values ±SEM. n=5, *: p<0.05 
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5.5 Dose mutation of the putative TG2 export sequence prevent 
TG2 export in stably transfected cells 
Stably transfection is characteristic by the permanent integrating of the 
transfected genes into a random position in the genome of mammalian cells 
and thus ensures long-term protein production. One of the criticisms in 
studying TG2 externalisation using transient transfected cells is the 
externalised TG2 can be released because of the cell membrane damage 
involved in the transfection procedure. To avoid this bias, previous 
experiments had inbuilt controls, i.e. cells transfected with 
pcDNA6.2/cTC-tag-DEST vectors containing constructs that were and were 
not exported in the same experiment. However to provide conclusive proof 
stably transfected cells were cloned out.  This  also provide the additional 
benefits of improved cell imaging and the ability to study protein interactions 
more closely. NRK52E cells were transfected with pcDNA6.2/cTC-tag-DEST 
vectors containing full length TG2, TG2 with β-sandwich domain missing and 
TG2 with a two point mutation (Asp94 & Asp 97). 
Stably transfected NRK52E cells were cloned out by blasticidin resistance and 
individual clones selected that had comparable TG2 expression between the 3 
vectors transfected full length (TG2 cDNA (tg), TG2 with β-sandwich domain 
missing (-bsw) and two point mutation of Asp94 and Asp97 (f3) (Figure 5.5-1). 
The expression of TG2, TG2 with β-sandwich domain missing and TG2 with 
mutations at amino acid 94 and 97 were measured using western blots 
immunoprobed for TG2 (Figure 5.5-1 A). Cells expressing both full length TG2 
(tg) and point mutant TG2 (f3) showed a clear band at 75 kDa. TG2 with 
β-sandwich domain missing (-bsw) produced a 60 kDa (-bsw) band (Figure 
5.5-1 A). The intracellular total TG activity increased 5 fold compared to wild 
type cells for full length TG2 and TG2 mutants (Figure 5.5-1 B). Only the full 
length TG2 was readily secreted extracellularly and can be detected in the 
culture medium (Figure 5.5-1 C-E). There was no detectable increase in TG2 
antigen or activity in the medium for wild type cells and cells transfected with 
the 2 point mutant TG2 (Figure 5.5-1 D, -bsw and f3). This confirmed studies 
performed in transiently transfected TECs that TG2 externalisation was 
prevented once the β-sandwich domain was deleted or Asp94 and Asp97 
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mutation added to the 88-106 amino acid fibronectin binding. 
 
Figure 5.5-1 Measurements of intracellular and extracellular TG in 
stable transfected NRK52E cells 
Cells were transfected using pcDNA6.2/cTC-tag-DEST vector containing full length 
TG2 cDNA (tg), TG2 with β-sandwich domain missing (-bsw), two point mutation 
Asp94 and Asp97 to Ala (f3) and stable clones isolated using blasticidin resistance. 
Stable clones were selected base the comparable TG2 expression. Wild type 
NRK52E cells (wt) was used as a non-transfection control. Data represents Mean ± 
SEM, n=5, * p<0.05 
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5.6 Characterisation of the TG2 export motif  
A key question to access is if the TG2 export motif (aa 88-106) itself is enough 
to target TG2 for externalisation in TECs or whether it is required to work with 
other parts of TG2 to facilitate this process as all our exported constructs 
previously contained at least the core of TG2 plus the β-sandwich. To address 
this, theTG2 export motif, the β-sandwich domain and the core domain (not 
transported, negative control) were inserted in to a HaloTag®  vector and the 
HaloTag®  protein (33 kDa) levels measured in the cell lysate and culture 
medium (Figure 5.6-1). Promega’s HaloTag®  system utilises has a series of 
synthetic ligands that forms strong covalent bonds with Halo-tagged protein 
which can be used in fluorescent imaging, quantification and protein 
immobilisation studies as well as various customizable ligand approaches. 
The HaloTag®  protein in the cell lysates was similar between all 3 constructs 
indicating similar transfection efficiency and production of HaloTag®  protein in 
the cell. However, the HaloTag®  protein was only found to be elevated in 
culture medium when fused to either TG2 export motif aa88-106 and 
β-sandwich domain construct (Figure 5.6-1), being significantly higher than that 
of TG2 core domain (p<0.05). This clearly indicates that the TG2 export motif 
aa88-106 is capable of targeting other proteins for externalisation 
independently of the rest of the β-sandwich or TG2. 
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5.7 Discussion 
In this chapter, two function amino acid sequences that are both fibronectin 
binding site were studied. The first, encompassing the first 7 amino acids of the 
b-sandwich had previously been linked to TG2 export in fibroblasts, where as 
the second spanning amino acids88-106 within β-sandwich domain had not 
been associated with TG2 externalisation.  The removal of first 7 amino acids 
(fibronectin binding site 1) had no effect on TG2 externalisation in TECs. A 
single point mutation of either amino acid 94 or 97 caused a decrease of 50%  
in TG2 externalisation while introduction of both point mutations prevented 
TG2 externalisation suggesting that the amino acid sequence 88-106 is critical 
for TG2 export and fibronectin is important in this process. This finding was 
further confirmed using stably transfected NRK52E cells using 
pcDNA6.2/cTC-tag-DEST vector containing TG2 with β-sandwich domain 
missing and TG2 with two points mutants (Asp94 & Asp97). However, knock  
 
Figure 5.6-1 Can the TG2 export motif target other proteins for cell 
export? 
NRK52E cells were transfected with pFC14K HaloTag®  CMV Flexi®  vector 
containing either the TG2 β-sandwich domain (bsw), TG2 core domain (core), or the 
TG2 export motif 88-106 (motif). HaloTag®  protein levels in culture medium and cell 
lysate were measured 48 hours post transfection using anti-HaloTag pAb. L: cell 
lysate, M:culture medium. Data represents mean ± SEM. n=5, *p<0.05 
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down of fibronectin in cells using co-transfection of anti-fibronectin siRNA and 
TG2 and no affect on TG2 externalisation suggesting that while this part of 
TG2 is critical for export, it is not linked directly to fibronectin binding, although 
one can not exclude it binding to fibronectin like domains in other proteins. 
As both amino acid sequences investigated are fibronectin binding sites, 
caution has to be used in interpreting some of the data as mutations in either 
could affect the extracellular TG2 antigen ELISA assay that is based on 
binding to a fibronectin coated  plate.  However cell lysate from NRK52E 
cells transfected with TG2 mutants such as TG2 with β-sandwich domain 
deleted and TG2 with Asp94 and Asp97 mutated retained a higher level of TG2 
antigen than that of wild type cells (data not shown). This suggested the 
presence of other fibronectin binding site outside β-sandwich domain, most 
likely within the core domain because the core domain also retained TG2 
antigen in the antigen ELISA assay. The gold standard method for studying 
protein interactions is co-immunoprecipitation (CO-IP); however, CO-IP can be 
difficult if the protein binding is not strong enough to be pulled down.  Cop-IP 
was not used in these two papers studying the fibronectin binding site (Gaudry 
et al. 1999; Hang et al. 2005). In Gaudry et als’ work, the fibronectin and TG2 
binding was determined by using β-galactosidase activity measurements in a 
fibronectin coated plate (Gaudry et al. 1999). They did not check if other 
domains of TG2 can interact with fibronectin. 
In Hang et als’ work, the interaction between TG2 and 42 kDa fibronectin 
fragment were determined using TG2/factor XIIIa chimeric constructs 
containing Myc-His tags followed by immobilisation using Sepharose beads 
(Hang et al. 2005). TG2/factor XIIIa chimeras were used because factor XIIIa 
do not interact with fibronectin and only β-sandwich domain of TG2/factor XIIIa 
chimera interacted with a 42 kDa fibronectin fragment.  A relatively weak 
interaction or an interaction between TG2 and outside the 42 kDa fibronectin 
fragment can be missed. Our finding suggested a possibility of novel 
fibronectin binding site on the core domain of TG2, but more studies are 
needed to confirm this preliminary observation. 
The 86 to 106 amino acid motif we have identified as crucial for TG2 export is 
an interesting part of the β-sandwich forming a β5/β6 hairpin that is exposed 
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on the surface of TG2. Asp94 and Asp97are crucial for the β5/β6 hairpin to form 
and subsequently the 3 dimensional folding here is also critical TG2 for export 
(Figure 5.7-2). Simply attaching this amino acid sequence to the C terminal of 
another protein (e.g. HaloTag protein) seems to target it for export which 
confirms that it is the part of TG2 required for TG2 trafficking and that no other 
part of TG2 is used in this process. There have been several hypotheses 
suggesting that TG2 could be co-transported with fibronectin however our 80% 
knockdown of fibronectin by siRNA with no effect on TG2 extracellular 
trafficking not only contradicts these hypotheses but also implies that the 
amino acid sequence 88-106 must have additional binding partners and/or 
properties. It is likely that this TG2 export motif can bind to other proteins that 
contain a fibronectin like domain and that this can act as a transmembrane 
binding partner. Identifying binding partners is therefore of importance. As 
most of the unconventional secretory proteins such as FGF-2 and IL-1β need 
to be recruited by plasma membrane or ER membrane residual proteins before 
externalised, it is possible the TG2 transport 88-106 binds to other proteins 
and facilitate TG2 externalisation. Based on the 3D protein structure (Figure 
5.7-2) the wideness of β5/β6 hairpin is about the same size of heparan sulfate 
proteoglycans (HSPGs) side chains. It is possible that the TG2 transport motif 
binds to HSPGs of syndecan 4 and thus externalised through a direct 
molecular trap. 
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Using bio-informatics it has been confirmed that the sequence 
88WTATVVDQQDCTLSLQLTT106 is specific to TG2. Two very similar 
sequences were identified in two mammalian cell membrane proteins.  The 
first is the P2X purinoceptors family (15 of 19 amino acids in common with 
TG2).  These are cell membrane ion channels and are activated by ATP (Bo 
et al. 1992; Bo et al. 1995; James et al. 2002). The other is 
Semaphorin/CD100 antigen (16 of 19 amino acids in common with TG2).  
This belongs to a large family of secreted and transmembrane proteins that 
function as repellent signals during axon guidance (Bougeret et al. 1992; 
Herold et al. 1995; Hall et al. 1996).  Semaphorin, in particular is interesting 
as it can be secreted and thus may have some common elements with TG2 
export. However little is known about Semaphorin export. 
 
Figure 5.7-2 3D structure of β-sandwich domain and motif 88-106 
The structure of β-sandwich domain (white), motif 88-106, β5/β6 (black), 
Asp94 and Asp97 are shown as spheres (gray) 
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Chapter 6 Characterising the 
process of TG2 extracellular 
trafficking and the role of the TG2 
export motif 
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6.1  Introduction 
In the previous chapter, it was demonstrated that the TG2 export motif 
consisting of amino acids 88-106 within β-sandwich domain is critical for TG2 
extracellular trafficking and this process is independent of fibronectin. In this 
chapter, physiological characteristics of TG2 extracellular trafficking will be 
investigated.  
In normal renal tubular, tubular epithelial cells are grown surrounding tubular 
lumen maintained by basement membrane and extracellular matrix of the 
tubule (Figure 6.1-1). In tissue culture, if the cell is correctly polarised the side 
cell that sits on the plastic surface represents the basolateral surface and 
typically will generate a basement membrane between itself and the plastic to 
aid cell growth and adhesion. The side of the cell that faces upwards into the 
culture medium is the apical side. Apical side of the cells which typically has a 
brush border normally forms the tubular lumen facing the urine. 
 
 
Figure 6.1-1 Diagram of tubular epithelial cells in renal tubule 
Renal tubules are formed by renal tubular epithelial cells (TECs).TECs attached 
to extracellular matrix on the basement membrane that is the basal side of the 
cell. The surface facing tubular lumen is the apical side of TECs. 
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6.2 Direction of TG2 secretion 
To determine if β-sandwich domain and the motif 88-106 of N-terminal 
β-sandwich domain can target a protein extracellular trafficking, three pFC14K 
HaloTag® CMV Flexi® vectors containing β-sandwich domain, the motif 
88-106 and the core domain of TG2 were constructed (Table 6.2-1). HaloTag®  
should be measured in the culture medium in the constructs containing 
β-sandwich domain and the motif 88-106; however, not in the construct 
containing core domain. The proteins that bind to the motif 88-106 can be 
pulled down using HaloTag®  magnetic beads and analysed using SDS-PAGE 
gel with silver stains. The proteins that bind to both β-sandwich domain and 
the motif 88-106 but not bind to the core domain of TG2 can be the candidate 
proteins that facilitate TG2 externalisation. 
Table 6.2-1 Primers for HaloTag®  constructs 
 Forward primers Reverse primers 
HaloTag-bsw 
AGGAGCGATCGCCATGGCCGAG
GAGCTGGTCTTAGAGAGG 
GGCGGTTTAAACATCCGCTGGGC
ACCAGGCGT 
HaloTag-core 
TAAAGCGATCGCCATGGCTGTGT
ACCTGGACTCGGAA 
GTCGGTTTAAACCCCTGTCTCCT
CCTTCTCGG 
HaloTag-motif 
AGCAGCGATCGCCATGTGGACAG
CCACCGTGGTGGA 
AACTGTTTAAACGGTGGTGAGCT
GCAGCGAGAGG 
These primer pairs were used to generate cDNA for insertion into pFC14K HaloTag CMV Flexi 
vector to generate the following plasmids HaloTag-bsw: HaloTag® containing β-sandwich 
domain, HaloTag-core: HaloTag®  containing the core domain of TG2,p HaloTag-motif: 
HaloTag®  containing the motif 88-106 of N-terminal β-sandwich domain of TG2. 
To investigate if TG2 was being transported basolaterally (i.e. towards the 
tubular basement membrane) or apically (i.e. into the lumen), cells were grown 
in cell culture well inserts (353090 BD, UK) which contain a 0.4µm pore 
membrane at the bottom which allows free movement of proteins and 
metabolites. TECs where then grow into a tight monolayer on the insert such 
that molecules secreted from either the apical or basolateral side of the cell 
would be compartmentalised. Culture medium inside the insert represented 
apical secretion of TG2 and had a TG activity below the detection limit of the 
assay (Figure 6.2-1).  In contrast, TG activity was 3 mIU/mg of protein in the 
culture medium below the cell culture insert indicating basolateral TG secretion 
to the basement membrane. 
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6.3 Visualisation of basal secretion of TG2 
To confirm TG2 was being excreted solely from the basolateral surface of the 
cell, TG2 export was visualised by immunofluorescence using a combination 
of deconvolved Z stacks of immunofluorescent images and 3D rendering to 
generate a complete 3D image of the cell. NRK52E cells transfected with 
pcDNA6.2/cTC-tag-DEST vector carrying TG2 with a tetracysteine tag were 
stained with FlAsH. Subsequently cells were stained with a basement 
membrane marker, collagen IV. Taking a 3D rendered cell image (Figure 6.3-2 
A-F) looking directly on the apical surface (ie from above) then the image is 
almost exclusively green (ie TG2) with the blue nucleus (DAPI) visible (Figure 
6.3-2 A). Turning the image side way into a lateral view (Figure 6.3-2 B) clearly 
shows the red collagen IV under the cell, green TG2 towards the basolateral 
 
Figure 6.2-1 TG2 is exported across the basolateral membrane 
Total TG activity of culture medium was measured by the incorporation of 
Biotinylated TVQQEL peptide into casein using a modified ELISA. Cells were 
transfected with pcDNA6.2/cTC-tag-DEST containing full length TG2 cDNA and 
culture medium was replaced with serum free medium 48 hours post transfection. 
Total TG activity was measured after 4 hour of incubation at 37°C. Culture medium 
from the culture well inserts represent TG2 export to the apical side (a) and culture 
medium outside of the culture well inserts represent TG2 export to the basolateral 
side (b).Data represents Mean ± SEM, n=5, *p<0.05  
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membrane with no TG2 at all toward the upper apical membrane with the blue 
nuclei sitting just above the bulk of the green TG2. Looking at the bottom of the 
cell, ie a basal view (Figure 6.3-2 C), then all that is visible in some red 
collagen staining but mainly yellow to white staining which represents 
co-localisation of TG2 with collagen IV. Cartoons of the 3D images obtained 
from Figure 6.3-2 A-C are shown in Figure 6.3-2 D-F. Here the volume of the 
fluorescent signal is calculated based on the threshold of the fluorescent signal 
and marked as the same colour. The advantage of this is a clearer observation 
of the fluorescence with middle to low intensity and a calculation of the 
fluorescent volume.   
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To confirm the basal externalisation for TG2, NRK52E cells were also stained 
with an apical marker-phalloidin. TG2 was again introduced using a 
tetracysteine tag vector stained green with FlAsH and phalloidin stained red. 
Three dimensional rendered fluorescent images (Figure 6.3-1 A-F) are again 
shown as true images (Figure 6.3-1 A-C) and 3D cartoon models. Phalloidin 
primarily stained the apical surface of the cell and cell junctions, appearing in 
 
Figure 6.3-2 3 Dimensional imaging for NRK52E cells stained with TG2 
(green) and collagen IV (red) 
NRK52E cells transfected with pcDNA6.2/cTC-tag-DEST containing full length TG2 
were stained with FlAsH green and stained collagen IV red. Z stacks were acquired, 
deconvolved and 3D rendered. The direct fluorescent signal (A-C) and carton 3D 
image (D-F) are generated from the same image based on the area and intensity of 
the fluorescent stain. Apical or top (A, D) , lateral or side (B, E) and basal or bottom 
(C, F) views are shown. The co-localisation for TG2 and collagen IV is represented by 
yellow. 
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the apical view to be floating above the green TG2 and blue nuclear stain 
(Figure 6.3-1 A, D). It is clear in the lateral view (Figure 6.3-1 B, E) that the red 
phalloidin is concentrated at the apical surface of the cell with no red present at 
the basal membrane. In contrast, TG2 in green was exclusively found at the 
basal side of the cell and no co-localisation was found at the basal side of the 
cell. The basal view (Figure 6.3-1 C, F) shows exclusively TG2 and the bottom 
of the nucleus. This further confirms that TG2 is exclusively externalised at the 
basal side of the cell. 
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6.4 Discussion 
Perhaps unsurprisingly, we found that TG2 is transported basolaterally into 
what would be the tubular basement membrane in vivo. This finding is 
consistent with TG2s function in cell adhesion process and its role in ECM 
deposition and stabilisation (Fisher et al. 2009) that becomes pathological in 
 
Figure 6.3-1 Three dimensional imaging of NRK52E cells stained for TG2 
and phalloidin 
NRK52E cells transfected with pcDNA6.2/cTC-tag-DEST containing wild type TG2 
were stained with FlAsH to show TG2 as green and then co-stained with phalloidin 
red to mark the apical membrane. Z stacks were acquired and using deconvolution 
and 3D rendering apical (A), lateral (B) and basal views (C) were obtained. 3D 
rendered image was then transformed into volume cartoons based on the area and 
intensity of the fluorescent stain to generate a clearer picture of where the stains were 
residing in the cell (D-F). 
 157 
 
fibrosis (Johnson et al. 2007). In terms of understanding the process of TG2 
trafficking then this may help if differences can be identified between the basal 
and apical membranes in terms of potential transmembrane proteins or 
channels (Fisher et al. 2009). The basolateral externalisation of TG2 can be 
further visualised using deconvolution microscopy and 3D rendering. The 
apical and basal side of the cell can be clearly distinguished in the 3D 
rendering imaging using basement membrane marker (ie collagen IV) and 
apical membrane marker (ie phalloidin). 
As TG2 is solely externalised through basement membrane of the cells, it is 
possible that TG2 is carried through basement membrane by a 
trans-membrane proteins. This trans-membrane protein should be dominantly 
expressed at the basement membrane side of the cell. Heparan sulfate 
proteoglycans (HSPGs) is one of the trans-membrane proteins that localised 
at the basement membrane side of the cell. Basement membrane-type HSPGs 
are the main proteoglycans synthesised by glomerular epithelial cells (Stow et 
al. 1989) and other types of epithelial cells (David et al. 1985; Mohan et al. 
1991). Cell surface HSPGs are co-localised with TG2 and TG2 has a high 
affinity to heparan sulfate (Scarpellini et al. 2009). It is possible that TG2 is 
externalised through a HSPGs-mediate molecular trap. 
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Chapter 7 Identify possible 
transport binding partners for TG2 
externalisation 
  
 159 
 
7.1 Introduction 
In chapter 5, the amino acid sequence from 88 to 106 has been identified as 
that responsible for TG2 externalisation. Further proteins tagged with this motif 
can be externalised from the cell. The aim of this section is to identify the 
protein or proteins that can bind to the TG2 export motif. To do this the initial 
approach was to use the TG2 export motif linked to a HaloTag®  which can be 
used to immobilise the tagged protein using magnetic beads or resin. Any 
protein binding to the motif could then be detected using silver stain. Once a 
band that is specific to the motif (ie not shown in the core domain construct), 
the band could be further analysed using mass spectrometry to identified the 
protein sequence. 
A second approach was to use yeast two hybrid screen. The TG2 export motif 
was inserted into pGBKT7 vector that is an expression vector. This was 
co-transfected into yeast as “bait” with a human protein library in the pGADT7 
vector used as “prey”. Any protein interaction between bait and prey actives 
the reporter genes and thus yeast is able to synthesis amino acids essential for 
yeast growth and Aureobasidin A antibiotics resistance. The prey vectors were 
then recovered from surviving yeast and amplified in E. Coli to identify the 
protein sequence. The TG2-protein interaction was subsequently confirmed 
using co-immunoprecipitation (CO-IP). The effect of candidate proteins on 
TG2 externalisation was determined using intra- and extra-cellular TG2 
measurements following the candidate proteins knocked down by siRNA. 
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7.2 HaloTag pull down of proteins binding to the TG2 export motif 
To identify the protein binds to the TG2 export motif, magnetic beads (G9311, 
Promega) bound to the HaloTag ligand were used to pull down the constructs 
containing β-sandwich domain, core domain and TG2 export motif from cell 
lysates of NRK52E cells transfected with pFC14K (HaloTag 7) CMV flex vector 
containing the β-sandwich domain of TG2 (bsw), core domain of TG2 (core) 
and TG2 export motif (motif) (Figure 3.1-7). 
The proteins-TG2 export motif complex was eluted using Factor Xa and run on 
a reducing SDS-PAGE followed by sliver stain. Any bands that were presented 
 
Figure 7.2-1 Schematic for HaloTag protein pull down experiments 
Cells were transfected with HaloTag vectors containing protein of interest (POI) (ie 
TG2 export motif) and allowed to grow for 48 hours to produce an optimal amount of 
protein synthesised. The cells were lysed and the cell lysate is pulled down using 
Halolink magnetic beads. POI-HT (HaloTag protein)-proteins complex (ie any protein 
that binds to the TG2 export motif) bind to Halolink magnetic beads and POI-protein 
complex was then cleaved from the beads using Factor Xa proteinase. The Factor 
Xa elution is then run on SDS-PAGE and downstream analysis to identify the 
interacting protein. 
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on β-sandwich and TG2 export motif pull downs (ie exported), but not on the 
pull down from the core domain construct (ie not exported). From a 7.5% gel 
(Figure 7.2-2), it should be possible to see the β-sandwich domain (15 kDa, 
bsw), core domain (36 kDa, core) and the TG2 export motif (2 kDa, motif), 
however, it was not possible to see clear bands at any of these sizes 
suggesting that either the proteins were too low in abundance, HaloTag 
harvesting was poor or the HaloTag was not separated from the HaloTag 
ligand on the magnetic beads. Multiple other bands were visible in the cell 
lysate pull down from non-transfected cells (wt) indicating a lack of binding to 
the beads. As the HaloTagged protein can be detected in HaloTag ELISA used 
 
Figure 7.2-2 Silver stain of SDS-PAGE from HaloTag pull down 
experiments 
Cell lysate pull downs from NRK52E cells transfected with pFC14K (HaloTag 7) CMV 
flex vector containing the β-sandwich domain of TG2 (bsw), core domain of TG2 
(core) and TG2 export motif (motif) were run on 7.5% SDS-PAGE followed by silver 
stain. It should be possible to see any band that is specific to β-sandwich domain and 
TG2 export motif pull downs but no in core domain construct pull down. However, no 
specific band was found. Cell lysate from non-transfected NRK52E cells (wt) was 
used as a negative control. 
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to measure export in Section 6.2, clearly the labelling and detection system 
works with the constructs used which makes the lack of identification of the 
inserted protein surprising. Together this data suggests that HaloTag pull down 
may be not specific or strong enough to be pulled down by this process. 
Attention was therefore transferred to a Yeast two hybrid approach to explore 
the possible binding proteins. 
7.3 Potential protein binding partners for TG2 externalisation 
using yeast two hybrid screen 
As HaloTag experiments fail to pull down even the proteins that were 
transfected into cells, a yeast two hybrid screen was used to identify possible 
candidate proteins. The TG2 export motif was cloned into bait vector pGBKT7 
and two-hybrid library screening with yeast mating using a normalised human 
protein library was performed (Section 3.5.4). The expression of TG2 export 
motif in yeast was first tested for autotoxicity and autoactivation. In autotoxicity 
test, yeasts transfected with pGBKT7 vector containing TG2 export motif had 
similar numbers and size of colonies as yeasts transfected with empty vector. 
The expression of TG2 export motif is therefore not toxic to yeast and yeast 
two hybrid system can be used to study TG2 export motif interacting partners. 
In autoactivation, no colonies was found in selected culture plate of both yeast 
transfected with pGBKT7 vector containing TG2 export motif and the yeast 
mating of pGBKT7 vector containing TG2 export motif and pGADT7 empty 
vector. This confirms that yeast carrying the TG2 export motif expressed can 
be selected with selective culture plate systems and subsequently yeast two 
hybrid system can be used in studying TG2 export motif binding proteins. 
Yeast mating resulted in yeasts diploids containing pGADT7 vector with protein 
sequence that interact with the TG2 export motif growing in selected culture 
plate. The yeast diploids were picked and the yeasts containing pGADT7 were 
grown on selected culture plate. A total of 152 positive colonies were identified 
in two-hybrid screening using normalised human library. 34 pGADT7 vector 
containing candidate protein sequences were extracted and amplified using 
JM109 E.coli. The candidate protein DNA sequence was identified using DNA 
sequencing (Core Genomic Facility of the University of Sheffield) using a T7 Promoter 
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primer. 
To confirm genuine protein interactions in yeast two hybrid system, yeasts 
were co-transfected with the pGADT7 containing candidate protein DNA 
sequence and the pGBKT7 vector containing TG2 export motif. Yeasts 
co-transfected with pGADT7 containing the candidate protein DNA sequence 
and empty pGBKT7 vector were used as negative controls. Positive colonies 
on selection plates from yeast co-transfected with pGADT7 vector containing 
the candidate protein DNA sequence and pGBKT7 vector containing TG2 
export motif but no colonies of yeast co-transfected with pGADT7 vector 
containing candidate protein DNA sequence and empty pGBKT7 vector 
indicating a genuine protein interaction (Section 3.5.5.2). The DNA sequences 
were identified using BLAST (Basic Local Alignment Search Tool) (Table 
7.3-1).  
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Table 7.3-1 Potential binding protein sequences and BLAST (Basic Local 
Alignment Search Tool) results ranked in the frequency of appeared 
Identified Prey Sequence Blast result 
MPSSDDEATADSQHSTPPKKKRKVEDPKDF
PSELLSFLSHAVFSNRTLACFAIYTTKEKAALL
YKKIMEKYSVTFISRHNSYNHNILFFLTPHRH
RVSAINNYAQKLCTFSFLICKGVNKEYLMYSA
LTRDPFSVIEESLPGGLKEHDFNPEEAEETK
QVSWKLVTEYAMETKCDDVLLLLGMYLEFQ
YSFEMCLKCIKKEQPSHYKYHEKHYANAAIF
ADSKNQKTIC 
Large T antigen 
MYLNEVAGKHGVGRIDIVENRFIGMKSRGIY
ETPAGTILYHAHLDIEAFTMDREVRKIKQGLG
LKFAELVYTGFWHSPECEFVRHCLSTMRSW 
Argininosuccinate synthase 
MTPVDVPVTNPAATILPVHVYPLPQQMRVAF
SAARTSNLAPGTLDQPIVFDLLLNNLGETFDL
QLGRFNCPVNGTYVFIFHMLKLAVNVPLYVN
LXXNEEVLVSAYANDGAPDHETASNHAILQLF
QGDQIWXRLHRGAIYGSS 
C1q domain 
MQADVRWLYTNMSFYVRDLSILGFLVSVGW
GDGPGTNTPWIPRDNCTYLPLLSLQASYGN
FIGMKIYMLRRLNIR 
Cytochrome oxidase subunit I 
MIFTYLVNFVYKNTRQSVLPMETGFRLLCFY
C 
Translocon-associated protein 
gamma 
MGFYGGLAGGKDQGEMMSDGGYVVFRRM
QL 
Neurobeachin-like protein 2 
MHHQLWVFMGVWQVERTRER Ubiquitin-like protein ATG12 
MDTKGQLYLFTFIVIASFLWKLYRNENIHVKEI
KH 
Sodium-dependent dopamine 
transporter 
MEASEFXPSSGINAEWPLRPGHLLYLYYSICT
FPGTRNTKLTFLCTEAQTSREQLGTPLIIN 
Tapasin 
MYLGLKILLSTPLAVCLTVFSYGDYCLFLMGI
SDSKCI 
Voltage-dependent L-type calcium 
channel subunit alpha-1C 
MAYGLINEFMDSWTTFIDDHISRDVVDPHTAL
RYIIETVLFPFFLFPDNKCI 
Dynein heavy chain 1 
MFFLQLESFFFKRKRYQMPAATTLFNCYLLK
GTSMCFRLISLFQGNHGQ 
Ganglioside-induced 
differentiation-associated protein 2 
MKTSASPFFLAVGYHKPHIPFRYPKEFQKLY
PLENITLAPDPEVPDGLPPVAYNPWMDIRRR
EDVQALNISVPYGPIPVDFQRKIRQSYFASVS
YLDTQVGRLLSALDDLQLANSTIIAFTSDHGF
LMRTNT 
Isoform 2 of Iduronate 2-sulfatase 
MNITCKAVKIHNFSARDFVTYFLMCVGGVNK
SLALHLLIVSFTISKEHSYILSRKSSNLILNSDY
NLQLYFECTSISFN 
HUMAN Netrin receptor UNC5C 
precursor 
MSRELMRLVLLLGSTLKNFLINEXSKTINICQK
FMPXYXQ 
S45A4_HUMAN Solute carrier 
family 45 member 4 
MLVWSFHDRIYTFCKSVLFSNIECLIFEFFRFL
NWRKALKVFYI 
LAT1_HUMAN Large neutral 
amino acids transporter 
MTREKCLKADWLLALPQWRKPRNLQ 
Heparan sulfate glucosamine 
3-O-sulfotransferase 3A1 
MTSCRTSASQKRTRKKTWHFWKKPSW MDN1_HUMAN Midasin 
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MHYIERIWVFKEILKVRYCKCS 
Dermatan-sulfate epimerase-like 
protein 
MLTLRSVFFSLYLKIVNILISS Integrin alpha-X 
MGDIVMLCLYFFFLTHLXS Anoctamin-6 (Ca2+ channel) 
MQWPSVPSARSTTTAKGT 
Aflatoxin B1 aldehyde reductase 
member 4 
MSDFKELSLILIYSKM 
Alpha1A-voltage-dependent 
calcium channel 
MSFTLRQAYTGTWL 
TOM70_HUMAN Mitochondrial 
import receptor subunit TOM7 
MSMKDADTCINSLKNTTPSLK 
KCNB1_HUMAN Potassium 
voltage-gated channel 
MVNGFWILTVQAQFLLKIFYLSHL 
SYT16_HUMAN 
Synaptotagmin-16 
MTXYTHFVNLYFFQILNALFLNSLXF MEP1A protein 
MHYLLLKLYLLRFHSWHFCHEQRTDATCFAA
W 
Toll interacting protein variant 
MSRELMRLVLLLGSTLKXFLINEESKTINICQN
SCPSISXELXALV 
KCND3_HUMAN Potassium 
voltage-gated channel subfamily 
MLVWSFHDXIYTFCKSVLFSNIECLIFEFFXFL
NWRKALKVFYI 
CAN7L_HUMAN Calpain-7-like 
protein 
MCTYSPFQREEALQ 
UBR4_HUMAN E3 
ubiquitin-protein ligase UBR4 
MLCLYFFFLTHLAS 
WLS_HUMAN Protein wntless 
homolog precursor 
MGDIVMLCLYFFFLTHLAS 
O52E4_HUMAN Olfactory 
receptor 52E4 
Based on this protein list, a literature search was undertaken to identify 
potential functions of each protein paying particular attention to proteins that 
may be involved in protein secretion or presented on plasma membrane. 
Secondly we wanted to identify if these proteins were actually present in the 
cells exporting TG2 as otherwise they were irrelevant. This was undertaken by 
reverse transcription polymerase chain reaction (RT-PCR). The candidate 
proteins identified to be present in NRK52E cells by RT-PCR (Section 3.5.6) 
were Iduronate 2-sulfatase, large neutral amino acids transporter small subunit 
1, neurobeachin-like protein 2, voltage-dependent calcium channel subunit 
alpha-1A, voltage-dependent L-type calcium channel subunit alpha-1C, 
tapasin, translocon-associated protein gamma. 
Tapasin and translocon-associated protein gamma showed a particularly 
strong band at the corresponding size in 1% agarose gel (Figure 7.3-1) 
suggesting the expression of tapasin and translocon-associated protein 
gamma in mRNA levels in NRK52E cells. 
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Resources were available to investigate 3 of these more closely. Large tumour 
antigen (LTA), tapasin and translocon-associated protein γ was selected. 
Tapasin and translocon-associated protein γ were presented in NRK52E cells 
analysed using RT-PCR. Tapasin is involved in the assembly of MHC class I 
and presented peptides at the cell surface and therefore seemed a possible 
 
Figure 7.3-1 Analysis of reverse transcription polymerase chain 
reaction (RT-PCR) products from NRK52E cells in 1% agarose gel 
RT-PCR products with RNA extract from NRK52E cells using specific primers for 
detecting  the following proteins in order Iduronate 2-sulfatase, large neutral 
amino acids transporter small subunit 1, neurobeachin-like protein 2, 
voltage-dependent calcium channel subunit alpha-1A, voltage-dependent L-type 
calcium channel subunit alpha-1C, voltage-dependent L-type calcium channel 
subunit alpha-1C, tapasin and translocon-associated protein gamma. Tapasin 
and translocon-associated protein gamma showed a clear band at the 
corresponding size in an 1% agarose gel. 
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partner in moving TG2 to the cell surface. Translocon-associated protein γ is a 
glycosylated endoplasmic reticulum (ER) membrane receptor associated with 
protein translocation across the ER membrane and therefore one could 
hypothesise a similar role at the plasma membrane. LTA while not an 
endogenous mammalian protein was by far the most frequent sequence pulled 
out by this technique (eg 3 out of 22 colonies in run 1) and for this reason alone 
warranted investigation. Further there is a link between the BK virus that 
produces the LTA and the development of chronic allograft nephropathy and 
we hypothesised that this may cause inappropriate export of TG2 by 
interacting with the TG2 export motif. 
7.4 Confirmation of protein-protein interaction using 
co-immunoprecipitation 
To confirm that these proteins interacted at the cellular levels, a 2 stage set of 
immunoprecipitation experiments was put in place. Firstly by introducing 
exogenous TG2 by transfection and then secondly if the former was positive, 
using endogenous cell levels of the protein. 
7.4.1 Large tumour antigen (LTA)-TG2 co-immunoprecipitation in TECs 
The expression of LTA was initially confirmed in our TEC lines using western 
blot (WB) of lysates from wild type NRK52E, OK, MDCKII cells immunoprobed 
for LTA. NRK49F was used as a positive control because NRK49F was 
transformed using SV40 virus and should produce LTA. The WB of positive 
control (NRK49F) showed a band at 100 kDa that is the correct size for LTA 
(Figure 7.4-1 A). Similarly, NRK52E, OK and MDCKII cells all showed a band 
at the same molecular weight suggesting the expression of LTA in all TECs 
(Figure 7.4-1 A). Duel co-immunoprecipitation was performed using cell lysate 
from NRK52E cells transfected with pcDNA6.2/cTC-Tag-DEST vector 
containing full length TG2 cDNA and PBS was used as a negative control. A 
WB of a TG2 immunoprecipitation was probed with an anti-LTA antibody 
(Figure 7.4-1 B). This demonstrated a band at 100 kDa that corresponds to 
LTA confirming that TG2 interact. No band was found in the negative control 
(+v with anti-TG2 antibody). An anti-LTA pulldown was subsequently 
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fractionated by SDS-PAGE and western blotted before being probed with an 
antibody to TG2 (cub 7402). This gave a 75 kDa that is TG2 (Figure 7.4-1 C) 
and no band was found in PBS negative control (Figure 7.4-1 C, +v). These 
duel co-immunoprecipitation studies confirmed a protein-protein interaction 
between LTA and TG2 at exogenous TG2 levels in NRK52E cells. Duel 
co-immunoprecipitation using wild type NRK52E cells clearly showed a band 
in both anti-TG2 pulldown (Figure 7.4-1 D) and anti-LTA pulldown (Figure 7.4-1 
E) at the corresponding molecule weight. No band was found in the PBS 
negative control pulldown with either an anti-TG2 antibody or anti-LTA antibody. 
These duel co-immunoprecipitation studies confirmed a LTA-TG2 interaction in 
endogenous levels of protein in TECs. 
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Figure 7.4-1 Co-immunoprecipitation of large tumour antigen (LTA) and 
TG2 
A Western blot (WB) immunoprobed with an anti-LTA antibody using cell lysate from 
wild type NRK52E, NRK49F, OK and MDCKII cells confirmed the expression of LTA 
(A). A WB of cell lysate from NRK52E cells transfected with 
pcDNA6.2/cTC-Tag-dest vector containing full length TG2 cDNA 
immunoprecipitated using an anti-TG2 antibody (cub7402) was immunoprobed for 
LTA giving a band at 100 kDa that corresponds to LTA (B). Immunoprobing a WB for 
TG2 from a LTA pulldown showed a band at 75 kDa that corresponds to TG2 (C). 
LTA-TG2 interaction at endogenous protein levels was determined using cell lysates 
from wild type NRK52E cells. This gave a band corresponding to LTA (100 kDa) 
from a TG2 pulldown (D) and a band corresponding to TG2 at 75 kDa (E) from a LTA 
pulldown suggesting a protein-protein interaction at endogenous protein levels in 
NRK52E cells. 
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7.4.2 Tapasin-TG2 co-immunoprecipitation in TECs 
The endogenous expression of tapasin in TECs was analysed by 
immunoprobing WBs of cell lysate obtained from wild-type cells (Figure 7.4-2 
A). A band of 50 kDa which would correspond to the tapasin was seen in all 
three cell lines confirming there production of tapasin at the protein level. 
Tapasin-TG2 interaction was firstly investigated using duel 
co-immunoprecipitation studies using cell lysate from NRK52E cells 
transfected with pcDNA6.2/cTC-Tag-dest vector containing full length TG2 
cDNA and PBS was used as a negative control. Cell lysates were initially 
incubated with an anti-TG2 antibody to pulldown TG2. This was then 
fractionated by reducing SDS-PAGE western blotted and immunoprobed with 
an anti-tapasin antibody. A band at 50 kDa that corresponds to tapasin was 
clearly visible (Figure 7.4-2 B). No band was found in the negative control (+v 
with an anti-TG2 antibody). This was then reversed using an anti-tapasin 
antibody pulldown with a subsequent WB immunoprobed for TG2 giving a 
band at 75 kDa that corresponds to TG2 (Figure 7.4-2 C). No band was found 
in the PBS negative control. Tapasin-TG2 interaction in an endogenous protein 
levels was determined using cell lysate from wild type NRK52E cells and PBS 
was used as a negative control. A Tapasin WB for TG2 pulldown (Figure 7.4-2 
D) and TG2 WB for tapasin pulldown (Figure 7.4-2 E) resulted in a clear band 
at the corresponding size. This data clearly demonstrates a protein-protein 
between tapasin and TG2 in TECs in both exogenous and endogenous protein 
levels. 
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7.4.3 Translocon-associated protein γ-TG2 interaction 
The protein expression of translocon-associated protein γ (TRAP-γ) in TECs 
was determined using WB as in the previous 2 sections. OK, NRKE and 
MDCKII all showed a 20 kDa band in response to an anti- TRAP-γ antibody 
(Figure 7.4-3 A). Duel co-immunoprecipitation studies were then performed 
using cell lysate from NRK52E cells transfected with pcDNA6.2/cTC-Tag-dest 
vector containing full length TG2 cDNA and PBS was used as a negative 
 
Figure 7.4-2 Co-immunoprecipitation for tapasin and TG2 
A Western blot (WB) immunoprobed with an anti-tapasin antibody using cell lysate 
from wild type NRK52E, OK and MDCKII cells confirmed the expression of tapasin 
protein in these cells (A). A WB of cell lysate from NRK52E cells transfected with 
pcDNA6.2/cTC-Tag-dest vector containing full length TG2 cDNA 
immunoprecipitated using an anti-TG2 antibody (cub7402) was immunoprobed for 
Tapasin, giving a band at 50 kDa that is the correct size for tapasin (B). A WB of 
tapasin pulldown immunoprobed for TG2 showed a band at 75 kDa that is the 
correct size for TG2 (C). Cell lysate from wild type NRK52E cells was used to 
determine protein-protein interaction at endogenous protein levels. TG2 pulldown 
and tapasin pulldown generated a clear band at the corresponding molecule weight 
when immunoprobing WB for tapasin (D) and TG2 (E). PBS was used as a 
negative control. 
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control. Initially using an anti-TG2 antibody pulldown (Figure 7.4-3 B) it was not 
possible to detect any band when this was fractionated by SDS-PAGE and the 
WB immunoprobed with an anti-TRAP-γ antibody (Figure 7.4-3 B). However, 
when an anti-TRAP-γ pulldown was subsequently fractionated by SDS-PAGE, 
western blotted and immunoprobed with an anti-TG2 antibody, a band at 75 
kDa that would correspond to TG2 is clearly visible (Figure 7.4-3 C). The 
protein-protein interaction in endogenous protein levels was determined by 
repeating the same experiment. No band was detected in a TRAP-γ 
immunoprobed WB from a TG2 pulldown using cell lysate from wild type 
NRK52E cells (Figure 7.4-3D). A clear band was seen in TG2 immunoprobed 
WB from a TRAP-γ pulldown (Figure 7.4-3 E). No band was seen in pulldown 
experiments using PBS as a negative control. Although the 
co-immunoprecipitation only works in Anti-TRAP-γ pulldown, this result still 
suggested a protein-protein between translocon-associated protein γ and TG2 
in both exogenous and endogenous protein levels. 
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7.4.4 The motif 88-106 binds to origin binding domain of Large T 
antigen 
The sequence indentified in yeast two hybrid screen is the origin binding 
domain of LTA. To determine if the binding of LTA and TG2 is dependent on the 
TG2 export motif and origin binding domain of LTA, the TG2 export motif 
 
Figure 7.4-3 Co-immunoprecipitation for translocon-associated protein 
γ (TRAP-r) and TG2 
A Western blot (WB) immunoprobed with an anti-TRAP-r antibody using cell lysate 
from wild type NRK52E, OK and MDCKII cells confirmed the expression of TRAP-r 
in protein levels (A). TRAP-r immunoprobing of a WB of cell lysate from NRK52E 
cells transfected with pcDNA6.2/cTC-Tag-dest vector containing full length TG2 
cDNA immunoprecipitated using an anti-TG2 antibody (cub7402) showed no band 
at 20 kDa for TRAP-r (B) and TG2 immunoprobing of a WB from a TRAP-γ pulldown 
of the same cell lysate showed a band at 75 kDa that corresponds to TG2 (C). 
TRAP-γ immunoprobing of a WB from a TG2 pulldown of a wild type NRK52E lysate 
(D) showed no band, while TG2 immunoprobing of a WB from a TRAP-γ pulldown 
(E) showed a band at 75 kDa for TG2. PBS pulldown with an anti-TG2 antibody (D) 
and anti-tapasin antibody (E) was used as negative controls. 
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containing HA-tag and origin binding domain of LTA containing Myc-tag was 
cloned into pcDNA 3 (Invitrogen, UK) vector between BamH I and Xho I 
multiple cloning site as described in section 3.1.7. The primers for PCR 
products are listed in Table 7.4-1. The digestion and ligation reaction was 
performed as described in section 3.5.1 and confirmed using DNA sequencing. 
Table 7.4-1 Primers for pcDNA 3 vector containing HAtag-moitif and 
MycTag-LTA origin binding domain 
 Forward primers Reverse primers 
HA-motif 
GGTCGTGGATCCGCCACCATGT
GGACA 
CTCGTACTCGAGTTAAGCGTAAT
CTGGTACGTCGTAGGAGGA 
Myc-LT 
GGTCGTGGATCCGCCACCGGA
ACT 
CTCGAGTCACAGGTCCTCCTCT
GAGATCAGCTTCTGCTCCTCGC
AGAG 
HA-motif: pcDNA 3 vector containing HA Tag and the TG2 export motif, Myc-LT: 
pcDNA 3 vector containing Myc Tag and the origin binding domain of large tumour 
antigen 
 
Duel co-immunoprecipitation studies using an anti-HA-Tag antibody and 
anti-Myc-Tag antibody was performed to determine the exogenous protein 
interaction. The pcDNA3 vector containing TG2 export motif with HA-Tag and 
pcDNA 3 vector containing origin binding domain of LTA and Myc-Tag was 
co-transfected into NRK52E cells. Cells co-transfected with the HA tagged 
TG2 export motif and empty vector or Myc tagged origin binding domain of LTA 
and empty vector was used a negative control. The expression of HA tagged 
TG2 export motif was analysed using the cell lysate from NRK52E cells 
transfected with pcDNA3 vector containing TG2 export motif with HA-Tag and 
the expression of Myc tagged origin binding domain of LTA was analysed using 
the cell transfected with pcDNA 3 vector containing origin binding domain of 
LTA and Myc-Tag. HA tagged immunoprobing of a WB from an anti-Myc 
antibodies pulldown (Figure 7.4-4 A) showed a strong band at 6 kDa that would 
represent the TG2 export motif-HA tag construct. The co-transfection of 
Myc-tagged origin binding domain of LTA and empty vector (LTM+V) had no 
antigen detected. Correspondingly, immunoprobing for Myc tag of a WB from 
an anti-HA antibody pulldown (Figure 7.4-4 B) gives a band at 25 kDa that is 
compatible with the Myc tagged origin binding domain of LTA construct. No 
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antigen detected in the co-transfection of LTM with empty vector (LTM+V). This 
suggested that origin binding domain of LTA binds to the TG2 export motif 
aa88-106. The origin binding domain of LTA also binds to cellular DNA and 
transits to DNA helicase (Paucha et al. 1986). The finding may explain the 
co-localisation of TG2 in cell nucleus that will be detailed in the next section 
and the role of TG2 in cell proliferation (Barone et al. 2007). 
  
 
Figure 7.4-4 Co-immunoprecipitation for origin binding domain of large 
tumour antigen (LTA) and TG2 export motif 
Cells lysate from NRK52E cells co-transfected with pcDNA 3 vector carrying the 
origin binding domain of large tumour antigen and Myc Tag (LTM) and the TG2 
export motif aa 88-106 and HA Tag (MHA) were immunoprecipitated by anti-Myc 
antibodies or anti-HA antibodies. HA immunoprobing of a WB from Myc Tag 
pulldown (A. LTM+MHA) displayed a band at 6 kDa that corresponds to the TG2 
export motif aa 88-106 and HA Tag construct. Myc immunoprobing of a WB from 
HA Tag pulldown (B. MTA+MHA) displayed a band at 25 kDa that corresponds to 
the origin binding domain of large tumour antigen and Myc Tag construct. Cells 
co-transfected with pcDNA 3 vector carrying carrying origin binding domain of large 
tumour antigen and Myc Tag or the TG2 export motif and empty vector was used as 
negative controls (A: MHA+V, B: LTM+V). The expression of MHA and LTM 
construct in NRK52E cells (A: MHA & B: LTM). 
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7.5 Discussions 
In this section, it has been demonstrated that the large tumour antigen (LTA), 
tapasin and translocon-associated protein γ (TRAP-r) interact with TG2 at both 
exogenous and endogenous protein levels in TECs. LTA is a virus protein 
produced by polyomavirus that is involved in cancer and cell transformation 
such as SV40 in tissue culture (Ewen et al. 1989). LTA can be also produced 
by BK and JC virus in human allograft rejection in kidney recipients (Binet et al. 
1999). Cell transformation by SV40 in tissue culture may be related to the 
LTA-p53 (Deppert et al. 1989) and LTA-retinoblastoma binding protein (Rb 
protein) (Ali et al. 2001) interactions. TG2 can modify Rb protein in the cell 
nucleus via transamindation and provide protection against apoptotic insults to 
ensure that cells remain viable during differentiation (Boehm et al. 2002; 
Milakovic et al. 2004). TG2-LTA interaction might be involved in the 
nuclear-targeted TG2 and the role of TG2 in cell apoptosis. A small portion of 
LTA a high affinity to plasma membrane can be expressed on cell surface 
(Lange-Mutschler et al. 1983; Lange-Mutschler et al. 1984). Based on this 
observation, It is possible that the plasma membrane-associated LTA carried 
TG2 to plasma membrane and released it into extracellular space, however 
whether LTA has a role in TG2 externalisation will be determined using 
measurements of extra- and intra-cellular TG activity levels following 
knockdown of LTA by co-transfection of anti-LTA siRNA and TG2 cDNA in 
TECs. Co-localisation analysis of LTA by co-transfection of anti-LTA siRNA and 
TG2 cDNA in TECs in the next chapter. 
Beforehand, it was not expected to find the expression of LTA in TECs 
because OK (Malstrom et al. 1987), NRK52E (de Larco et al. 1978) and MDCK 
II cells (Richardson et al. 1981) were not transformed using SV40. The 
incidence of polyomavirus infection among animal is unknown and thus it is 
possible that the animals used to construct the cell lines were infected with 
polyomavirus. This is logical as TECs with LTA expression would have a higher 
chance to escape cell apoptosis and be selected in the process of establishing 
immortal cell lines. 
Tapasin is an ER membrane protein that is essential for the appropriate 
antigen peptide loading assembly and folding of major histocompaliblity 
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complex (MHC) class I. In tapasin knockout mouse, the peptides have a low 
affinity in MHC class I receptor on cell surface MHC class I molecules and the 
expression of MHC class I molecular is decreased on cell surface (Ortmann et 
al. 1997). Subsequently hosts are immunocompromised in tapasin knockout 
mice and bare lymphocyte syndrome in human (Touraine 1981). The major 
role of tapasin is to assemble the antigen peptide on MHC class I molecule in 
ER and tapasin is responsible for the antigen peptide pass through the ER 
membrane. Based on the observation i.e. TG2 synthesised in the cytosol and 
accumulated around the cell nucleus in ER membrane-formed vesicles 
(Section 4.8 & Section 9.2.1), it is possible that tapasin recruited TG2 in the 
ER-membrane formed vesicles. It will be determined in the next chapter if 
tapasin in involved in TG2 externalisation using measurements of extra- and 
intra-cellular TG activity following co-transfection of anti-tapasin siRNA and 
TG2 cDNA. Visualisation and co-localisation analysis will be needed to 
determine the possible role of tapasin in TG2 externalisation. TRAP-r is a 
glycosylated ER membrane receptor associated with protein translocation 
across the ER membrane (Wang et al. 1999). It is possible that TRAP-r may 
responsible for transport TG2 from rough ER after TG2 synthesised to cytosol 
or other organelles that is involved in TG2 externalisation. TRAP-γ knockdown 
will be performed using siRNA technique to determine the role of TRAP-γ in 
TG2 externalisation in the following chapter. 
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Chapter 8 The effect of knock down 
of Large Tumour Antigen, Tapasin 
and Translocon-associated protein 
γ on TG2 externalisation in TECs 
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8.1 Introduction 
In Chapter 7 the interaction of large tumour antigen (LTA), tapasin and 
translocon-associated protein γ with the TG2 export motif was described at the 
protein level. However, the fact that these 3 proteins interact with the TG2 
export motif does not prove that these proteins are involved in TG2 export from 
the cell and thus determining their significance to the extracellular trafficking of 
TG2 is critical if that are to be implicated in an export pathway. The aim of this 
chapter is to knockdown LTA, tapasin and translocon-associated protein-γ 
(TRAP-γ) using siRNA technology and determine the effect of this on TG2 
externalisation. To undertake this, intra- and extra-cellular TG levels were 
measured 48 hours following the co-transfection of pcDNA6.2/cTC-Tag-dest 
vector containing full length TG2 cDNA with anti-LTA, anti-tapasin or 
anti-TRAP-γ siRNA. 
8.2 Intracellular and extracellular TG activity following knockdown 
Large T-antigen 
OK, NRK52E and MDCKII cells were co-transfected with 
pcDNA6.2/cTC-Tag-dest vector containing full length TG2 cDNA and either 
non-sense siRNA (tg+ns) or anti-LTA siRNA (tg+lt) (siRNA  ID: ABGJPMF, 
applied Biosystems). Wild type cells were used as a negative control (wt). The 
normal expression of LTA (wt, tg+ns) in all 3 cell lines was knocked down by 
approximately 50% when transfected with siRNA (Figure 8.2-1 A, tg+lt) when 
measured by densitometry. Total TG activity in the cell lysates increased by 5 
fold for the cells co-transfected with TG2 cDNA and siRNA (Figure 8.2-1 B, 
tg+ns and tg+lt) compared to wild type cells (wt). Extracellular TG activity 
(Figure 8.2-1 C) and extracellular TG2 antigen (Figure 8.2-1 D) showed a 
significant decrease in extracellular TG levels following LTA knock down 
(p<0.05). This result is consistent with measurements of TG activity in culture 
medium (Figure 8.2-1 E) that is also reduced. This data clearly suggests that 
large tumour antigen is involved in TG2 externalisation.  
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Figure 8.2-1 Extracellular and intracellular TG activity following large 
T-antigen (LTA) knockdown 
OK, NRK52E and MDCKII cells were co-transfected with pcDNA6.2/cTC-tag-DEST 
expression vector containing TG2 cDNA (tg) with either non-sense siRNA (tg+ns) or 
anti-LTA siRNA (tg+lt). Non-transfected cells (wt) were used as a negative control. 
Western blots from cell lysates were immunoprobed for LTA (A) and densitometry 
used to quantify LTA expression. The intracellular TG activity was determined by a 
peptide incorporation assay (B). The extracellular TG activity (C), extracellular TG 
antigen (D) and TG activity in medium (E) were assayed as previously described. 
Data represents: Mean ± SEM, n=5, *p<0.05, **p<0.01. 
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8.3 Extracellular and intracellular TG activity following Tapasin 
knockdown 
Intra- and extra-cellular TG activity was measured in TECs after being 
co-transfected with TG2 plus either anti-tapasin siRNA (tg+tap) (siRNA ID: 
s129197, applied Biosystems) or non-sense siRNA (tg+ns). Non-transfected 
cells (wt) were used as a negative control. TECs all contain a strong tapasin 
expression as shown by Western blot analysis (Figure 8.3-1 A). Densitometry 
demonstrated that the expression of tapasin was knocked down by 70% by 
siRNA (Figure 8.3-1 A). The co-transfection of TG2 cDNA resulted in a 5-fold 
increase of total TG activity in the cell lysate compared to wild type cells 
(Figure 8.3-1 B). The cells co-transfected with TG2 and non-sense siRNA had 
a corresponding 5-fold increase of extracellular TG activity (Figure 8.3-1 C) 
and extracellular TG antigen (Figure 8.3-1 D) compared to wild type cells. 
Despite having the same level of total TG activity in the cell lysate, cells 
co-transfected with TG2 and anti-tapasin siRNA (tg+tap) had an extracellular 
TG activity (Figure 8.3-1 C), antigen (Figure 8.3-1 D) and TG activity in culture 
medium (Figure 8.3-1 E) 5 fold lower than cells transfected with non-sense 
siRNA constructs. This data indicates that tapasin is linked to TG2 
externalisation with almost a compete prevention of TG2 export. 
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Figure 8.3-1 Extracellular and intracellular TG activity following Tapasin 
knockdown 
OK, NRK52E and MDCKII cells were co-transfected with pcDNA 6.2/cTC-tag-DEST 
expression vector containing TG2 cDNA plus either non-sense siRNA (tg+ns) or 
anti-tapasin siRNA (tg+tap). Non-transfected cells (wt) were used as a negative 
control. Western blots of cell lysates were immunoprobed for tapasin and 
densitometry used to quantify the reduction of tapasin expression (A). TG activity in 
the cell lysate was measured by peptide incorporation assay (B), with extracellular 
TG activity (C), extracellular TG antigen (D) and TG activity in medium (E) used to 
measure TG2 externalisation as described in previous chapters. Data represents: 
Mean ± SEM, n=5, *p<0.01. 
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8.4 Extracellular and intracellular TG levels following 
translocon-associated protein γ (TRAP-γ) knockdown 
Measurement of intra- and extra-cellular TG activity following TECs 
co-transfected with TG2 plus either anti-TRAP-γ siRNA (tg+trap) (siRNA ID: 
s135754, applied Biosystems) or non-sense siRNA (tg+ns) was performed. 
The tapasin expression was measured using western blot with densitometry 
(Figure 8.4-1 A) and the expression of TRAP-γ was knocked down by 80% 
using anti-TRAP-γ siRNA. The co-transfection of TG2 cDNA and anti-TRAP-γ 
siRNA or non-sense siRNA both had a 5-fold increase of total TG activity 
(Figure 8.4-1 A) in the cell lysate compared to wild type cells (wt). The 
extracellular TG activity (Figure 8.4-1 C), extracellular TG antigen (Figure 8.4-1 
D) and TG activity in medium (Figure 8.4-1 E) mirrored the intra-cellular 
measurement. This suggested that TRAP-γ knock down had no effect on TG2 
externalisation.  
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Figure 8.4-1 Intracellular and extracellular TG levels following 
translocon-associated protein γ (TRAP-r) knockdown 
OK, NRK52E and MDCKII cells were co-transfected with pcDNA 6.2/cTC-tag-DEST 
vector containing TG2 cDNA plus either non-sense siRNA (tg+ns) or anti-TRAP-γ 
siRNA (tg+trap). Non-transfected cells (wt) were used as a negative control. Western 
blots of cell lysates were immunoprobed for TRAP-r and densitometry used to quantify 
the reduction of tapasin expression (A). TG activity in the cell lysate was measured by 
peptide incorporation assay (B), with extracellular TG activity (C), extracellular TG 
antigen (D) and TG activity in medium (E) used to measure TG2 externalisation as 
described in previous chapters. Data represents: Mean ± SEM, n=5, *p<0.01. 
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8.5 Discussion 
8.5.1 Possible sequence that binds to TG2 export motif 
It is reported that the TG2 export motif covering amino acids 88-106 in the TG2 
β-sandwich domain is a fibronectin binding site. However, we identified that 
both tapasin and LTA also binds to this motif. It is possible that there are similar 
domains or sequence within these three proteins associate with this TG2 
export motif. If the amino acid sequences for human fibronectin, BK virus large 
T antigen and human tapasin are aligned (Figure 8.5-1), then similar sequence 
between fibronectin 1, tapasin from human and LTA from BK virus can be 
 
Figure 8.5-1 Amino acid sequence alignment for candidate proteins that 
binds to the TG2 export motif aa88-106 
Amino acid sequence alignment for Human tapasin (TPSNR_HUMAN, top), human 
fibronectin 1(FINC_HUMAN, middle) and BK virus large T-antigen (LT_POVBK, 
bottom). The red box demonstrate a potential key sequence *C*G* that bind may be 
common to binding TG2 export motif. 
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highlighted. Unfortunately there is no clear consensus sequence; however, 
*C*G* is held across the three proteins (red box) and could possibly be 
importance. The sequences (red box, amino acid sequence 109-118) of 
tapasin located in N-terminal β-barrel (Dong et al. 2009) that is the cytoplasmic 
side on ER membrane. This supports the hypothesis that TG2 synthesised in 
the cytosol can be recruited by the vesicles formed by the ER membrane 
containing tapasin around the cell nucleus. We showed TG2 export motif binds 
to origin binding domain of LTA (Section 7.4.4) and this amino acid sequences 
185-194 is part of DNA binding domain of LTA (Kim et al. 2001) that is facing 
the cytosol for the plasma membrane associated LTA (Klockmann et al. 1984). 
It is possible that the plasma membrane associated LTA binds TG2 at the 
periphery of the cells and externalised through plasma membrane blebbing 
(Section 9.3.1).  The TG2 export motif may have the ability to interact with 
multiple sequences or any interaction could be conformational meaning it 
would not be possible to link to any linear amino acid sequence.  
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Chapter 9 Determining possible 
TG2 externalisation pathways using 
co-localisation analysis and live cell 
imaging 
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9.1 Introduction 
In the previous chapter, it was demonstrated that the TG2 export motif in the 
TG2 β-sandwich domain (88-106) that is critical to TG2 extracellular trafficking 
binds to large tumour antigen (LTA), tapasin and translocon-associated protein 
γ. Further a 50% knock down of LTA using anti-LTA siRNA decreased 50% of 
TG2 externalisation and an 80% knock down of tapasin using anti-tapasin 
siRNA decreased 80% of TG2 externalisation. According to the sequential 
visualisation (described in Section 4.6) of TG2 with tie post transfection, TG2 
was synthesised around the cell nucleus on the surface on the ER and then 
moved peripherally to the plasma membrane amassing in vesicular structures 
within the cytoplasm. 
We hypothesise that TG2 follows one of the 4 recognised unconventional 
externalisation pathways (Figure 9.1-1). These are by inclusion in secreted 
 
Figure 9.1-1 Possible for unconventional protein externalisation 
processes 
Proteins without leader sequence that are not externalised through endoplasmic reticulum 
and Golgi apparatus network can be externalised through 1) Lysosomes, 2) multivesicular 
bodies (MVBs), 3) plasma membrane blebbing and 4) Direct molecular trap by plasma 
membrane-resident transporters. : secretory protein (Nickel 2005) 
 
 
 189 
 
lysosomes; by inclusion in exosomes; via plasma membrane blebbing; and 
using a direct molecular trap approach using plasma membrane-resident 
transporters. 
Therefore in this chapter, the initial aim is to use co-localisation studies with 
various cell organelles to determine where, if and a what stage in the cell TG2 
co-localises with cell organelles and if this can yield clues as to how TG2 
export from the cell is facilitated. Further if the data would be consistent with 1 
of the unconventional export pathways.  
To demonstrate this, fluorescent image co-localisation analysis of FlAsH 
labelled TG2 and organelle light stains was used to determine the involvement 
of organelles including ER, Golgi apparatus and lysosomes in the TG2 
externalisation pathway. The second aim is to use live cell imaging to see how 
TG2 moves in the cell with time. To do this NRK52E cells transfected with 
pcDNA6.2/cTC-tag-DEST expression vector containing full length TG2 cDNA. 
48 hours post transfection cells were visualised to determine possible 
morphological changes that could be link to TG2 externalisation in TECs.  
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9.2 Determination of possible TG2 externalisation pathways 
To determine possible TG2 externalisation pathway, cells were transfected 
with the pcDNA6.2/cTC-Tag-dest vector carrying full length TG2 cDNA with a 
tetracysteine tag which was subsequently revealed using FlAsH staining. Cells 
were co-stained for organelles including endoplasmic reticulum (ER), Golgi 
apparatus and lysosome. 
On commencing this work some assumptions were made. Firstly, as TG2 does 
not have a leader sequence and shoulder not be transported through ER/Golgi 
network. It was expected that TG2 would have very limited co-localisation with 
ER and Golgi staining. If TG2 is externalised through the vesicles ER derived 
vesicles (ie MVBs) then there would be some co-localisation of TG2 and ER 
membrane stains in the cytosol. Secondly, if TG2 is externalised through 
recruitment to lysosomes, some of TG2 fluorescent signal should be 
co-localised with lysosome staining.    
9.2.1 Co-localisation of TG2 and endoplasmic reticulum 
NRK52E cells transfected with full length TG2 (green) and ER stain (red) were 
visualised 48 hour post transfection. The ER stain using organelle light ER 
(Figure 9.2-1 A) appears throughout the cell as punctuate staining that is 
concentrated around the periphery of the cell nucleus. The greatest amount of 
TG2 also appears to be around the cell nucleus (Figure 9.2-1 B, yellow arrows) 
indicated by a considerable amount of co-localise with the ER stain around the 
cell nucleus (Figure 9.2-1 C, yellow arrows). The peripheral TG2 indicated by 
white arrows is not co-localised with the ER stain suggesting that TG2 is not 
externalised through exosomes derived from ER. In co-localisation analysis, 
23.7% of the TG2 fluorescent signals are co-localised with ER overall.  
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To obtain more information as to the spatial positioning of TG2 and ER in the 
cell, a 3D image was rendered from a deconvolved Z stack of images (Figure 
9.2-2). The direct fluorescent signals displayed on a grey background can be 
seen in apical view (Figure 9.2-2 A), lateral view (Figure 9.2-2 B) and 
basolateral (bottom) view (Figure 9.2-2 C). After the light had been tracked to 
its origin by deconvolution, most of the ER (red) is clearly around the nucleus 
(blue) with TG2 concentrated toward the basolateral membrane. The 
co-localisation of TG2 and ER spots can be only seen around the cell nucleus. 
By converting the 3D rendered image to a 3D cartoon the ER and TG2 stain 
can be displayed as blocks between certain thresholds (Figure 9.2-2 D-F). 
Green and red fluorescent signals above the set threshold are labelled as the 
same colour. Low red and green fluorescent signals below the selected 
threshold were ignored to generate a clearer image. Using this approach, the 
apical view (ie from above the cell) shows the ER (red) is concentrated around 
the nucleus while the TG2 (green) is located at the bottom of the cell where it is 
attached to the cover-slip (Figure 9.2-2 D). The accumulation of TG2 at the 
bottom of the cells is more clearly shown in the bottom, basal view (Figure 
 
Figure 9.2-1 Fluorescent co-localisation of TG2 and endoplasmic 
reticulum (ER) 
NRK52E cells were transfected using pcDNA6.2/cTC-tag-DEST containing full length 
TG2. 48 hours post transfection ER was stained red using organelle light ER (A) and 
TG2 was stained green using FlAsH reagent (B). The cell was stained blue using 
DAPI and ER, TG2 and nuclear images merged (C). The co-localisation of TG2 and 
ER is yellow. TG2 co-localised around the cell nucleus with the ER stain is indicated 
by yellow arrows. Peripheral TG2 are indicated by white arrows. The cell nucleus was 
stained blue with DAPI. 
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9.2-2 F). In the 3D co-localisation analysis, only 15.1% of TG2 (green) volume 
within the cell is co-localised with ER while 34% of ER around the cell nucleus 
is co-localised with TG2. All co-localisation is around the cell nucleus. 
9.2.2 Co-localisation of TG2 and Golgi apparatus 
To determine if TG2 is trafficked to the cell exterior via the Golgi apparatus, 
NRK52E cells transfected with pcDNA6.2/cTC-Tag-dest vector containing full 
length TG2 cDNA were stained with Golgi apparatus using organelle light Golgi 
 
Figure 9.2-2 Three dimensional imaging of a cell co-stained for TG2 
(green) and ER (red) 
NRK52E cells were transfected using pcDNA6.2/cTC-tag-DEST containing full length 
TG2. 48 hours post transfection ER was stained red using organelle light ER and TG2 
was stained green using FlAsH reagent. A Z stack images acquired at 200nm 
separation was acquired using cell F and F-view camera. The Z stack images were 
deconvolved using Autoquant software and 3D rendered using Imaris software to 
produce a 3D model of the cell. A direct fluorescent signal 3D image blending all 3 
colours is seen in apical view (A), lateral (B) and basal (C) views which related to top 
side and bottom views of the cell respectively. Images A to C were re-mapped into 
corresponding 3D cartoon models using Imaris (D-F) in which the fluorescent signals 
above a set threshold are marked as the same colour with the same intensity. The cell 
nucleus was stained blue with DAPI. 
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(red) and TG2 (green) 48 post transfection. Golgi apparatus appeared as 
vesicle shape around the cell nucleus (Figure 9.2-3 A), TG2 staining was 
throughout the cell cytoplasm (Figure 9.2-3 B). Merging TG2 and Golgi 
staining (Figure 9.2-3 C) demonstrated some co-localisation (white arrows) of 
TG2 and Golgi apparatus. The construction of a 3D cartoon image of the same 
cell (Figure 9.2-3 C) as described above demonstrates that in apical (Figure 
9.2-3 D), lateral (Figure 9.2-3 E) and basal (Figure 9.2-3 F) views the Golgi 
apparatus form discrete punctuate structures while TG2 concentrates at the 
base of the cell. It is clearer in 3D images that majority of Golgi and TG2 were 
not in the same focal plane and some co-localisation of TG2 and Golgi 
apparatus is displayed in yellow colour (white arrows). There is less than 0.5% 
of TG2 stain that co-localise with Golgi apparatus. The negligible 
co-localisation between TG2 and Golgi apparatus suggests TG2 
externalisation is independent of the Golgi apparatus. 
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9.2.3 Co-localisation of TG2 and lysosomes 
To determine if lysosomes are implicated in TG2 extracellular trafficking, 
NRK52E cells transfected with tetracysteine pcDNA6.2/cTC-Tag-dest vector 
containing full length TG2 cDNA were co-stained with lysosomes using 
organelle light lysosomes (red) and TG2 with FlAsH (green) 48 hours post 
transfection. Lysosomes were visualised as small high density spots 
throughout the cytoplasm (Figure 9.2-4 A), with TG2 appearing in variable 
density patches within the cytoplasm (Figure 9.2-4 B). Merging TG2, 
lysosomes (Figure 9.2-4 C) and the cell nucleus (DAPI) yields very little yellow 
 
Figure 9.2-3 Fluorescent and 3D images of NRK52E cells stained for 
Golgi apparatus and TG2 
NRK52E cells were transfected using pcDNA6.2/cTC-tag-DEST containing full 
length TG2. 48 hours post transfection ER was stained red using organelle light ER 
(A), TG2 was stained green using FlAsH reagent, (B) and the merged image (C) of 
ER, TG2 and the cell nucleus (blue, DAPI) generated. Co-localisation of ER and 
TG2 are seen in yellow and indicated by white arrows. A Z stack of images acquired 
at 200nm separation was acquired using cell F and F-view camera. The Z stack 
images were deconvolved using Autoquant software and 3D rendered using Imaris 
software to produce a 3D model of the cell. A 3D image blending all 3 colours is seen 
in apical view (D), lateral (E) and basal (F) views which related to top side and 
bottom views of the cell respectively. The cell nucleus was stained blue with DAPI. 
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co-localisation by eye suggesting that TG2 is not co-localised with lysosomes. 
Using a Z stack and 3D rendering as described above, cartoon 3D images 
shown in apical (Figure 9.2-4 D), lateral (Figure 9.2-4 E) and basal (Figure 
9.2-4 F) views demonstrate that most of the lysosomes are in different planes 
from the TG2 stains confirming there is little co-localisation (0.002%). 
 
 
  
 
Figure 9.2-4 Fluorescent and 3D images of NRK52E cells stained with 
Lysosomes and TG2 
NRK52E cells were transfected using pcDNA6.2/cTC-tag-DEST containing full 
length TG2. 48 hours post transfection ER was stained red using organelle light 
lysosome (A), TG2 was stained green using FlAsH reagent, (B) and the image of 
lysosome, TG2 and the cell nucleus (blue, DAPI) merged (C). A Z stack images 
was acquired at 200nm separation using cell F software controlling a F-view 
camera. The Z stack images were deconvolved using Autoquant software and 3D 
rendered using Imaris software to produce a 3D model of the cell. A 3D image 
blending all 3 colours is seen in apical view (D), lateral (E) and basal (F) views 
which related to top side and bottom views of the cell respectively. The cell nucleus 
was stained blue with DAPI. 
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9.3 Live cell imaging 
Plasma membrane blebbing can be seen with phase contrast microscopy. 
Therefore the aim here is to use live cell imaging under phase contrast 
microscopy to identify plasma membrane blebbing while tracking TG2 
movement by transfecting cells with TG2 carrying a tetracysteine tag. If TG2 is 
externalised through plasma membrane blebbing, TG2 fluorescence 
co-localised with plasma membrane derived blebs should be seen. If TG2 is 
externalised through a direct molecular trap mechanism, fluorescent TG2 
should pass through the plasma membrane without any morphological 
changes of the plasma membrane. 
9.3.1 Visualisation of plasma membrane blebbing 
Two different types of plasma membrane blebbing can be seen using live cell 
imaging in NRK52E cells at 100 x magnification (ie low power). If 48 hours post 
transfection of TG2 is taken as time zero for imaging purpose in this particular 
field (Figure 9.3-1 A), then at 45 minutes (Figure 9.3-1 B) a cell in the right 
corner of the field showed the appearance of typical plasma membrane 
blebbing (white arrow). At higher magnification using digital zoom (ie 400 x) the 
cell has multiple cell blebs into which the green TG2 appears to be packed 
(Figure 9.3-1 C).  As these images were taken on an inverted microscope the 
visible surface is in fact the basal (underside) surface of the cell. These 
multiple small vesicles are therefore being generated at basolateral side of the 
cell. Intestinally, under high power magnification (Figure 9.3-1 C), the blebs 
directly under the cell appear clear and have either released TG2 or do not 
contain it. However, some vesicles that have moved away from the periphery 
of the cell are darker green than the background suggesting they may still 
contain TG2. 
In addition to this type of blebbing, many cells only generate 1-2 large vesicles 
at the basal surface that are indicated by a red arrow at 45minutes (Figure 
9.3-1 B) that are clearly not present 45 minutes before this (Figure 9.3-1 A). 
Investigation of these cells at 400 x magnification (Figure 9.3-1 D), these 
blebs/vesicles contain TG2 as the fluorescent signal of these vesicles is 
greater than the background cytoplasmic TG2 stain. When watched as a 
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movie it can be seen that the cell concentrates the green TG2 into these blebs 
prior to colour release as the blebs burst (Low power view, High power view). 
 
  
 
Figure 9.3-1 Visualisation of plasma membrane blebbing by live cell 
imaging 
NRK52E cells transfected with pcDNA6.2/nTC-tag-DEST vector containing full 
length TG2 were visualised 48 hours post transfection. TG2 was stained green with 
FlAsH and the images were merged with phase contrast images to show the 
peripheral of the cells. Sequential images were acquired with an interval of 1 
minutes at 100x magnification on an inverted microscopy such that imaging 
represents the basal surface of the cell. Images are shown at time 0 (A) then at 45 
minutes (B). Cells developing multiple blebs that are present over the 45 minutes 
are indicated by a white arrow and displayed at a high magnification using digital 
zoom. The cell with plasma blebbing was marked with red dot circle (C). Other cells 
indicated by red arrows generate 1-2 TG2 containing vesicles (ie green) at the basal 
side over the 45 minutes and displayed at a high magnification using digital zoom 
(D). 
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From live imaging every 2 minutes with 100 x magnification, the time interval 
was decreased to 20 seconds and magnification increased to 400 x. Starting 
with a cell that had no plasma membrane blebs visible at time 0 (Figure 9.3-2 
A). At 45 minutes, the cell generated plasma membrane blebs at lateral side 
(Figure 9.3-2 B) with the blebs visible between cells (white arrows). Blebs 
continually enlarge and move across the basal membrane (Figure 9.3-2 C) 
with some blebs fusing into one bleb (Figure 9.3-2 D, red arrow). It is therefore 
possible to conclude that there are two different morphological changes of the 
plasma membrane seen in 100 x magnification that are both plasma 
membrane blebbing. The blebs developed at the basal side fuse with another 
bleb and generate 1 or 2 single big bleb that is visualised in low power view. 
The detailed changes can be missed using 100 x magnification or a long time 
interval such as 2 min. As the blebs contain high levels of TG2 (green) and 
decreased with blebs size, it is likely that plasma membrane is involved in TG2 
externalisation. 
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9.3.2 A comparison by live cell image of cells transfected with full 
length TG2 and TG2 with a mutation in the export sequence 
To further explored the mechanism of TG2 cell export and the role of the TG2 
export motif in this process, cells transfected with full length TG2 and a mutant 
TG2 that is not externalised were compared using live cell imaging. NRK52E 
cells transfected with full length TG2 or a mutant TG2 (Asp94 and Asp97 to Ala) 
 
Figure 9.3-2 Visualisation of plasma membrane blebbing by live cell 
imaging 
NRK52E cells were visualised 48 hours post transfection with 
pcNDA6.1/cTC-tag-DEST vector containing full length TG2. TG2 was stained 
green with FlAsH and the fluorescent images were merged with phase contrast 
image to show the periphery of the cells. Single cell imaging was performed at 
400x magnification every 20 seconds for 60 minutes starting with a cell showing no 
blebs at time 0 (A). At 45 minutes blebs start to visualise on the surface (B) and 
became pronounced after 45 minutes (C). At the centre of the cell blebs fused into 
a big bleb that containing a high level of fluorescence (D).White arrows indicate 
blebs and red arrows indicate merging blebs. 
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were visualised 48 hours after transfection. The green fluorescent images 
showing TG2 were merged with phase contrast images. The morphology of 
the cells was similar at time 0 (Figure 9.3-3 A, B). By 45 minutes, the full length 
TG2 showed some vesicle blebs at the basal side of the cell (Figure 9.3-3 C, 
indicated by yellow arrow). However, with cells transfected with the TG2 with 
mutation of the export motif there was some accumulation of green 
fluorescence at the periphery of the cell in sub-plasma membrane area (Figure 
9.3-3 D, indicated by white arrow) without its entry into plasma membrane 
blebs. Therefore, the major difference for mutant TG2 from full length TG2 is 
the lacking of plasma membrane blebbing. 
The differences between cells that performed plasma membrane blebbing and 
the cells that did not perform plasma membrane blebbing are easier to 
appreciate when placed into a time laps video for NRK52E cells transfected 
with TG2 was shown in (video 1) and NRK52E transfected with mutant TG2 
(mutation of export motif) was shown in (video 2).  
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Figure 9.3-3 Live cell images for NRK52E cells transfected with full 
length TG2 and mutant TG2 
NRK52E were visualised 48 hours post transfection with pcDNA6.2/cTC-tag-DEST 
vector containing either full length TG2 (A and C) or mutant TG2 (mutation of 
export motif) (B and D) for 1 hour at a magnification of 400x with images acquired 
every 20 seconds. The green fluorescence for TG2 and mutant TG2 was merged 
with phase contrast images. Images are shown at 0 minute for full length TG2 (A) 
and mutant TG2 (B) and 45 minutes (C and D). The yellow arrows (C) indicate 
TG2 in plasma membrane blebs and white arrows (D) indicate accumulation of 
TG2 at the periphery of the cells in a vesicle shape in a sub-plasma membrane 
location. 
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9.4 Discussion 
The aim of co-localisation studies for TG2 and cell organelles was to 
determine possible TG2 externalisation pathways. Four un-conventional 
protein externalisation pathways have been described via lysosomes secretion, 
exosomes secretion, plasma membrane blebbing and a direct molecular trap 
(Nickel 2005). Very few lysosomes are co-localised with TG2 and thus TG2 is 
not likely to be externalised through lysosomes. In the exosomes secretion 
pathway, the exosomes are derived from ER membrane and as such should 
express ER markers such as calnexin. As the mutant TG2 that is not able to be 
exported from the cell, it accumulates in vesicle shapes in the sub-plasma 
membrane area. Co-localisation of TG2 and ER was found around the cell 
nucleus only rather than towards the plasma membrane. Therefore TG2 is not 
likely to be externalised through exosomes secretion pathway. To date the 
morphological characteristics expected for a direct molecular trap secretion 
pathway have not been described, however the accumulation of TG2 in the 
sub-plasma membrane area when the export motif is mutated would likely be 
consistent with this mechanism. Equally the visualisation of TG2 containing 
plasma membrane blebs suggests that TG2 could be exported through a cell 
blebbing route. 
The co-localisation of TG2 and Golgi apparatus was less than 0.3% of the 
fluorescent signal for TG2 is co-localised with Golgi apparatus stain. This 
confirms that TG2 does not follow the classical export pathway for secreted 
proteins. The fact there was some co-localisation can be explained by the 
presence of ribosomes (at which proteins can be synthesised) on Golgi 
apparatus. Therefore typically a small portion of un-conventionally secreted 
proteins can be co-localised with Golgi apparatus, although not transported 
through the Golgi apparatus route. This was described previously for FGF-2 
(Ko et al. 2005). Electron microscopy images were used in early work for 
studying un-conventional protein secretion to determine if Golgi apparatus was 
involved (Rubartelli et al. 1990; Andrei et al. 1999) or which organelles the 
protein associated with. We also tried ReAsH photoconversion of 
diaminobenzidine (DAB) (Gaietta et al. 2002), however, no electron dense 
particles could be identified in the cytosol possibly because of inadequate DAB 
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oxidised from ReAsH fluorescent in the cytosol and thus it has been 
impossible to identify more accurately TG2 location in the cell.  
Recent studies looking at the direct molecular trap mechanism of cell export 
for FGF-2 secretion clearly showed that FGF-2 accumulated as a vesicle 
shape at the sub-plasmic membrane area before being secreted (Taverna et al. 
2003; Seelenmeyer et al. 2008). The formation of vesicle shapes in the plasma 
membrane for TG2 suggests a direct molecular trap pathway may be a 
possibility. The proposed direct molecular trap mechanism for FGF-2 is based 
on the expression FGF-2/HSPG complex on cell surface. The mutation of 
FGF-2 binding to HSPG as and knockdown of HSPG decrease cell surface 
FGF-2 when measured by flow cytometry. No direct visualisation of the protein 
interaction that lead to protein secretion has been reported in the literature 
(Zehe et al. 2006). Before starting this study, it was thought possible to 
visualise protein secretion at basal side of the cell using deconvolution 
microscopy. Deconvolution microscopy does have some of the advantages of 
confocal microscopy such as the identification of apical and basal surface of 
the cell using Z-stack image acquisition. However, the factor that limits the 
visualisation of protein externalisation at the basal side of the cell is plasma 
membrane stain. Unsurprisingly, plasma membrane staining generates better 
fluorescent signals at lateral side of the cell than the apical side. When the 
cells were incubated with plasma membrane dye, the apical surface of the cell 
has more chance exposure to the dye than the basal side of the cell. However, 
simply increasing the incubation time resulted in a high background and did 
not generate a clear plasma membrane at the apical side. In addition, the 
difference in strength of fluorescent signals for the plasma membrane at the 
basal side of the cells produced punctuate and discrete signals after 
deconvolution. Consequently it was not possible to produce a convincing 
plasma membrane image at the basal side of the cell using plasma membrane 
staining. Electron microscopy or atomic force microscopy (Chen et al. 2000) 
may provide a better visualisation at the basement membrane of the cells, 
although these techniques were not readily available for this study. 
Live cell imaging showed that TG2 can be secreted through basolateral 
plasma blebbing because the live cell image was taken from an inverted 
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microscopy. FlAsH stains was applied to live cells and generated little back 
ground. Importantly plasma membrane blebs only occurred in the cells 
transfected with full length TG2, with no blebs (containing TG2 or not) visible in 
the cells transfected with TG2 with mutation of the export motif. This strongly 
suggests that the export motif must trigger some type of blebbing either 
directly or via its interaction with a partner protein. However, plasma 
membrane blebbing is more likely to occur in apical side than basolateral side 
because of the differences in cytoskeleton support (reviewed in Aumuller et al. 
1999) and thus TG2 entering blebs on the basal surface is unusual. In the 
literature, most of the studies that supports plasma membrane blebbing as a 
protein secretion pathway came from tissue culture (Bellomo et al. 1988; Keller 
et al. 1998) and microparticles from plasma membrane blebbing in the 
circulation (Furie et al. 2004; Chironi et al. 2006). In vivo the basal side of the 
cells are supported by basement membrane such that the formation of blebs 
may need to overcome the resistance of basement membrane and 
extracellular matrix pressure (reviewed in Hagmann et al. 1999; Fackler et al. 
2008). However, for proteins involved in ECM regulation as TG2 is believed to 
do direct delivery to the underlying basement membrane by basolateral 
blebbing makes sense from efficiency and targeting perspectives. In this study, 
we showed that TECs can perform basal plasma membrane blebbing using 
live cell imaging in vitro only. Further studies are subsequently needed to 
determine if TECs can export TG2 in vivo against the resistance of the 
basement membrane and perform basal plasma membrane blebbing. 
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Chapter 10 Possible TG2 
externalisation pathways related to 
the interaction of the TG2 export 
motif with large tumour antigen and 
tapasin 
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10.1 Introduction 
In the previous chapter, it was demonstrated that Golgi apparatus and ER 
derived exosomes and lysosomes are not involved in TG2 externalisation. No 
co-localisation of TG2 and Golgi apparatus was found between the rough ER 
and the plasma membrane where typically ER-Golgi carried classical secretory 
proteins are found. No co-localisation of lysosomes or MVBs derived 
exosomes with TG2 was observed in the cytosol. In chapter 5 the TG2 export 
motif was identified in the TG2 β-sandwich domain, while Chapter 7 and 8 it 
was demonstrated that LTA and tapasin bind to this motif and both are critical 
for TG2 export. In Chapter 9, plasma membrane blebbing in cells with elevated 
TG2 was observed and TG2 containing vesicles were released at the basal 
surface of the cells. Mutant TG2 that is not externalised accumulated in the 
cytosol and no plasma membrane blebbing was observed. Given all this 
knowledge regarding TG2 export, it still remains unclear as to how do all this 
information fits together into a coherent export pathway for TG2. Therefore in 
this chapter the aim is to demonstrate how tapasin and LTA are involved in 
TG2 externalisation. To do this both co-localisation analysis and live cell 
imaging studies will be undertaken. Live cell imaging will be applied both cells 
transfected with labelled full length TG2 and mutant TG2 with mutation of the 
TG2 export motif.  
10.2 Co-localisation of TG2 and large tumour antigen (LTA) 
The knock down of LTA in TEC cells is associated with a decrease in TG2 
externalisation. However, it is unclear how the interaction of LTA and TG2 is 
linked to TG2 externalisation. To determine the distribution of LTA in the cell 
and the possible location of TG2 and LTA interaction in the cytosol, wild-type 
cells were subjected to immunofluorescent co-localisation studies for LTA and 
TG2. 
NRK53E cells were stained with LTA using a Texas red conjugated secondary 
antibody (red) (Figure 10.2-1 A) and TG2 using a FITC conjugated secondary 
antibody (green) (Figure 10.2-1 B). By merging LTA and TG2 images (Figure 
10.2-1C), some co-localisation can be identified at the peripheral of the cytosol 
indicated by the white arrow. Some fluorescent signals (Figure 10.2-1 B) are 
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on top of the cell nucleus that could be TG2 synthesised on the ER. NRK52E 
cells incubated with TRITC secondary antibodies (Figure 10.2-1 D) and FITC 
antibodies (Figure 10.2-1 E) are used as negative controls showing that 
staining is not non-specific binding of the secondary antibodies.  
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Figure 10.2-1 Co-localisation of large tumour antigen (LTA) and TG2 in 
NRK52E cells 
Wild type NRK52E cells were grown to 80% confluency and fixed with 4% PFA. 
LTA was stained red with a rat anti-LTA antibody (ab18187, Abcam) followed by an 
anti-rat IgG-TRITC (ab7094, Abcam) (A). TG2 was stained green with a Mouse 
anti-transglutaminase 2 antibodies cub7402 (ab2386, Abcam) and an anti-mouse 
IgG FITC (ab7064, Abcam) (B). Co-localisation of TG2 and LTA was observed 
merging the images (C). Omission of anti-LTA antibody (D) and an anti-TG2 
antibody (E) was used as controls for secondary antibody non-specific binding. 
Peripheral co-localisation of TG2 and LTA is indicated with white arrows. The cell 
nucleus was visualised with DAPI (blue). 
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Most TG2 is externalised via the basal surface which is not easily visible by 
conventional microscopy as it is the apical (top) surface that is visible from 
above. Therefore Z stacks of the cell were taken, the image deconvolved and a 
3D image of a NRK52E cell stained for endogenous TG2 (green) and LTA (red) 
generated (Figure 10.2-1). The direct fluorescent signals obtained are shown 
in apical (Figure 10.2-1 A), lateral (Figure 10.2-1 B) and bottom views (Figure 
10.2-1 C). LTA (red) was distributed throughout the cytosol with some 
expression at the periphery of the cell that could be plasma membrane and 
TG2 was localised in the cytosol especially in the basal side of the cell. 
Co-localisation of LTA and TG2 is displayed in yellow, however no 
co-localisation can be seen in the apical and lateral views. When the cell 
inverted and viewed from the underside, co-localisation for LTA and TG2 can 
be clearly seen at the basal side of the cell indicating TG2 and LTA associate 
towards the basal membrane only. A 3D cartoon between set thresholds of 
staining was generated as previously described (Figure 10.2-1 D-F) from the 
same image. The co-localisation of TG2 and LTA is clearly seen at the basal 
side of the cell (Figure 10.2-1 F) as by white arrows confirming the direct 
fluorescent imaging. A72% of plasma membrane LTA was co-localised with 
TG2 at the basal side of the cell. 
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Figure 10.2-2 Three dimensional imaging of NRK52E cells stained with 
large tumour antigen (LTA) and TG2 
Wild type NRK52E cells were grown to 80% confluency and fixed with 4% PFA. 
LTA was stained red with a rat anti-LTA antibody (ab18187, Abcam) followed by an 
anti-rat IgG-TRITC (ab7094, Abcam). TG2 was stained green with a Mouse 
anti-transglutaminase 2 antibodies cub7402 (ab2386, Abcam) and an anti-mouse 
IgG FITC (ab7064, Abcam).A Z stack images acquired at 200nm separation was 
acquired using Cell F and F-view camera. The Z stack images were deconvolved 
using Autoquant software and 3D rendered using Imaris software to produce a 3D 
model of the cell. A image using direct fluorescent signals is shown in apical (A), 
lateral (B) and bottom (C). A cartoon model image based on the fluorescent density 
(D-F) in the same views. Co-localisation of TG2 and LTA is indicated by white 
arrows. The cell nucleus was visualised with DAPI (blue). 
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10.3 Co-localisation of TG2 and tapasin 
Knockdown of tapasin in the cell is linked to a proportional decrease in TG2 
externalisation and thus co-localisation of native TG2 and tapasin was used to 
determine the possible location of TG2/tapasin interaction in the cytosol. 
NRK52E cells stained with tapasin (red, Figure 10.3-2 A), TG2 (green, Figure 
10.3-2 B) and the two images merged (Figure 10.3-2 C). Tapasin and TG2 had 
very good co-localisation around the cell nucleus and at the periphery of the 
cytosol. As most of the tapasin was expressed on the ER membrane that might 
represent co-localisation with TG2 around the cell nucleus. A small portion of 
tapasin can be presented on cell surface that might represent the periphery 
co-localisation of TG2 with tapasin. To confirm the fluorescent signal is specific 
to tapasin and TG2 antibodies, cells were put through the immunofluorescent 
 
Figure 10.3-1 Co-localisation of tapasin and TG2 in NRK52E cells 
Wild type NRK52E cells were grown to 80% confluency and fixed with 4% PFA. 
Tapasin was stained red with a goat anti-tapasin antibody (sc11473, Santa Cruz 
biotechnology) followed by an anti-goat IgG TRITC (T7028, Abcam). TG2 was 
stained green with a Mouse anti-transglutaminase 2 antibodies cub7402 (ab2386, 
Abcam) and an anti-mouse IgG FITC (F0257, Sigma) (B). Co-localisation of TG2 
and tapasin was displayed by merging the images (C). Omission of anti-tapasin 
antibody (D) and anti-TG2 antibody (E) were used as controls for secondary 
antibody non-specific binding. The cell nucleus was visualised with DAPI (blue). 
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procedure with omittion of the primary antibody (Figure 10.3-2 D, E). 
To assist with the determining the spatial co-localisation of tapasin and TG2, a 
Z stacks of cell was obtained, the images were deconvolved to trace the 
source of light for the staining and the data used to construct a 3D rendered 
image of NRK52E cells stained for TG2 (green) and tapasin (red) (Figure 
10.3-3 A-F). The direct fluorescent signal in apical (Figure 10.3-3 A), lateral 
(Figure 10.3-3 B) and bottom view (Figure 10.3-3 C) shows no co-localisation 
in the apical and lateral views. However, like LTA, by inverting the cell 
co-localisation of tapasin and TG2 can be clearly seen at the basal side of the 
cell. Subsequent generation of the 3D cartoon model (Figure 10.3-3 D-F) 
clarifies co-localisation occurring predominantly on the basal membrane 
although there are clear associations of TG2 and tapasin completely through 
the cell cytoplasm suggesting that it is tapasin that may “carry” TG2 to the 
basal membrane. 
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Figure 10.3-2 Three dimensional imaging of NRK52E cells stained with 
tapasin and TG 
Wild type NRK52E cells were grown to 80% confluence and fixed with 4% PFA. 
Tapasin was stained red with a goat anti-tapasin antibody (sc11473, Santa Cruz 
biotechnology) followed by an anti-goat IgG TRITC (T7028, Abcam). TG2 was stained 
green with a Mouse anti-transglutaminase 2 antibodies cub7402 (ab2386, Abcam) 
and an anti-mouse IgG FITC (F0257, Sigma). A Z stack images acquired at 200nm 
separation was acquired using cell F and F-view camera. The Z stack images were 
deconvolved using Autoquant software and 3D rendered using Imaris software to 
produce a 3D model of the cell. A 3D model of the cell was generated using direct 
visualisation of the fluorescent in apical (A), lateral (B) and basal (C) views. A cartoon 
model of the cell using the same image (A-C) based on a set of threshold for 
fluorescent signals (D-F). Co-localisation of TG2 and tapasin is displayed in yellow 
colour. The cell nucleus was visualised with DAPI (blue). 
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10.4  Live cell imaging of TG2 externalisation in NRK52E cells 
following siRNA Knock down of large tumour antigen (LTA) & 
Tapasin 
In Chapter 9, it was demonstrated that TECs transfected with full length TG2 
underwent plasma membrane blebbing with fluorescent TG2 being 
concentrated within these blebs before being released as the bleb perforated. 
TECs transfected with TG2 with mutation of the export motif did not performed 
plasma membrane blebbing. 
To determine the effect of LTA and tapasin knock down on TG2 extracellular 
trafficking, NRK52E cells were co-transfected with TG2 expression vector 
pcDNA6.2/cTC-Tag-dest containing full length TG2 cDNA and either anti-LTA 
or anti-tapasin siRNA. Cells were imaged 48 hours post co-transfection in 
serum free medium. NRK52E cells transfected with TG2 expression vectors 
alone were used as negative controls. In cells transfected with full length TG2 
cDNA alone, once TG2 reached a suitable intensity in the cell image 
acquisition was started at 20 second intervals for 45 minutes. Initially the ell 
would appear green and quiescent (Figure 10.4-1 A), but in most cells, a 
period of plasma membrane blebbing would frequently commence (Figure 
10.4-1 B). These blebs would grow, contain highly fluorescent material (ie TG2) 
then perforate releasing the contents into the extracellular space. When this 
was repeated in NRK52E cells co-transfected with anti-tapasin siRNA along 
with the TG2 vectors, the plasma membrane blebs in the same way as the cell 
transfected with full length TG2 (Figure 10.4-1 D). However, in these cells with 
tapasin knock down the plasma membrane blebbing did not appear to burst, 
but rather the green TG2 was pulled back into the cytoplasm and 
re-condensed in the cytosol (Figure 10.4-1 E). Following co-transfection with 
anti-LTA siRNA and full length TG2, the cell failed to bleb (Figure 10.4-1 F). 
Therefore the LTA is associated with plasma membrane blebbing into which 
TG2 is moved, while the tapasin is related to the bleb being pinched and the 
TG2 released from the blebs (video3, video4, video5).  
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Figure 10.4-1 Live cell imaging of TG2 cell export in NRK52E cells with 
knockdown of large tumour antigen (LTA) or tapasin 
NRK52E cells were imaged 48 hours post co-transfection with pcDNA6.2/cTC-tag-DEST 
vector containing full length of TG2 plus either anti-tapasin siRNA or anti-LTA siRNA. At 
time zero cells were stained with FlAsH to stain tetracysteine tagged TG2 green and 
images were then acquired every 20 seconds for up to one hour for cells just transfected 
for TG2 (A,D), for cells having addition tapasin knockdown (B, E) or LTA knockdown (C, 
F). Still images are shown at time zero (A, B, C) and at 45 minutes (B, D, F). The video 
for each of these are shown as video 3, 4, 5.  
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10.5 Discussion 
Using live cell imaging, it is clearly possible to demonstrate plasma membrane 
blebbing into which TG2 is concentrated and released from the cell. The 
removal of LTA in NRK52E cells stops the blebbing process and TG2 masses 
under the plasma membrane. The removal of tapasin still allows blebs to form, 
however the TG2 seems to be dragged back into the cytoplasm and the blebs 
do not appear to perforate or release. Of particular note is that when NRK52E 
cells transfected with either mutant TG2 that cannot be exported or following 
LTA knock down, many cells undergo a process that looks very similar to 
apoptosis with cell shrinkage and detaching from the culture plate. 
Interestingly both these actions would lead to an elevated intracellular level of 
TG2. High cellular TG2 has been associated with both apoptosis (Oliverio et al. 
1999) and a transglutaminase mediate cell death process (Johnson et al. 1998)  
that is very similar to apoptosis but lacking DNA condensation and 
fragmentation. 
The duration of episodes of plasma membrane blebbing is very short lasting 
about 2-3 minutes and thus unless a large field is viewed on a continual basis 
cell instigating this event are easily missed. Further, we believe that this 
process is difficult to see on fixed cells as the process is very dynamic and the 
fixation process itself seems to lessen the contour of the bleb on the cell 
making then hard to see. These reasons may explain the failure to visualise 
TG2 export process previously as well in other novel export routes described 
such as that for FGF-2 externalisation (Seelenmeyer et al. 2008). It is 
important to consider that the blebbing could be triggered in some way by 
either the transfection procedure or serum starvation, however, these are 
conditions used throughout the study under various experimental regimes and 
thus it seems unlikely they may play a role. 
In determining the possible protein secretion pathway for TG2, live cell imaging 
has provided some compelling but not conclusive information. Firstly, 
fluorescence generated by FlAsH to track TG2 movement can only be used for  
detection for about 1hour or around 150 images at 300ms exposure time 
before it becomes bleached. Unfortunately anti-fade reagents are toxic to cells 
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and cannot be used in live cell imaging. We therefore believe that the fading 
fluorescence intensity between 40-60 minutes of the visualisation is more likely 
due to photo bleaching of the fluorescence than the complete externalisation of 
TG2 into the culture medium. Secondly, we noticed that cells were visualised 
for more than 2 hours they tended to die, photo or heat insult to the cells may 
be responsible for this and thus we tried to use only brief periods of imaging to 
avoid artefacts resulting from cell damage. Overall the export process we 
report occur very quickly and intermittently indicating that TG2 builds to a 
determined cell level at which point the export process is activated. 
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In this study, we demonstrated that extracellular trafficking of TG2 is 
dependent of the N-terminal β-sandwich domain of TG2 using deletion 
analysis. The TG2 export motif (aa 88-106) was identified to be critical in 
extracellular trafficking of TG2 and no TG2 exported if Asp94 and Asp97 
mutated (Chou et al. 2011). Although the TG2 export motif has been reported 
to be a fibronectin binding site, TG2 extracellular trafficking is independent of 
fibronectin and no decrease in TG2 export was observed following an 80% 
knockdown of intracellular fibronectin in TECs. Meanwhile, TG2 was solely 
externalised through the basolateral side of the plasma membrane using 
measurement of TG activity in culture medium from cell monolayer grown in 
culture inserts and deconvolution microscopy imaging. The TG2 export motif 
binds to large tumour antigen (LTA), tapasin and translocon-associated protein 
γ using yeast two hybrid screen. Knockdown of intracellular LTA or tapasin 
proportionally decreased TG2 export suggesting that TG2-LTA and 
TG2-tapasin interaction is linked to TG2 extracellular trafficking. Using 
chorological imaging, it was shown that TG2 was synthesised in rough ER 
around the cell nucleus and moved to periphery of the cells and extracellular 
accumulation of TG2 could be maximally visualised 48 hours post transfection. 
In contrast, mutant TG2 that does not undergo extracellular export tented to 
accumulate in sub-plasma membrane area in a vesicle shape. The main 
morphological change related to TG2 extracellular trafficking seemed to be 
plasma membrane blebbing. This was more frequently observed in cells with 
elevated TG2 levels and much less in cells transfected with mutant TG2 that 
does not get exported. This suggests that plasma membrane blebbing could 
be involved in TG2 extracellular trafficking. Plasma membrane blebbing was 
seen in the cells with tapasin knockdown but the TG2 containing blebs were 
retracted to the centre of the cell rather than the TG2 containing bleb being 
pinched and released. Knockdown of LTA in TECs prevented cells displaying 
plasma membrane blebs (or at least ones that were visible containing “green” 
TG2) suggesting that LTA and tapasin are both involved in TG2 extracellular 
trafficking. 
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As knockdown of tapasin and LTA both decrease extracellular TG2 export, we 
therefore hypothesise the potential TG2 externalisation pathways: TG2 could 
be carried by the vesicles formed by the tapasin associated ER membrane to 
sub-plasmic membrane area, binding to plasma membrane associated LTA 
and then released to extracellular space through plasma membrane blebbing 
(Figure 10.5-1). TG2 associated plasma membrane blebbing was also noted in 
an early study by Gentile et al (1992) showing extensive plasma membrane 
blebbing in fibroblasts with a high TG2 expression. A recently study by Belkin 
et al showed the recruitment of TG2 by perinucleus recycling endosomes and 
VAMP3, SNAP23 SNAREs mediated plasma membrane-endosome fusion 
prior TG2 externalisation (Zemskov et al. 2011). Although plasma membrane 
blebbing was not observed in their study, this suggests a possible route of TG2 
externalisation via plasma membrane blebbing as SNAREs on late 
endosomes membrane could mediate the fusion of endosome with the plasma 
membrane. It is possible that plasma membrane blebbing was not observed in 
 
Figure 10.5-1 Possible TG2 externalisation pathways 
After TG2 synthesised in the cytosolic ribosomes, tapasin on the membrane of 
vesicles (the membrane came from ER membrane) recruited TG2 in to the secretary 
vesicles i.e. multiple vesicular bodies (MVBs) and carried TG2 to the periphery of 
the cells i.e. sub-plasma membrane. The large tumour antigen (LTA) on plasma 
membrane binds to TG2 and TG2 was released following plasma membrane 
blebbing. 
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their study due to the lack of live cell imaging, spotting blebs is extremely 
difficult on still images and indeed it was only in this study when live cell 
imaging was attempted were blebs noticeable despite extensive 
immunofluorescent studies prior to this. 
Previous work has shown that the ability of TG2 to bind fibronectin is important 
for TG2 trafficking (Gaudry et al. 1999; Verderio et al. 2003; Telci et al. 2008). 
However work presented here contradicts this suggesting that fibronectin is 
not essential for TG2 externalisation, at least in TECs. The TG2 export motif 
spanning aa 88-106 is crucial for TG2 externalisation in TECs is still a 
fibronectin binding site (Hang et al. 2005). The TG2 Antigen assay used in this 
study (Section 3.4.7) is based on fibronectin binding, and as such, constructs 
that remove or mutate the either of the described fibronectin binding sites 
should lower TG2 binding to fibronectin. However if either or both of the known 
fibronectin sites are altered, TG2 still binds to fibronectin (cell lysate analysed 
using biotin-cadaverine incorporation showed in section 3.4.7). This finding 
raises the suspicion that there might be other fibronectin binding site in TG2 
molecule most likely on core domain of TG2 because core domain was still 
able to bind to fibronectin. Early works looking at TG2 extracellular trafficking 
focused on the co-localisation of TG2 with fibronectin (Martinez et al. 1994; 
Jones et al. 1997; Sechler et al. 1998; Verderio et al. 1998; Gaudry et al. 1999) 
or integrin (Gaudry et al. 1999; Akimov et al. 2000; Janiak et al. 2006) on cell 
surface. Subsequently fibronectin and integrin were considered as 
co-transport partners for TG2. The role of extracellular TG2 in cell adhesion is 
associated with fibronectin and integrin which may be one of the major 
reasons to link fibronectin and integrin also with TG2 export. Fibronectin and 
integrin are both externalised through classical ER-Golgi networks. If TG2 is 
carried by fibronectin or integrin to the plasma membrane, TG2 should be 
observed in ER-Golgi networks. TG2 extracellular trafficking is independent of 
the function of ER-Golgi networks because the inhibition of ER-Golgi networks 
with agents such as brefeldin and tunicamycin did not interfere with TG2 
extracellular trafficking (Zemskov et al. 2011). In this study, it was 
demonstrated that knocking down 80% of intracellular fibronectin did not 
decrease TG2 extracellular trafficking (Chou et al. 2011). Based on the 
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available data, it is not likely that fibronectin or integrin can be the extracellular 
trafficking partners of TG2. In the four possible unconventional protein 
transport mechanisms (Figure 9.1-1), binding partners are always need for the 
extracellular trafficking. For example, FGF2 is recruited by PI(4,5)P2 on the 
inner side of the plasma membrane. Ist2 is recruited by the COPI coat on the 
cortical ER membrane. A mannose 6-phosphate moiety is added to IL-1β such 
that it can be recognized by mannose 6-phosphate receptor on lysosomes and 
imported into secretary lysosomes. According to our data, it is possible that the 
TG2 export motif binds to tapasin that presenting on the membrane of the 
vesicles formed by ER membrane i.e. MVBs and carried TG2 to the periphery 
of the cell by an unknown process. The plasma membrane associated LTA 
then recruited TG2 and TG2 can be externalised through plasma membrane 
blebbing. This pathway dose associated well with mechanisms related to other 
novel pathways. It is possible that other protein can be involved in the TG2 
externalisation process. 
Fibroblast growth factor 2 (FGF-2) is one of the most expensively studied 
unconventionally secreted protein. It is suggested to be secreted through a 
direct molecular trap system via heparan sulfate proteoglycans (HSPGs) on 
cell surface. The FGF-2 extracellular trafficking route may provide some clues 
for unravelling TG2 extracellular trafficking pathway more completely. The 
hypothesis for a direct molecular trap is derived from data showing FGF-2 is 
being secreted through a ternary complex with high-affinity FGF receptors and 
HSPGs, mutants defective for HSPG binding and cells with impaired HSPG 
biosynthesis have defective FGF-2 export (Zehe et al. 2006). An early study 
suggested that FGF-2 can be secreted from plasma membrane 
blebbing/shedding (Taverna et al. 2003). This was contradicted by a later study 
that showed that FGF-2 is not secreted through plasma membrane derived 
vesicles and subsequently lead to the hypothesis of a direct molecular trap 
mechanism (Seelenmeyer et al. 2008). In both plasma membrane blebbing 
and direct molecular trap, the secretion of FGF-2 relies on the binding to 
another protein such as HSPGs to recruit FGF-2 in the sub-plasmic area. This 
equates to the current hypothesis for TG2 export where tapasin and LTA are 
implicated as both bind to the TG2 export motif and both prevent export when 
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knocked down. As TG2 also had some affinity to HSPGs (Scarpellini et al. 
2009), it is also hypothesised that TG2 can be secreted through the HSPGs 
associated direct molecular trap mechanism. The TG2 export motif is 
composed of the β5/β6 hairpin in the N-terminal β-sandwich domain of TG2. 
The size of this hairpin is about the same size of the HSPGs side chain. When 
beginning of yeast two hybrid screens, it was expect that HSPGs or fibronectin 
would be on the list of potential binding proteins. However, neither fibronectin 
nor HSPGs was appeared on the list. Dynein is another protein that identified 
in Y2H screening (section 7.3) and may be interesting to look into its role in 
TG2 externalisation. Dynein is a motor protein that able to move cellular 
cargos along the cytoskeletal microtubules. Dynein was not selected because 
no co-localisation of TG2 and cytoskeleton stain (actin, data not shown) was 
found in our work. 
Although plasma membrane blebbing is the only morphological finding that we 
found different between cells transfected with full length of TG2 and mutant 
TG2, it is difficult to confirm conclusively that TG2 is externalised through 
plasma membrane blebbing. Further experiments will be needed to confirm if 
plasma membrane blebbing is responsible for TG2 externalisation. For 
example if inhibition of plasma membrane blebbing stops TG2 externalisation 
using ROCK inhibitor (Emre et al. 2010), this would strongly link blebbing as 
part of the mechanism. In the case of FGF-2, inhibition of plasma membrane 
blebbing using a ROCK inhibitor did not decrease FGF-2 extracellular 
trafficking (Seelenmeyer et al. 2008) leading to description of the molecular 
trap mechanism.  
Microparticles (MPs) are small vesicles released from the plasma membrane 
blebbing / shedding and can carry specific markers from the derived cells such 
as platelet and endothelial cells. As platelet derived MPs contains Factor XIII 
(Garcia et al. 2005), it is possible that epithelial cells derived MPs contains 
TG2. A recent study also suggested that TG2 can be found in the 
microparticles from smooth muscle cells (van den Akker et al. 2011). The 
microparticles can be formed from plasma membrane blebbing suggesting the 
association between plasma membrane blebbing and TG2 extracellular 
trafficking. So far no study has suggested that TECs produce MPs, therefore, 
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the role of MPs in fibrosis comes from the studies regarding circulating MPs 
and atherosclerosis. MPs in the circulation are extensively studied in the 
association with various diseases (Furie et al. 2004; Chironi et al. 2006). 
Circulating MPs derived from endothelial cells and platelets are linked to acute 
coronary syndromes (Mallat et al. 2000). Granulocytic origin MPs are linked to 
metabolic syndrome (Diamant et al. 2002). Platelet MPs are linked to 
atherosclerosis and peripheral arterial disease (van der Zee et al. 2006). 
Circulating MPs bear tissue factor on the surface that is critical for thrombus 
spreading and fibrin formation (Chou et al. 2004). The circulating MPs can be 
captured by thrombus-associated-platelets and initiate blood coagulation and 
fibrin formation (Hrachovinova et al. 2003). Circulating MPs can also stimulate 
the release of pro-inﬂammatory endothelial cytokines such as interleukin (IL)-6 
and IL-8 and induce expression of the adhesion molecules including ICAM-1, 
VCAM-1 and E-selectin (Nomura et al. 2001). Nitric oxide is an important 
mediator for endothelial cells in control vascular tone and the impairment of 
nitric oxide release indicate vascular dysfunction. MPs can impair the release 
of nitric oxide from vascular endothelial cells in patients with end-stage renal 
disease (Amabile et al. 2005) and patients with myocardial infarction 
(Boulanger et al. 2001) but not the MPs from normal individuals. In addition, 
MPs can stimulate angiogenesis medicated by vascular endothelial growth 
factor or sphingomyelin (Kim et al. 2002; Brill et al. 2005). It is not clear if renal 
epithelial cells produced MPs from plasma membrane blebbing and what is the 
function of MPs on extracellular matrix. As shown in a recent study, endothelial 
origin MPs can interact with extracellular matrix through the activation of 
MMP-2 (Lozito et al. 2011), it is possible that tubular epithelial cells produce 
TG2 containing MPs that adhere to the tubular basement membrane, TG2 
would thus be released into the extracellular matrix (ECM) and thus instigating 
ECM remodeling. Further studies are needed to determine if TECs can 
produce MPs and the role of MPs in kidney fibrosis in vivo. The live cell images 
shown in the final results chapter suggest that TECs can product MPs at the 
basal side of the cells and the MPs fused into 1-2 big vesicles in tissue culture 
plates. It would be interesting to visual this process in vivo and if MPs attach to 
the ECM and release MPs containing protein in the ECM. 
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In the literature, autophagy had been suggested as another unconventional 
protein secretion pathway. As mentioned in Section 1.3.1.2, autophagy is a cell 
self-eating process that occurs in normal and stimulated condition such as 
starvation. Cellular components including damaged or redundant organelles 
are packed into double-membrane vesicles called autophagosomes 
(Manjithaya et al. 2010). Although autophagy is not listed in the four potential 
unconventional protein externalisation pathways (Figure 9.1-1), autophagy can 
be considered as a combination of lysosomes and exosomes secretion. 
Autophagosomes usually fuse with lysosomes in autophagy and thus the 
contents are degraded and recycled. However, more and more evidences 
have shown that autophagy can be an unconventional protein secretion 
pathway (reviewed in Todde et al. 2009). Multivehicle bodies (MVBs) are 
essential for protein externalised in autophagy (reviewed in Piper et al. 2007). 
The exported proteins are transported into MVBs (i.e. from the ribosomes in 
cytosol or rough ER), the contents of MVBs moved to autophagosomes and 
released into extracellular space while autophagosomes fused with the plasma 
membrane. MVBs express markers such as LAMPs that is used for lysosome 
identification (LAMP-2). As no co-localisation of TG2 and lysosomes at the 
peripheral of the cells was found, this suggests that TG2 is not externalised 
through autophagy. However, it is worth further study if autophagosomes using 
microtubule-associated protein 1 light chain 3 (LC3) (Kabeya et al. 2000) could 
be co-localised with TG2. 
In this study, we explored TG2 externalisation using TG2 cDNA or mutant TG2 
transfected into TECs followed by the measurements of total cellular TG activity 
and extracellular TG. One disadvantage for this approach is the TG2 
externalisation measurement is in an overloaded environment compared to the 
native TG2 synthesised in the cell. We believed that the approach is valid to 
determine TG2 externalisation based on following reasons. Firstly, the TG2 
level that we measured in transfected cell was increased by just 5-10 fold 
compared to wild type TECs in culture. TECs when placed in primary culture 
use 99% of their TG2 activity by passage 3. In vivo TEC have a lot more TG2 
and was below what is seen in post transfection. This increase of TG2 levels 
was much less than that (30-100 fold increase) of TG2 levels measured in 
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patients with chronic kidney disease (Johnson et al. 2003). Therefore, the 
increase of TG2 levels after transfection was at best 5% of the TG2 levels in 
vivo and thus the cells were not overloaded. Secondly, the basal levels of TG2 
in the cell are at the lowest end of the assay and are very difficult to be detected 
by western blotting, it is more difficult to measure the intracellular and 
extracellular TG levels after knockdown endogenous TG2 using specific siRNA. 
Therefore the transient expression of exogenous TG2 was needed to study 
TG2 extracellular trafficking. Therefore, the approach that we took could be the 
most suitable approach for studying TG2 extracellular trafficking. 
It was demonstrated that a 50% knock down of intracellular LTA was linked to a 
50% decrease of TG2 export (Section 8.2). This indicated LTA is crucial for 
TG2 extracellular trafficking in TECs. The leading question is therefore how 
LTA, a viral protein, can facilitate TG2 extracellular trafficking. LTA is known for 
the binding to tumour suppressor gene such as p53 (reviewed in Pipas et al. 
2001) and retinoblastoma susceptibility gene pRB (reviewed in Stiegler et al. 
1998) that may be related to tumorgenesis in human and cell transformation. A 
small portion (5%) of LTA can be presented on cell surface but the function for 
the plasma membrane form LTA protein is unknown (Deppert et al. 1982). The 
expression of plasma membrane associated LTA is positively correlated to 
cells growth rate and cells with a loss of plasma membrane associated LTA 
expression precede growth arrest (Santos et al. 1985). The plasma membrane 
associated LTA has a higher affinity to antibodies and p53 (Soule et al. 1979) 
than LTA that target the cell nucleus. The transport of plasma membrane 
associated LTA to the cell surface is a rapid process (Santos et al. 1984; 
Santos et al. 1984) and is independent of Golgi networks (Tartakoff 1983). 
Thus the plasma membrane associated LTA might mimic a growth factor that 
generate a growth signal transmitting to the cell nucleus and phenotypic 
changes characteristic of complete transformation. Knock down of LTA is 
linked to a decrease of TG2 externalisation and prevents of plasma membrane 
blebbing in TECs. Our findings i.e. co-localisation of LTA and TG2, live cell 
imaging, lead to the hypothesis that plasma membrane associated LTA might 
recruit TG2 at the sub-plasma membrane area and subsequently TG2 was 
externalised through a LTA dependent plasma membrane blebbing mechanism. 
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This find was also supported by a previous study (Birckbichler et al. 1978) that 
intracellular TG activity is significantly lower for the cells transformed by SV40 
virus that theoretically this could be caused by an increase of externalised TG2. 
As cells without LTA should export TG2, this LTA mediated externalisation 
pathway may be an extra-pathway from a native TG2 externalisation pathway 
as if this was the only mechanism then TG2 externalisation would not occur 
unless an individual is infected by polyomavirus. However, it is unknown if TG2 
can be exported without LTA simply because the association between TG2 and 
LTA has never been found. Subsequently a major question is what is the 
relevance to TG2 export in healthy individuals or in fact those with CKD. If this 
is of true biological importance then LTA is expressed in humans and 
consequently can be related to disease progression in man. LTA is a protein 
produced by polyomavirus such as Simian Vacuolating Virus 40 (SV40), BK 
and JC virus in human. BK virus in particular is more prevalent in human in the 
literature and thus LTA produced by BK virus might be linked to the role of TG2 
in CKD. BK virus was first identified from the urine of a kidney transplantation 
patient (Gardner et al. 1971). The infection source for BK virus infection in 
human is not clear and the infection of BK virus is not needed to treat because 
of the mild symptom and sign in normal individuals. In immune-compromised 
host the activation of BK virus is linked to the underlying immuno-supression 
status such as overuse of immunosuppressant. The treatment for organ 
transplant recipients is straight forward that is reducing immunosuppressant 
dosage. About 80% of the general population in UK, US and EU are infected 
by the BK virus without clinical symptoms (Gardner 1973; Mantyjarvi et al. 
1973; Portolani et al. 1974; Egli et al. 2009). BK virus infection only develops 
symptoms and signs such as viruria and viremia, ureteral ulceration and 
stenosis and hemorrhagic cystitis in immunocompromised hosts (Mylonakis et 
al. 2001). The reactivation of BK virus in patients with kidney transplantation is 
associated with progressive loss of graft function (Hogan et al. 1980). The 
chance for human cells with LTA expression without viremia can be even 
higher because up to 85% of human normal tissue samples or tumour tissues 
had wild-type LTA coding analysed by PCR (De Mattei et al. 1995). 
SV40 is a potent DNA tumour virus that can induce tumour in rodent and 
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transformed cell in culture. SV40 infection also occurred in human. Millions of 
people were inadvertently exposed to live SV40 from 1955 through early 1963 
when they were administered SV40-contaminated virus vaccines that are 
mostly polio vaccines (Fraumeni et al. 1963). Although individuals exposed to 
SV40-contaminated vaccines are not more at risk for developing cancer than 
those who received SV40-free vaccines (Shah et al. 1976; Strickler et al. 1998; 
Strickler et al. 2003). SV40 DNA can be detected in tumour samples obtained 
from some types of human cancer such as pediatric and adult brain tumours, 
mesotheliomas, osteosarcomas, bronchopulmonary carcinomas, pituitary 
tumours and papillary thyroid carcinomas (reviewed in Butel et al. 1999) with a 
frequency of 35%. The expression of LTA can be detected in approximately 
50% of tumour samples. Therefore, LTA not only presents in tissue culture but 
also presents in human with a very high prevalence. 
SV40 is wildly used for cell transformation in tissue culture; however, OK 
(Koyama et al. 1978), NRK52E (Huu et al. 1966) and MDCKII cells 
(Richardson et al. 1981) are not transformed using SV40. However, OK, 
NRK52E and MDCKII cells do express LTA by western blot. The incidence of 
polyomavirus infection in animals is unknown and it is possible that the animal 
from which the primary cell culture was obtained had been infected by 
polyomavirus and consequently the cells expressed LTA protein. It is also 
possible that spontaneously immortal cells also expressed LTA. In mouse 
embryo ﬁbroblasts or rat embryo fibroblasts, the expression of LTA drive the 
cell into S-phase and the cell becomes immortal. This is more complicated in 
other cells. For example, human fibroblast expressing LTA can be propagated 
for an extended period but eventually senesced. An active telomerase is 
therefore required to escape senesce in human fibroblasts (Ahuja et al. 2005). 
The interaction between LTA and p53 (Deppert et al. 1989) or retinoblastoma 
(Rb) family of tumour supressor proteins (Ludlow et al. 1989) is clearly 
contribute to the SV40 transformation. It is less clear, LTA associated cell 
transformation also involved other transcriptional proteins and mechanisms 
such as SEN6 (Jha et al. 1998), TEF-1, Nbs1 and Fbw7 that may be also 
modulated by LTA that contribute to cell transformation (Ahuja et al. 2005). As 
expression of LTA on the cell surface is a critical step in determining a 
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successful transformation, this suggested that the plasma membrane 
associated LTA plays an important role in cell transformation. 
TG2 has a diverse biologic function including differentiation, receptor-mediated 
endocytosis, cell adhesion, and induction of apoptosis (Mehta et al. 2006). 
Early studies suggested that the interaction between importin-3 and TG2 may 
be linked to TG2 nucleus translocation (Peng et al. 1999; Milakovic et al. 2004). 
TG2 staining is frequently found to be co-localised with the cell nucleus as is 
also seen in this study. The nucleus localisation of TG2 plays a key role in its 
protective function against cell death in HEK293 cells (Gundemir et al. 2009). 
The expression of TG2 can be associated with chemotherapeutic drugs 
resistance in human breast cancer cells (Ai et al. 2008). The cell nucleus 
localisation for TG2 may be related to the expression of genes related to 
neutrophil functions and may be involved in several intracellular and 
extracellular functions of extravagating neutrophil (Balajthy et al. 2006). The 
interaction between large tumour antigen (LTA) and TG2 may explain how TG2 
is transported to the cell nucleus because of the nucleus origin sequence on 
LTA. It is known that LTA can enter the cell nucleus and serve as a helicase 
(Titolo et al. 2003), subsequently it is possible that the interaction between TG2 
and LTA is involved in the function of TG2 in the cell nucleus. The major 
function of LTA on cell surface is not clear and is generally considered to be 
involved in complete cell transformation (Butel et al. 1986). Based on our 
finding, the plasma membrane associated LTA might be able to carry proteins 
cross the plasma membrane. As LTA also interacts with p53 and RB protein 
that may be related to cell apoptosis. LTA also has a nuclear localization signal 
(LXCXE) located before the origin-binding domain that is the domain that 
interact with the TG2 export motif. LTA therefore can be a potential player in 
process of TG2 nucleus localisation and possibility the role of TG2 in the cell 
nucleus. It would be interesting to explore the association between LTA and 
specific TG2 functions according to TG2 expression in different component of 
the cell i.e. the cell nucleus, cytoplasm, and the plasma membrane. 
Based on the fact that a viral protein is related to TG2 externalisation raises 
the question as to whether the level of LTA expression within an individual is 
related to the development of TG2 extracellular trafficking and thus tissue 
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fibrosis in general. Since LTA is a virus protein and may not be part of the 
native TG2 secretion pathway in mammalian cells, LTA related TG2 
externalisation can be considered as a pathological TG2 externalisation 
pathway compared to the normal TG2 secretion. Abolish of LTA expression 
can be harmless for mammalian cells and has minimal effect on normal cell 
physiology but potentially a dramatic affect on TG2 export. It is possible to 
prevent cells from expressing LTA protein by virus vaccination and thus the 
data generated within this thesis strongly suggests that this may be a way of 
mitigating TG2 export that is so tightly linked to the development of CKD.. 
More epidemiological studies are initially needed to support the clinical 
application of this finding. For example, if individuals with BK virus infection 
have a higher incidence of CKD and those without a history of BK virus 
infection had a lower risk of CKD. Further if CKD patients have a high 
incidence of LTA expression in kidney tissue and a high viral titter. 
Tapasin is a transmembrane protein that tethers empty class I molecules to the 
peptide transporter associated with antigen processing (reviewed in Grandea 
et al. 2001). The structure of tapasin is composed of a short cytoplasmic tail 
containing an ER retention signal, a transmembrane region and a large 
N-terminal intraluminlar part (Li et al. 1997). The assembly of MHC class I 
molecules is a series of coordinated and regulated interactions with 
ER-resident chaperones. Tapasin is majorly involved in the assembly of MHC 
class I molecules and peptide-loading complex interaction. Proteins 
associated with the assembly of peptide-loading complex with tapasin include 
β2-microglobulin, calreticulin, MHC class I heavy chain, ERp57, protein 
disulphide isomerise and transporter associated with antigen-processing 
proteins (reviewed in Cabrera 2007). The major function of tapasin is to 
enhance peptide loading in peptides loading complex (Figure 10.5-2). The 
mature MHC class I molecular is transported to Golgi apparatus and 
externalised to cell surface through the classical ER-Golgi network. In the 
process, tapasin interact with transporter associated with antigen-processing 
proteins and is responsible for an optimal peptides load in MHC class I 
molecules (Sadasivan et al. 1996). Tapasin is related with quality control of 
peptides loading complex. Deficiency of a functional tapasin results in a 
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low-affinity peptides loaded in MHC class I molecules (Garbi et al. 2000).  
Unstable MHC class I molecules on cell surface (Grandea et al. 2000) and 
consequently severe immune-deficiency (reviewed in Grandea et al. 2001). As 
unstable MHC I molecules can present on the cell surface suggesting, tapasin 
is not essential for the MHC I molecule extracellular trafficking, the MHC class I 
molecule externalisation pathway may not apply to the tapasin dependent TG2 
externalisation. Tapasin predominately resides on ER membrane, retains 
immature class I molecules in the ER and transports the mature class I 
molecular to Golgi apparatus. Approximately 10% of tapasin can be presented 
 
Figure 10.5-2 Tapasin related MHC class I molecular antigen presenting 
process 
Mature MHC class I complex that is composed of a MHC class I molecule and 
β2-microglobulin heterodimers and is expressed on the cell surface. The mature 
MHC class I molecule is externalised through Golgi apparatus after interaction with 
tapasin, ERp57, calrecitulin, transporter associated with antigen-processing 
proteins in ER. 
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on plasma membrane (Teng et al. 2002), but the function for these plasma 
membrane associated tapasin is unknown. The plasma membrane-associated 
tapasin may be also related to TG2 externalisation based on the data 
generated in this study. TG2 was still seen at the plasma membrane following 
knockdown of tapasin (Section 10.4) with accumulation into vesicles shaped 
structure in the sub-plasma membrane area. Fluorescent microscopy 
co-localised TG2 and tapasin around the cell nucleus that is mostly likely in the 
ER as well as at the cell periphery in the sub-plasma membrane area. Both 
these locations are consistent with tapasin know cellular location (Teng et al. 
2002). Interestingly plasma membrane blebbing was observed in TECs 
following tapasin knock down suggesting that while tapasin is essential for 
TG2 externalisation it is not part of the plasma membrane blebbing machinery. 
In live cell imaging of TECs following tapasin knockdown, TG2 was retracted 
back to the centre of the cell while cell shrinkage and formed vesicle in the 
centre of the cell. We therefore proposed that TG2 is carried by tapasin from 
ER to the periphery of the cell and released to extracellular space following 
LTA-associated plasma membrane blebbing. As both knockdown of tapasin 
and LTA resulted in a proportional decrease of TG2 externalisation, this 
suggests that tapasin and LTA may be involved in the same externalisation 
route. It is possible that LTA replace another normal protein in TG2 export. 
Compared to the LTA related TG2 externalisation, the tapasin pathway for TG2 
externalisation seems to be a physiological TG2 externalisation mechanism. 
Tapasin is one of ER residual protein in normal condition and is associated 
with MHC class I molecules expressed on cell surface. The MHC class I 
molecules are transported to the cell surface through the ER-Golgi network. As 
TG2 is not exported through the ER-Golgi network, it is likely that tapasin 
carried TG2 to the cell surface through a different mechanism such an 
exosomal secretion, plasma membrane blebbing or a direct molecular trap. As 
tapasin deficiency is linked to severe immune dysfunction, therefore targeting 
TG2 export motif or LTA may have more potential in fibrosis treatment under 
pathological condition. 
It is not clear whether TG2 externalisation is limited to one of the 
unconventional protein secretion pathways or is involved in more than one 
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pathway. As knock down of LTA and tapasin both decrease TG2 
externalisation, it is likely that the extracellular trafficking of TG2 is involved in 
one pathway that needs both LTA and tapasin to work. As TG2 is a multiple 
function protein, it would be beneficial to clinical application if we can target 
pathological TG2 externalisation without affecting its normal cellular 
physiological functions as well. Based on the findings of this study i.e. tapasin 
carried TG2 to the periphery of the cell and TG2 is secreted via LTA related 
plasma membrane blebbing. Targeting LTA could be a potential treatment 
target to prevent TG2 externalisation.  
It is possible to avoid the cells expression LTA in human disease. Vaccination 
is an effective treatment for virus infection in clinical practice. The infection by 
BK virus and SV40 do not cause acute illness and thus has not been a major 
concern, however, the development of a LTA vaccine started because of the 
association between LTA and some types of human cancers (reviewed in Butel 
et al. 1999). A modiﬁed SV40 LTA has been cloned into a vaccine virus vector 
and tested in animal tumour model systems (Bright et al. 1994) with the 
transforming domains removed. The vaccine is effective against both 
subsequent tumour challenge and pre-existing tumours (Imperiale et al. 2001). 
As it is possible to develop vaccine against LTA, the expression of LTA can be 
abolished using vaccination and consequently decrease pathological TG2 
externalisation that is related to the accumulation of ECM proteins and 
accelerate fibrosis formation. This approach can potentially be a treatment 
target in atherosclerosis, liver, lung, kidney fibrosis, Coeliac disease, cancer 
and Alzheimer’s disease where TG2 externalisation is a key event in driving 
the pathology. 
Although autophagy was not involved in TG2 externalisation in this study, 
autophagy has an import role in kidney injury (reviewed in Anders et al. 2010) 
and glomeronephritis (Hartleben et al. 2010). Autophagy allows stressed cells 
to reduce intracellular microorganisms, protein aggregates, and cellular 
organelles by moving and digesting them in autophagolysosomes. In the 
autophagolysosome, endogenous molecules and danger-associated 
molecules may be presented to Toll-like receptors. Toll-like receptors are part 
of immune receptor families that detect danger signals in extracellular and 
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intracellular compartments. Toll-like receptors loaded the molecules digested 
in autophagolysosomes onto the major histocompatibility complex and 
presented as autoantigens (Anders et al. 2010). As TG2 is also wildly involved 
in cell proliferation, antigen presenting process and apoptosis, it would be 
interesting to explore the association between autophagy and TG2. In our 
study, LAMP-2 was used as a marker for autophagolysomes. As autophagy is 
involved in a series of vesicles formation during the digestion process, 
microtubule-associated protein 1 light chain 3 (LC3) is also a maker for 
autophagosome (Kabeya et al. 2000). It would be interesting to explorer the 
co-localisation between LC3 and TG2. 
Some questions regarding the proposed TG2 extracellular trafficking pathway 
(Figure 10.5-1) remains un-answered and thus more studies are needed. 
Firstly, where is tapasin-TG2 interaction occurred while tapasin carried TG2 to 
the periphery of the cells (ie rough ER, cortical ER). Secondly, is tapasin 
interacted with LTA? Therefore tapasin can transfer TG2 to LTA on the plasma 
membrane and another protein may be also involved to release TG2 from 
tapasin. Thirdly, if TG2 extracellular trafficking is dependent on plasma 
membrane blebbing. Fourthly, is there other organelles are involved in TG2 
extracellular trafficking (ie late endosomes or MVBs). We believe these 
questions can be answered using live cell imaging with co-localisation analysis 
or fluorescence resonance energy transfer. 
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